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Acute myocardial infarction 
Although mortality rates have declined the last decades, ischemic heart disease 
(IHD) is still a leading cause of death, accounting for 12% of all deaths worldwide 
and 7.9% in the Netherlands in 2009. 1, 2 Of these deaths from IHD, 67% were attri-
butable to acute myocardial infarction (AMI). 2 In AMI, occlusive coronary artery 
thrombosis results in myocardial ischemia and necrosis, firstly starting in the suben-
docardial myocardium and subsequently progressing as a ‘wavefront’ toward the 
epicardium. 3, 4 Without restoration of blood flow, the acutely hypoperfused region 
of the infarct related artery, the area at risk (AAR), will be subject to near transmur-
al necrosis after 6 hours. 
 Timely reperfusion therapy with either direct percutaneous coronary interven-
tion (PCI) or thrombolytic agents has significantly reduced mortality and AMI com-
plications. 5, 6 Compared with the prereperfusion era, ventricular arrhythmias, cardi-
ogenic shock, cardiac rupture, and fatal ventricular arrhythmias are less common 
complications nowadays. Despite successful restoration of epicardial coronary ar-
tery patency, adequate reperfusion at the microvascular level is not always estab-
lished. This phenomenon of ‘no-reflow’ or microvascular obstruction (MVO) has 
been observed both experimentally as well as clinically. 7, 8 Potential mechanisms of 
MVO include regional endothelial cell swelling, swollen surrounding myocytes, infil-
tration and activation of neutrophils and platelets and the deposition of fibrin that 
occlude the capillaries. 9 In addition, coronary microembolization of atherosclerotic 
debris after PCI may be responsible for a substantial part of clinically observed 
MVO. 10 Reperfused AMI also frequently results in intramyocardial hemorrhage 
(IMH), which is believed to be the result of leakage of erythrocytes from the severe-
ly damaged microvasculature. 11, 12 Myocyte necrosis, MVO and IMH are strong-ly 
related, time-sensitive phenomena and the real mechanisms underlying these fea-
tures are not yet well understood in humans. Animal studies have shown that both 
MVO and IMH depend on the duration of coronary occlusion but lag behind myo-
cyte death. 13-16 Although MVO and IMH increase with duration of reperfusion 17, 18, 
there is still lack of clinical evidence that this increase causes additional myocyte 
death or that its prevention would salvage any additional myocytes. 9 
 Prognosis after AMI has been mainly related to end-systolic volume index 
(LVESVi) and left ventricular ejection fraction (LVEF). 19, 20 In addition to these tradi-
tional risk factors, MVO as assessed with myocardial contrast echocardiography 
(MCE) and coronary angiography, has also been shown to predict adverse ventricu-
lar remodeling and clinical outcome. 21-23 However, the published reports on the 
prognostic significance of MVO are inconsistent, partly because studies have used 
different techniques to assess MVO. Some studies have suggested that MVO is in-
dependently associated with more frequent cardiovascular complications and ad-
verse outcome 24-27, whereas others have failed to prove this concept. 28-31 With 
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many previous techniques it was not possible to simultaneously assess MVO, infarct 
size and infarct transmurality in one investigation. Because these infarct characteris-
tics are mutually related, the association between MVO and outcome might there-
fore be merely associative and mainly determined by infarct size.  
Cardiovascular magnetic resonance  
Assessment of function and infarction 
Cardiovascular magnetic resonance (CMR) has emerged as a useful tool to compre-
hensively examine multiple infarct characteristics in one investigation. It consists of 
multiple distinct techniques that each provide separate pieces of information. Cine 
CMR, using a balanced steady-state free procession sequence, is the current stan-
dard to accurately measure volumes and systolic function and with better interstu-
dy reproducibility than echocardiography. 32 It is therefore a powerful tool for global 
evaluation of post-infarction left ventricular remodeling. 
 The technique of contrast-enhanced CMR (CE-CMR) - late gadolinium enhance-
ment or delayed enhancement CMR (LGE- or DE-CMR) - accurately measures infarct 
size in vivo in both acute and chronic settings. 33 The technique involves the admin-
istration of gadolinium-based contrast media that decrease T1-relaxation time of 
infarcted tissue. It is believed that this increase in T1-relaxivity is caused by a larger 
volume of distribution and retention of Gadolinium in edematous (in AMI) and scar 
tissue (in chronic MI). Using a T1 weighted (T1W) pulse sequence, infarcted myo-
cardium appears bright (hyperenhanced) relative to normal myocardium. Currently, 
the most widely used method is an ECG-triggered segmented inversion-recovery 
fast gradient echo pulse sequence with application of a preparatory pulse to null 
normal myocardium. 34 DE-CMR is commonly carried out at 10-15 minutes after 
contrast administration, which produces greater contrast between normal and in-
farcted tissue as more Gadolinium washes out the normal myocardium and accumu-
lates in infarcted tissue. 
 Infarct size measurement by DE-CMR has been shown to provide an added 
value to the traditional predictors of adverse outcome, LVESVi and LVEF. 35, 36 Be-
cause of its high spatial resolution, DE-CMR allows determining the transmural ex-
tent of infarction, which has been shown to provide supplemental information to 
infarct size in predicting improvement of contractile function. 37, 38 
Detection of MVO and IMH 
MVO can be detected with CMR using different contrast-enhanced techniques, but 
a gold standard has not yet been established. Due to differences in wash-in and 
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wash-out kinetics as compared to normal and infarcted myocardium, MVO can 
either be shown as hypoenhanced areas 1-2 minutes after contrast administration 
using first pass perfusion CMR (FPP-CMR, early MVO) 18,  39 or as hypoenhanced 
areas within hyperenhanced areas using traditional DE-CMR (late MVO). 24, 25 Micro-
vascular flow after reperfusion is spatially and temporarily complex. 40 The extent of 
MVO decreases going from early to late imaging which is caused by slow diffusion of 
gadolinium into the infarct core. 41 The dynamic changes in appearance of MVO in 
relation to infarct characteristics and remodeling are unknown. 
 Occlusion and subsequent reperfusion of a coronary artery leads to inflamma-
tion and myocardial tissue edema in the vascular bed downstream of the occlusion 
site. This increased mobile water content causes a prolongation of T2-relaxation 
which can be detected on T2-weighted (T2W) sequences as areas of increased signal 
intensity. 42, 43 Studies have shown that central areas of hypoenhancement within 
these hyperintense areas on T2W imaging correspond to IMH. 44-46 
 Conflicting results have been published on the clinical significance of MVO and 
IMH beyond infarct size. 25, 27, 29-31, 47-50 This may largely be explained by their mutual 
correlation with infarct size. 11, 13  
Early risk stratification 
Early identification of patients with a good or an unfavorable prognosis remains 
crucial to decide if patients may need adjunctive infarct size limiting therapies. 51 
Incomplete resolution of ST segment elevation (STR) early after reperfusion has 
prognostic significance and is widely accepted to reflect compromised myocardial 
perfusion, even after successful epicardial flow establishment. 52-55 However, only a 
limited number of studies has directly related incomplete STR to microvascular 
dysfunction. 56, 57 The relation of STR with underlying infarct characteristics and ad-
verse remodeling as assessed by CMR are not well known.  
The area at risk 
Accurate measurement of the AAR and infarct size is important, because this would 
allow the assessment of myocardial salvage and the efficacy of reperfusion thera-
pies. For measuring the AAR, electrocardiographic and angiographic methods have 
been used. 58, 59 Several studies also suggest that the hyperintense area on T2W 
images delineates the AAR. 60, 61 A novel CMR method for measuring the AAR is the 
determination of infarct endocardial surface area (ESA) by DE-CMR. 62 Although 
promising, validation of these techniques against a proper reference standard is 
limited. 
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Objectives of this thesis 
1. To assess characteristics of injury in reperfused AMI using CMR and investigate 
their clinical significance in relation to adverse remodeling. 
2. To relate early electrocardiographic measures of reperfusion (ST segment reso-
lution) with underlying infarct characteristics and remodeling as assessed with 
CMR. 
3. To evaluate the performance of different AAR measurement methods using 
established physiological concepts as a reference standard. 
Outline of the thesis 
In chapter 2, the underlying pathophysiology of myocardial ischemia with an em-
phasis on MVO and current techniques to detect MVO are reviewed. 
 
In chapter 3, the prevalence and dynamic changes of MVO over time are evaluated 
using an optimized technique for early and traditional late contrast-enhanced CMR. 
 
In chapter 4, the clinical implications of MVO and IMH in AMI regarding adverse 
remodeling are investigated. 
 
In chapter 5, the relation of early STR to underlying infarct characteristics and ad-
verse remodeling as assessed with CMR are investigated. 
 
In chapter 6, established physiological concepts were used to evaluate the perfor-
mance of angiographic, electrocardiographic and CMR methods to assess the AAR in 
AMI.  
 
Chapter 7 discusses the results of this thesis in the light of existing evidence or con-
troversy and directions for future research will be given. 
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Abstract 
Successful restoration of epicardial coronary artery patency after prolonged occlu-
sion might result in microvascular obstruction (MVO) and is observed both experi-
mentally as well as clinically. In reperfused myocardium, myocytes appear edemat-
ous and swollen from osmotic overload. Endothelial cell changes usually accompany 
the alterations seen in myocytes but lag behind myocardial cell injury. Endothelial 
cells become voluminous, with large intraluminal endothelial protrusions into the 
vascular lumen, and together with swollen surrounding myocytes occlude capilla-
ries. The infiltration and activation of neutrophils and platelets and the deposition 
of fibrin also play an important role in reperfusion-induced microvascular damage 
and obstruction. In addition to these ischemia-reperfusion-related events, coronary 
microembolization of atherosclerotic debris after percutaneous coronary interven-
tion is responsible for a substantial part of clinically observed MVO. Microvascular 
flow after reperfusion is spatially and temporally complex. Regions of hyperemia, 
impaired vasodilatory flow reserve and very low flow coexist and these perfusion 
patterns vary over time as a result of reperfusion injury. The MVO first appears 
centrally in the infarct core extending toward the epicardium over time. Accurate 
detection of MVO is crucial, because it is independently associated with adverse 
ventricular remodeling and patient prognosis. Several techniques (coronary angio-
graphy, myocardial contrast echocardiography, cardiovascular magnetic resonance 
imaging, electrocardiography) measuring slightly different biological and functional 
parameters are used clinically and experimentally. Currently there is no consensus 
as to how and when MVO should be evaluated after acute myocardial infarction.  
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Timely reperfusion in patients with acute myocardial infarction (AMI) salvages myo-
cardium and reduces mortality. 1 However, successful restoration of epicardial co-
ronary artery patency after prolonged occlusion does not always lead to adequate 
reperfusion at the microvascular level. This phenomenon of no-reflow or microvas-
cular obstruction (MVO) is observed both experimentally as well as clinically. 2, 3 
Accurate detection and quantification of MVO is important, because previous stu-
dies have shown that MVO is independently associated with adverse ventricular 
remodeling and patient prognosis. 2, 4-7 The “open epicardial artery hypothesis” 
should thus be shifted downstream to an “open micro-vessel hypothesis” for re-
flecting optimal reperfusion. 8 
 Although both the clinical as well as the experimental setting of ischemia-
reperfusion share important underlying pathophysiologic aspects, the experimental 
models of coronary occlusion and reperfusion are lacking certain aspects frequently 
present in the clinical situation. For instance, distal coronary microembolization of 
atherosclerotic debris or thrombotic material might be responsible for a substantial 
part of clinically observed MVO, which is not simulated in standard animal models 
of ischemia and reperfusion. 6 
 Imaging techniques play an important role in the development and evaluation 
of future cardioprotective interventions. 9 However, a “gold standard” for the detec-
tion of MVO has not been established, and several techniques measuring slightly 
different biological parameters are being used clinically and experimentally. The 
sensitivity and specificity of all these techniques is as yet undetermined. Following a 
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Abstract 
Successful restoration of epicardial coronary artery patency after prolonged occlu-
sion might result in microvascular obstruction (MVO) and is observed both experi-
mentally as well as clinically. In reperfused myocardium, myocytes appear edemat-
ous and swollen from osmotic overload. Endothelial cell changes usually accompany 
the alterations seen in myocytes but lag behind myocardial cell injury. Endothelial 
cells become voluminous, with large intraluminal endothelial protrusions into the 
vascular lumen, and together with swollen surrounding myocytes occlude capilla-
ries. The infiltration and activation of neutrophils and platelets and the deposition 
of fibrin also play an important role in reperfusion-induced microvascular damage 
and obstruction. In addition to these ischemia-reperfusion-related events, coronary 
microembolization of atherosclerotic debris after percutaneous coronary interven-
tion is responsible for a substantial part of clinically observed MVO. Microvascular 
flow after reperfusion is spatially and temporally complex. Regions of hyperemia, 
impaired vasodilatory flow reserve and very low flow coexist and these perfusion 
patterns vary over time as a result of reperfusion injury. The MVO first appears 
centrally in the infarct core extending toward the epicardium over time. Accurate 
detection of MVO is crucial, because it is independently associated with adverse 
ventricular remodeling and patient prognosis. Several techniques (coronary angio-
graphy, myocardial contrast echocardiography, cardiovascular magnetic resonance 
imaging, electrocardiography) measuring slightly different biological and functional 
parameters are used clinically and experimentally. Currently there is no consensus 
as to how and when MVO should be evaluated after acute myocardial infarction.  
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Timely reperfusion in patients with acute myocardial infarction (AMI) salvages myo-
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Case presentation 
A 49-year-old woman with a history of smoking presented to the emergency de-
partment after 3 hours of crushing retrosternal chest pain. The electrocardiogram 
(ECG) showed ST-segment elevation in leads V1 to V4, indicating acute transmural 
anteroseptal ischemia (Figure 1A). She was treated with aspirin 300 mg, clopidogrel 
600 mg, weight-adjusted low-molecular weight heparin, nitroglycerine, a beta-
blocker, and a glycoprotein IIb/IIIa inhibitor. 
 Coronary angiography showed an occlusive thrombus in the mid left anterior 
descending artery at the bifurcation of the second diagonal branch (Figures 2A and 
2B). Subsequently and approximately 4 hours after symptom onset, percutaneous 
coronary intervention (PCI) with thrombosuction and stenting was performed (Fig-
ure 2C). Despite an angiographically optimal result without residual stenosis, ante-
grade epicardial flow was only partially restored to Thrombolysis In Myocardial 
Infarction (TIMI) flow grade 2, even after intracoronary adenosine injection (Figure 
2D). 
Figure 2. Acute coronary angiogram. Proximal occlusion of the left ante-
rior descending artery (LAD) (A) (arrow). After introduction of the first 
guide wire, intraluminal thrombus (haziness) at the bifurcation of LAD 
(arrow) and second diagonal branch (*) can be seen (B). After thrombo-
suction and stenting followed by kissing balloon inflation (C), flow was 
only partially restored to Thrombolysis In Myocardial Infarction flow 
grade 2, despite an angiographically optimal result (D). 
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Figure 3. Cardiovascular MRI. A set of 2 corresponding short-axis images 
acquired with a single breathhold 3-dimensional inversion recovery 
gradient-echo pulse sequence. (A) Early (2 min after contrast injection) 
contrast-enhanced cardiovascular magnetic resonance imaging (MRI) 
showing a central hypoenhanced area corresponding to microvascular 
obstruction (MVO) in the anteroseptal region (arrows, early MVO). (B) 
Late gadolinium-enhanced cardiovascular MRI (10 min after contrast 
injection) showing hyperenhancement indicating an anteroseptal myo-
cardial infarction (arrowheads) with a central zone of MVO (arrows, late 
MVO). Note that the extent of late MVO is smaller than early MVO, due 
to contrast penetration over time (see Cardiovascular MRI section). 
 
In the Intensive Cardiac Care Unit, her chest pain completely subsided. Despite sig-
nificant ST-segment resolution (STR ≥70%), persistent ST-segment elevation in leads 
V1 to V3 was still present 40 min after PCI (Figure 1B). The peak creatine kinase level 
of 900 U/l was reached 12 h after admission. 
 Cardiovascular magnetic resonance imaging (MRI) on day 4 demonstrated ante-
ro-septal akinesia, a left ventricular end-diastolic volume of 149 ml, LV stroke vo-
lume of 67 ml, and ejection fraction (EF) of 45%. Early contrast-enhanced cardiovas-
cular MRI performed 2 min after contrast injection showed a central hypointense 
area in the anteroseptal wall corresponding to MVO (Figure 3A, arrows). Delayed 
enhancement cardiovascular MRI (DE-CMR) 10 min after contrast injection showed 
an anteroseptal myocardial infarction (Figure 3B, arrowheads) with a central zone of 
MVO (Figure 3B, arrows). 
 Her hospital course was uneventful, and she was discharged on day 6 with aspi-
rin, clopidogrel, statin, angiotensin-converting enzyme inhibitor and beta-blocker. 
After 3 months she was in New York Heart Association (NYHA) functional class III, 
and a repeat cardiovascular MRI showed an increased LV end-diastolic volume and 
decreased EF (41%). 
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Mechanisms of ischemic myocardial Injury 
The anatomic and biochemical events of ischemic cell injury and death have been 
well-described. 9, 10 Under normal aerobic conditions cardiac energy is acquired 
from fatty acids, which supply 60% to 90% of the energy for adenosine triphosphate 
(ATP) synthesis. The remaining energy comes from oxidation of pyruvate formed 
from glycolysis and lactate oxidation. Sudden occlusion of a coronary artery shifts 
aerobic or mitochondrial metabolism to anaerobic glycolysis within seconds. Re-
duced aerobic ATP formation stimulates glycolysis and increases myocardial glucose 
uptake and glycogen breakdown. A decrease in ATP inhibits Na+/K+-ATPase, increas-
ing intracellular Na+ and Cl−, leading to cell swelling. Derangements in transport 
systems in the sarcolemma and sarcoplasmic reticulum increase cytosolic Ca2+, in-
ducing activation of proteases and alterations in contractile proteins. Pyruvate is not 
readily oxidized in the mitochondria, leading to production of lactate, fall in intracel-
lular pH, reduction in contractile function, and greater ATP requirement to maintain 
Ca2+ homeostasis. 11 
Infarct region and Reperfusion 
Infarct size is directly related to the duration of coronary artery occlusion. In animal 
models, coronary artery occlusion of 15 to 20 min followed by reperfusion com-
pletely prevents myocardial cell necrosis, whereas 40 min of occlusion results in 
focal or diffuse subendocardial necrosis involving 38 ± 4% of the coronary bed at 
risk. 12 At 3 hours of occlusion, myocardial necrosis involves 57 ± 7% of the coronary 
bed, and an additional 3 hours results in an increase of infarct size to 71 ± 7%, simi-
lar to permanent coronary occlusion rates (79 ± 6%). To achieve benefit from reper-
fusion, as learned in animal models, it is reasonable to administer all therapeutic 
interventions within the 3-hour “window.”  
 In ischemic but reversibly injured myocardium, myocytes are edematous and 
swollen from osmotic overload. The cell size is increased with decreased glycogen 
content. 3 The myocyte fibrils are relaxed and thinned; I-bands are prominent sec-
ondary to noncontracting ischemic myocytes. 13 The nuclei show mild condensation 
of chromatin at the nucleoplasm. The cell membrane (sarcolemma) is intact with no 
breaks. The mitochondria are swollen with loss of normal dense mitochondrial gra-
nules or granular flocculent densities. Irreversible injured myocytes contain shrun-
ken nuclei with marked chromatin margination. The 2 hallmarks of irreversible in-
jury are cell membrane breaks and mitochondrial presence of small osmophilic 
densities. 3 
 Endothelial cell (EC) changes of ischemia usually accompany the alterations 
seen in the myocytes but lag behind myocardial cell injury. 14 In a canine model, EC 
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abnormalities are not seen until 60 min. These abnormalities include focal EC swel-
ling with loss of pinocytotic vesicles, which are observed in 20% of EC’s. 14 As ische-
mia advances, the number of affected ECs increases (40% at 90 to 180 min.). More-
over, as ischemia prolongs, greater endothelial changes result, including clumping 
and margination of nuclear chromatin, marked swelling of the cytoplasm, formation 
of intraluminal blebs, and even disruption of EC borders, hemorrhage, and fibrin 
deposition (Figure 4). 14-16 The microvasculature can also be obstructed by extravas-
cular compression from myocyte edema. Overall, it seems that microvascular dam-
age lags behind myocardial cell injury, ultrastructurally, and is probably not the 
primary cause of myocyte injury until reperfusion occurs. 14, 17 
The “no-reflow” phenomenon or microvascular obstruction 
A balance exists between the benefits of reperfusion to reduce infarct size and re-
perfusion injury, which depends on the duration of occlusion. In general, if ischemic 
myocardium is reperfused early, the degree of myocardial salvage greatly exceeds 
damage from free radicals and calcium-loading caused by reperfusion. These posi-
tive functional consequences of reperfusion are most beneficial within the initial 12 
hours after occlusion in humans. 
 Reperfusion injury is defined as reperfusion-related expansion or worsening of 
ischemic cardiac injury leading to decreased contractility, an increased arrhythmo-
genic threshold, conversion of reversible to irreversible myocyte injury, and micro-
vascular dysfunction. 3 At the time of myocardial reperfusion, there is an abrupt 
increase in intracellular Ca2+, leading to a disturbance in the normal mechanisms 
that regulate Ca2+ in the cardiomyocyte, known as the calcium paradox. 18 This 
intracellular Ca2+ overload induces death by causing hypercontracture of myocytes 
and mitochondrial permeability transition pore opening. 9, 18 
 Microvascular obstruction in the heart was first described by Kloner et al. 3 and 
consists of explosive EC swelling on reperfusion of an ischemic bed. 19 Endothelial 
protrusion by cell swelling together with neutrophils, red blood cells, and platelets 
cause capillary obstruction (Figure 4). 3 Microvessels ultimately rupture, with fibrin 
and platelet deposition and red and white blood cell extravasation. Furthermore, 
surrounding myocardial cells swell, potentially compressing capillaries. 
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Figure 4. Sequential changes in the microvasculature after varying periods 
of ischemia. At 60 min. of ischemia, endothelial cells are swollen with 
decrease in pinocytotic vesicles. Capillary damage (endothelial change) 
continues to occur with longer duration of ischemia as large intraluminal 
protrusions (P), absent or decreased pinocytotic vesicles, membrane-bound 
vesicles (V), and capillary obstruction with red (R) and white (W) blood cell 
plugging are observed. With permanent coronary occlusion, intravascular 
protrusions are less pronounced; however, membrane-bound vesicles and 
red and white blood cell plugging with fibrin deposition are seen only after 
longer duration of ischemia. N=nucleus; M=mitochondrium. Reproduced 
with permission from Virmani et al. 16 
 
These changes in the capillary bed can result in poor perfusion of the surrounding 
potentially viable myocytes with resultant cell death. 10, 20 The failure to reperfuse 
viable, severely ischemic myocytes (reversible injury) with resultant myocyte cell 
death (irreversible injury) at the time of reperfusion (the no-reflow phenomenon) 
has been described after 90 min. in a canine model. 3 Reperfusion, therefore, as 
described by Braunwald and Kloner 21 is a “double-edged” sword, because it can 
result in the death of potentially salvageable myocardium. 
 Neutrophils have also been implicated in causing reperfusion injury in the myo-
cardium and other organs. Neutrophils are activated early during myocardial ische-
mia and precede the appearance of histological tissue injury. 17 Reperfusion mar-
kedly enhances the infiltration of neutrophils into the ischemic region. 22 The essen-
tial initiating step involves interaction of neutrophils with vascular ECs (adhesion). 
This is followed by activation, diapedesis, and extravascular migration into sur-
rounding myocytes. Production of additional chemoattractants by activated neutro-
phils amplifies the initial inflammatory response. Neutrophil activation causes a 
greatly enhanced oxygen uptake by the cell, resulting in the production of large 
quantities of reactive oxygen species that might lead to disruption of EC and inacti-
vate antiproteases present in the plasma. 23 
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In addition to these ischemia-reperfusion-related events, distal coronary microem-
bolization of atherosclerotic debris or thrombotic material is responsible for a sub-
stantial part of clinically observed MVO 6, 24 (Figure 5). Microemboli are histopatho-
logically associated with MVO, myocyte necrosis and edema, and EC sloughing with-
in the intramyocardial capillaries. 25, 26 The rate of coronary microembolization is 
highest in documented epicardial coronary thrombosis, reaching 30% to 54% 27, 28 
and even higher (79%) in AMI patients. 29  
 Few data compare acute plaque rupture versus acute plaque erosion; however, 
the authors have noted a higher rate of thrombotic microembolization with plaque 
erosion. In hearts with acute coronary thrombi, evidence of distal embolization was 
more frequent in erosions than ruptures. These thrombi were associated with focal 
myocardial necrosis. Other potential sources of distal embolization include primary 
PCI, PCI of diseased (atherosclerotic) saphenous vein grafts, and thrombolysis. The 
reported incidence of distal embolization due to soft friable atherosclerotic plaque 
and adherent thrombus, after PCI of bypass grafts ranges from 2% to 42%. 30-32 An-
giographic evidence of distal embolization in patients treated with primary PCI has 
been shown to occur in approximately 15% to 19% (Figure 6). 33, 34 
 Microvascular flow within the reperfused bed is both spatially and temporarily 
complex. Apparently, blood flow in the area of structural MVO is not completely 
absent but rather very low, ranging between 0.13 and 0.37 ml/g/min, which is <50% 
of baseline blood flow. 35, 36 Microvascular obstruction first appears centrally in the 
infarct core extending toward the epicardium over time. Different myocardial re-
gions can be distinguished (Figure 7). 37 In the noninfarcted region, microvasculature 
is intact and blood flow is normal. In the noninfarcted (stunned) area-at-risk, micro-
vasculature is structurally and functionally still intact. The infarcted region has outer 
zones of intact microvasculature with co-existing areas of hyperemia, low reflow, 
and impaired flow reserve, depending on the degree of capillary damage. 
 Myocardial blood flow in certain areas of MVO is hyperemic during the first 2 
min. of reperfusion but progressively decreases within 2 to 3 hours after reperfu-
sion, resulting in a 2-fold increase of MVO. 35, 38 A further increase in MVO size has 
been demonstrated up to 48 hours after initiation of reperfusion. 39 This progression 
of MVO is presumably related to reperfusion injury. Therefore, therapeutic inter-
ventions trying to attenuate MVO are likely to be most successful when initiated 
early after reperfusion. 
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Figure 5. Obstructed microvessels and myocardial reperfusion injury. Distal 
platelet-rich (intramyocardial) embolus (A) when treated with thrombolytic 
therapy will result in reperfusion injury with (B) contraction band necrosis 
(arrowheads) and diffuse neutrophil and red cell infiltration in a patient with 
myocardial infarction secondary to epicardial coronary plaque rupture. 
 
Figure 6. Representative micrographs of distal microembolization of plaque 
material from ruptured atheroma. (A) Low-power (Movat's pentachrome) 
view of rupture site (arrow) showing luminal fibrin and cholesterol clefts. (B) 
Adjacent distal segment to rupture site demonstrates nonocclusive thrombus 
composed of necrotic core material. (C) High-power image demonstrating 
cholesterol clefts (arrows) with superimposed thrombus (Th) (hematoxylin 
and eosin). (D) High-power image of intramural coronary artery atheroembo-
lus consisting of cholesterol clefts (arrows) and surrounded by healing myo-
cardium in a patient who underwent percutaneous coronary intervention for 
acute myocardial infarction. 
 
P A T H O P H Y S I O L O G Y  A N D  D I A G N O S I S  O F  M V O  
 29 
Figure 7. Different regions of microvascular flow after re-perfusion. Schematic 
short-axis presentation showing the different regions of microvascular flow in 
reperfused acute myocardial infarction. 
Diagnosis of MVO 
Coronary angiography 
After the recognition that complete thrombotic coronary occlusion caused AMI and 
that early reperfusion with thrombolytic agents increased myocardial salvage and 
reduced mortality, there was a need to angiographically assess the quality of reper-
fusion. 40 Successful reperfusion is defined by assessing antegrade angiographic 
epicardial blood flow, graded as TIMI flow; TIMI flow grade 0: absent antegrade 
flow; TIMI flow grade 1: partial contrast penetration beyond an occlusion with in-
complete distal filling; TIMI flow grade 2: patent epicardial artery with opacification 
of the entire distal artery (however, contrast filling or washout is delayed); TIMI flow 
grade 3: patent epicardial artery with normal flow. 
 Early studies using this angiographic assessment found that mortality was signif-
icantly lower in patients with TIMI flow grade 3 than in those with other TIMI flow 
grades (4% vs. 8%, p<0.01), and importantly, TIMI flow grade 2 was not associated 
with a significant survival advantage compared with TIMI flow grades 0 or 1. 41 A 
TIMI flow grade ≤2 without a residual obstructive lesion has been generally re-
garded as the “angiographic no reflow”. 42 Although angiographic assessment of 
reperfusion is still useful in daily clinical practice, the clinician should be aware that 
TIMI flow grade 3 is not always synonymous with optimal tissue reperfusion, be-
cause MVO can be demonstrated in a substantial number of these patients. 2 
 Because the TIMI flow grading system is semi-quantitative and subjective, a 
more objective angiographic marker of tissue perfusion was developed. The cor-
rected TIMI frame count (CTFC) assesses the number of cine frames required for 
contrast to first reach standardized distal coronary landmarks in the culprit artery. A 
higher CTFC and thus slower epicardial flow 90 min. after administration of a 
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Figure 7. Different regions of microvascular flow after re-perfusion. Schematic 
short-axis presentation showing the different regions of microvascular flow in 
reperfused acute myocardial infarction. 
Diagnosis of MVO 
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After the recognition that complete thrombotic coronary occlusion caused AMI and 
that early reperfusion with thrombolytic agents increased myocardial salvage and 
reduced mortality, there was a need to angiographically assess the quality of reper-
fusion. 40 Successful reperfusion is defined by assessing antegrade angiographic 
epicardial blood flow, graded as TIMI flow; TIMI flow grade 0: absent antegrade 
flow; TIMI flow grade 1: partial contrast penetration beyond an occlusion with in-
complete distal filling; TIMI flow grade 2: patent epicardial artery with opacification 
of the entire distal artery (however, contrast filling or washout is delayed); TIMI flow 
grade 3: patent epicardial artery with normal flow. 
 Early studies using this angiographic assessment found that mortality was signif-
icantly lower in patients with TIMI flow grade 3 than in those with other TIMI flow 
grades (4% vs. 8%, p<0.01), and importantly, TIMI flow grade 2 was not associated 
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garded as the “angiographic no reflow”. 42 Although angiographic assessment of 
reperfusion is still useful in daily clinical practice, the clinician should be aware that 
TIMI flow grade 3 is not always synonymous with optimal tissue reperfusion, be-
cause MVO can be demonstrated in a substantial number of these patients. 2 
 Because the TIMI flow grading system is semi-quantitative and subjective, a 
more objective angiographic marker of tissue perfusion was developed. The cor-
rected TIMI frame count (CTFC) assesses the number of cine frames required for 
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thrombolytic agent is associated with increased mortality and composite end points 
and adds prognostic information even in patients with TIMI flow grade 3. 43 
Coronary blood flow velocity patterns 
In patients with substantial MVO the coronary blood flow velocity pattern is charac-
terized by a reduction in systolic antegrade flow, the appearance of abnormal retro-
grade flow in early systole (>10 cm/s), and a rapid deceleration time of diastolic flow 
velocity (<600 ms), which was found to be highly associated with TIMI flow grade 2. 
44, 45 
 These distinct coronary flow velocity patterns are associated with a decreased 
recovery of LV function over time and seem accurate predictors of long-term car-
diac events in reperfused AMI. 46 These altered coronary blood flow velocity pat-
terns are believed to be related to increased microvascular impedance as a conse-
quence of profound microvascular damage and obstruction. 
Myocardial blush grading 
The assessment of TIMI flow grade and CTFC and the identification of distinct coro-
nary flow velocity patterns only indirectly reflect the status of the microcirculation. 
Perfusion can also be assessed angiographically with a semi-quantitative description 
of myocardial contrast density on the final angiogram after reperfusion, described 
as TIMI myocardial perfusion (TMP) or myocardial blush grade. 47, 48 The TMP flow 
grades are defined as follows: TMP flow grade 0: failure of dye to enter the micro-
vasculature; TMP flow grade 1: dye slowly enters but fails to exit the microvascula-
ture; TMP flow grade 2: delayed entry and exit of dye from the microvasculature; 
TMP flow grade 3: normal entry and exit of dye from the microvasculature. 
 Myocardial perfusion grading also permits risk stratification and adds prognos-
tic information even in patients with TIMI flow grade 3. Achievement of both TIMI 
flow grade 3 and myocardial blush grade 3 is associated with mortality under 1%. 49 
 Previous studies have shown that 11% of patients who had established epicar-
dial patency and TIMI flow grade 3 had a myocardial blush grade of 0/1, again em-
phasizing that TIMI flow grading is an inaccurate marker of tissue reperfusion. 50 It is 
believed, however, that myocardial blush only indirectly reflects microvascular sta-
tus but predominantly describes varying degrees of extravasation and washout of 
dye that is caused by a combination of increased capillary permeability, capillary 
resistance, and interstitial edema. 51 
 The usefulness of angiographic and coronary blood flow velocity methods to 
detect MVO is disputable, because they are often performed immediately after 
mechanical reperfusion, a time point where microvascular flow is known to be 
hyperemic, and therefore they might not be an accurate reflection of the final mi-
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crovascular damage. Experimental studies have shown that the size of MVO in-
creases depending on the time after reperfusion as a result of reperfusion injury. 35 
Myocardial contrast echocardiography 
Myocardial contrast echocardiography (MCE) uses small microbubbles (<5 μm) that 
possess an intravascular rheology similar to that of red blood cells and remain en-
tirely within the microvasculature. During constant infusion, a steady state is 
achieved after approximately 2 to 3 min. After destruction with high energy pulses, 
the rate of microbubble replenishment is proportionate to blood flow. Myocardial 
contrast echocardiography is able to delineate the area-at-risk for necrosis during 
acute coronary occlusion and has gained tremendous insight into post-ischemic 
tissue reperfusion. 52 A persistent contrast defect despite a patent epicardial artery 
after reperfusion correlates with MVO. 2 
 Myocardial contrast echocardiography studies also made clear that substantial 
MVO could be observed in all patients with TIMI flow grade 2 and in 16% of patients 
with TIMI flow grade 3. 53 
 Myocardial contrast echocardiography predicted segmental myocardial recov-
ery with a sensitivity of 88% and a specificity of 74% and a positive and negative 
predictive value of 83% and 81%, respectively. 54 In addition, MCE studies have 
shown that pericardial effusion, early congestive heart failure, and adverse arr-
hythmias occur significantly more frequently in patients with MVO. 55 
 The technique of intracoronary injection of microbubbles before and shortly 
after coronary reflow make it less universally applicable, and although intravenous 
methods have become available, several disadvantages to the use of MCE remain: 
moderate spatial resolution, operator dependency, incomplete LV coverage with 
suboptimal visualization of the lateral wall, and semi-quantitative assessment of 
MVO. 54, 56 
Cardiovascular magnetic resonance 
Two contrast (gadolinium)-enhanced cardiovascular MRI (CMR) techniques are used 
to detect MVO in AMI. The primary technique is first-pass perfusion cardiovascular 
MRI (FPP-CMR). 7, 57, 58 With this technique, multiple imaging planes are dynamically 
imaged to track an intravenous bolus of contrast into the myocardium. A homogen-
ous increase in signal intensity in normal and infarcted myocardium is observed 
early after contrast administration, whereas MVO is seen as an area of reduced 
signal intensity (hypoenhancement) in the central core of the infarct that persists 
for >2 min. after contrast administration (early MVO). 
 The second technique is delayed enhancemant (DE-) CMR. 5, 59, 60 Due to slow 
washout and local accumulation of contrast 10 to 15 min. after contrast injection, 
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the infarcted myocardium appears hyperenhanced or “bright” compared with nor-
mal noninfarcted myocardium. 61 This hyperenhanced region closely corresponds to 
the area of necrosis as measured by triphenyltetrazolium chloride staining. 62 A 
central hypoenhanced region within the hyperenhanced region corresponds to 
MVO (late MVO). 
 FPP-CMR was found to be more sensitive for the detection of MVO compared 
with DE-CMR. 59 Experimental studies have demonstrated that the spatial extent as 
well as location of early MVO closely correlates with histopathological analyses. 36, 63 
 DE-CMR, as compared with FPP-CMR, underestimates the extent of MVO and 
might miss small regions of MVO due to slow penetration of contrast into the MVO 
region over time. 64 FPP-CMR is hampered by incomplete LV coverage, low signal-to-
noise ratio, and low spatial resolution interfering with MVO detection. Imaging 
protocols that combine early imaging and complete LV coverage might overcome 
this. 65 Not only the timing after contrast administration but also the timing of imag-
ing after AMI is important, because only persistent MVO after 1 week independent-
ly predicted adverse LV remodeling, unlike MVO that was present at 2 days but 
disappeared after 1 week. 58 
 In contrast to MCE, cardiovascular MRI allows multislice imaging with high tis-
sue contrast and high spatial resolution, enabling accurate quantification and locali-
zation of MVO and infarct size relative to the entire LV. Only one experimental study 
directly compared MCE and FPP-CMR with thioflavin-S staining and found MCE to 
overestimate and FPP-CMR to underestimate MVO size. This can be explained by 
the predominantly intravascular sojourn of microbubbles, whereas gadolinium as a 
freely diffusible tracer rapidly extravasates into the interstitium, thereby artificially 
decreasing the area of MVO. 63 In addition, microbubbles are larger than gadolinium 
molecules and might become temporarily plugged in microvessels that would allow 
passage of gadolinium. 
 Cardiovascular MRI studies have shown that the presence of MVO significantly 
increases with infarct transmurality and independently predicts adverse events, 
including adverse LV remodeling, congestive heart failure, and death. 7, 55 In a recent 
study, the extent of MVO was not found to be related to the change in LVEF at fol-
low-up, suggesting that MVO size might be clinically less important than its mere 
presence. 66 
ECG 
In patients treated with thrombolytic therapy, complete STR (≥70%) is a highly accu-
rate predictor of infarct-related artery (IRA) patency and is associated with lower 
mortality. 67-69 However, up to 50% of patients with absence of complete STR (STR 
<70%) might still have a patent IRA and TIMI flow grade 3. 68, 70 After successful 
primary PCI and establishment of TIMI flow grade 3, 30% to 50% of patients have 
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incomplete STR, indicating that microcirculatory perfusion might be impaired. 71, 72 
Only a limited number of studies have directly related incomplete STR to MVO by 
coronary Doppler flow velocity measurements, cardiovascular MRI, and MCE. 66, 73, 74 
The interpretation of STR data should be done cautiously, because methodologies, 
definitions, and time points of measuring STR differ between studies. 
 Most studies have used the sum of STR method from standard 12-lead ECG, in 
which ST-segment deviation in all leads is summed and compared before and after 
intervention. Single lead STR ≥50% in the lead with maximum initial ST-segment 
elevation is a simple, universally available alternative that predicts TIMI flow grade 3 
with 70% sensitivity and 54% specificity. 75 Single lead STR is comparably accurate in 
predicting outcome as sum STR measurements. 76 Minimal absolute ST-segment 
deviation after thrombolytic therapy can also be used to predict IRA patency. 77 
Because ST-segment elevation and STR can behave dynamically over time, conti-
nuous instead of serial ECG assessment might provide additional information on 
epicardial patency and quality of myocardial reperfusion. 78 
 Other electrocardiographic changes have been described as signs of successful 
angiographic reperfusion (TIMI flow grades 2 or 3). Terminal T-wave inversion was 
observed in 60% of patients, and a patent coronary artery was associated with an 
increased number of accelerated idioventricular rhythms in small studies. 79-81 These 
markers, however, only reflect IRA patency and have not been validated against 
other measures of MVO. 
Management of no-reflow 
Despite major advances in the understanding of the underlying pathophysiology of 
MVO, many different mechanical and pharmacologic therapeutic approaches to 
prevent or attenuate MVO have revealed very different and, in part, contradictory 
results. Interventions that were effective in the experimental setting did not show 
significant effects clinically, and vice versa. 
 The use of a microcirculatory protection device effectively retrieved embolic 
debris during PCI in AMI but failed to improve microvascular flow, reduce infarct 
size, or result in enhanced event-free survival. 32 Although the aspiration of throm-
bus significantly improved reperfusion compared with conventional PCI, a substan-
tial number of patients still experienced low myocardial blush grades and incom-
plete STR. 82 Likewise, intra-aortic balloon counterpulsation significantly reduced 
MVO experimentally, but a recent meta-analysis of clinical studies using intra-aortic 
balloon counterpulsation in the setting of ST-segment elevation myocardial infarc-
tion suggested that this is not associated with a change in LVEF and increased sur-
vival at follow-up. 83, 84 
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 A range of pharmacologic adjunctive measures of reperfusion have been eva-
luated. Glycoprotein IIb/IIIa inhibition significantly improved microvascular flow and 
reduced infarct size in a dog model of coronary occlusion/reperfusion and signifi-
cantly increased the rate of complete STR, coronary artery patency, and CTFC in 
clinical trials. 85-88 Possibly by reversing microvascular spasm, the administration of 
intracoronary verapamil after PCI decreased no-reflow zones leading to a better 
functional outcome in first AMI patients. 89 The extent of MVO is proportional to the 
number of polymorphonuclear leukocytes present in the infarcted area. The inhibi-
tion of complement pathways decreased polymorphonuclear leukocyte free radical 
generation and enhanced the recovery of coronary flow in an isolated rat heart 
model. 90, 91 
 Circulating levels of endothelin, a potent and long-acting vasoconstrictor, are 
low in normal individuals but increased during ischemia, with a further increase 
during reperfusion. 16 Endothelin-mediated vasoconstriction, neutrophil plugging, 
and microvascular permeability play a role in the pathogenesis of MVO. The signifi-
cant reduction of MVO and infarct size in a canine model after the administration of 
an endothelin A-receptor antagonist after 90 min of coronary occlusion supports 
this concept. 92 
 Selective administration of intracoronary adenosine attenuated functional and 
structural abnormalities of the microvasculature, leading to improved regional ven-
tricular function as compared with placebo in a canine model. 93 In the clinical set-
ting, however, although infarct size was reduced, a 3-hour infusion of adenosine in 
reperfused ST-segment elevation myocardial infarction patients failed to show an 
improved outcome in the AMISTAD II (Acute Myocardial Infarction STudy of ADeno-
sine) trial. 94 
 These discrepant results underscore the complex underlying mechanisms impli-
cated in the pathophysiology of MVO and suggest that successful therapy should be 
multitargeted. 
Conclusions 
Temporary coronary occlusion followed by reperfusion results in microvascular 
damage—with endothelial swelling, neutrophil activation, and entrapment—leading 
to reperfusion-induced myocardial damage. Microvascular flow after reperfusion is 
spatially and temporally complex. Regions of hyperemia, impaired vasodilatory flow 
reserve, and very low flow coexist. The magnitude and spatial extent of these perfu-
sion patterns vary over time as a result of reperfusion injury. Microvascular obstruc-
tion is independently associated with adverse LV remodeling and prognosis. There-
fore, its detection is crucial. Several techniques (coronary angiography, MCE, cardi-
ovascular MRI, ECG) measuring slightly different biological and functional parame-
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ters are used clinically and experimentally for the evaluation of MVO (Table 1). Cur-
rently, there is no consensus on how and when MVO should be evaluated after AMI. 
 
Table 1. Clinical Methods to Detect MVO. 
Technique Generally accepted as MVO reference 
Invasive 
Coronary angiography   
 TIMI flow ≤2 (42) 
 Corrected TIMI Frame Count >40 (49) 
Coronary blood flow patterns   
 Systolic retrograde flow >10 cm/sec (44, 45) 
 Diastolic flow velocity deceleration <600 msec (44, 45) 
Myocardial blush grade   
 TMP grade ≤1 (47, 50) 
   
Non-invasive   
MCE Contrast defect within area at risk despite angi- (2, 53) 
CMR  
 Early contrast enhancement Central hypoenhancement within the infarcted (7, 57, 58) 
 Late contrast enhancement  Central hypoenhancement within the area of (5, 59, 60) 
ECG   
 STR (60-90 min after reperfusion) <30%  (67, 70, 74) 
 STD (90 min after reperfusion) 1 mm for inferior MI (77) 
Abbreviations: MVO=microvascular obstruction; TIMI=Thrombolysis In Myocardial Infarction; TMP=TIMI 
myocardial perfusion; MCE=myocardial contrast echocardiography; CMR=cardiovascular magnetic reso-
nance; FPP=first pass perfusion; MI=myocardial infarction; STR=ST segment resolution; STD=ST segment 
deviation. 
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number of polymorphonuclear leukocytes present in the infarcted area. The inhibi-
tion of complement pathways decreased polymorphonuclear leukocyte free radical 
generation and enhanced the recovery of coronary flow in an isolated rat heart 
model. 90, 91 
 Circulating levels of endothelin, a potent and long-acting vasoconstrictor, are 
low in normal individuals but increased during ischemia, with a further increase 
during reperfusion. 16 Endothelin-mediated vasoconstriction, neutrophil plugging, 
and microvascular permeability play a role in the pathogenesis of MVO. The signifi-
cant reduction of MVO and infarct size in a canine model after the administration of 
an endothelin A-receptor antagonist after 90 min of coronary occlusion supports 
this concept. 92 
 Selective administration of intracoronary adenosine attenuated functional and 
structural abnormalities of the microvasculature, leading to improved regional ven-
tricular function as compared with placebo in a canine model. 93 In the clinical set-
ting, however, although infarct size was reduced, a 3-hour infusion of adenosine in 
reperfused ST-segment elevation myocardial infarction patients failed to show an 
improved outcome in the AMISTAD II (Acute Myocardial Infarction STudy of ADeno-
sine) trial. 94 
 These discrepant results underscore the complex underlying mechanisms impli-
cated in the pathophysiology of MVO and suggest that successful therapy should be 
multitargeted. 
Conclusions 
Temporary coronary occlusion followed by reperfusion results in microvascular 
damage—with endothelial swelling, neutrophil activation, and entrapment—leading 
to reperfusion-induced myocardial damage. Microvascular flow after reperfusion is 
spatially and temporally complex. Regions of hyperemia, impaired vasodilatory flow 
reserve, and very low flow coexist. The magnitude and spatial extent of these perfu-
sion patterns vary over time as a result of reperfusion injury. Microvascular obstruc-
tion is independently associated with adverse LV remodeling and prognosis. There-
fore, its detection is crucial. Several techniques (coronary angiography, MCE, cardi-
ovascular MRI, ECG) measuring slightly different biological and functional parame-
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ters are used clinically and experimentally for the evaluation of MVO (Table 1). Cur-
rently, there is no consensus on how and when MVO should be evaluated after AMI. 
 
Table 1. Clinical Methods to Detect MVO. 
Technique Generally accepted as MVO reference 
Invasive 
Coronary angiography   
 TIMI flow ≤2 (42) 
 Corrected TIMI Frame Count >40 (49) 
Coronary blood flow patterns   
 Systolic retrograde flow >10 cm/sec (44, 45) 
 Diastolic flow velocity deceleration <600 msec (44, 45) 
Myocardial blush grade   
 TMP grade ≤1 (47, 50) 
   
Non-invasive   
MCE Contrast defect within area at risk despite angi- (2, 53) 
CMR  
 Early contrast enhancement Central hypoenhancement within the infarcted (7, 57, 58) 
 Late contrast enhancement  Central hypoenhancement within the area of (5, 59, 60) 
ECG   
 STR (60-90 min after reperfusion) <30%  (67, 70, 74) 
 STD (90 min after reperfusion) 1 mm for inferior MI (77) 
Abbreviations: MVO=microvascular obstruction; TIMI=Thrombolysis In Myocardial Infarction; TMP=TIMI 
myocardial perfusion; MCE=myocardial contrast echocardiography; CMR=cardiovascular magnetic reso-
nance; FPP=first pass perfusion; MI=myocardial infarction; STR=ST segment resolution; STD=ST segment 
deviation. 
C H A P T E R  2  
 36
References 
1. An international randomized trial comparing four thrombolytic strategies for acute myocardial 
infarction. The GUSTO investigators. N Engl J Med. Sep 2 1993;329(10):673-682. 
2. Ito H, Tomooka T, Sakai N, et al. Lack of myocardial perfusion immediately after successful throm-
bolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction. 
Circulation. May 1992;85(5):1699-1705. 
3. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlu-
sion in the dog. J Clin Invest. Dec 1974;54(6):1496-1508. 
4. Gerber BL, Rochitte CE, Melin JA, et al. Microvascular obstruction and left ventricular remodeling 
early after acute myocardial infarction. Circulation. Jun 13 2000;101(23):2734-2741. 
5. Hombach V, Grebe O, Merkle N, et al. Sequelae of acute myocardial infarction regarding cardiac 
structure and function and their prognostic significance as assessed by magnetic resonance imaging. 
Eur Heart J. Mar 2005;26(6):549-557. 
6. Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of 'no-reflow' after percutaneous 
coronary intervention. Circulation. Jun 1994;89(6):2514-2518. 
7. Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by mag-
netic resonance imaging in patients with acute myocardial infarction. Circulation. Mar 3 
1998;97(8):765-772. 
8. Roe MT, Ohman EM, Maas AC, et al. Shifting the open-artery hypothesis downstream: the quest for 
optimal reperfusion. J Am Coll Cardiol. Jan 2001;37(1):9-18. 
9. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. Sep 13 2007;357(11):1121-
1135. 
10. Buja LM. Myocardial ischemia and reperfusion injury. Cardiovasc Pathol. Jul-Aug 2005;14(4):170-
175. 
11. Stanley WC. Cardiac energetics during ischaemia and the rationale for metabolic interventions. 
Coron Artery Dis. Feb 2001;12 Suppl 1:S3-7. 
12. Reimer KA, Lowe JE, Rasmussen MM, et al. The wavefront phenomenon of ischemic cell death. 1. 
Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation. Nov 1977;56(5):786-
794. 
13. Jennings RB, Steenbergen C, Jr., Reimer KA. Myocardial ischemia and reperfusion. Monogr Pathol. 
1995;37:47-80. 
14. Kloner RA, Rude RE, Carlson N, et al. Ultrastructural evidence of microvascular damage and myocar-
dial cell injury after coronary artery occlusion: which comes first? Circulation. Nov 1980;62(5):945-
952. 
15. Reimer KA, Jennings RB. The changing anatomic reference base of evolving myocardial infarction. 
Underestimation of myocardial collateral blood flow and overestimation of experimental anatomic 
infarct size due to tissue edema, hemorrhage and acute inflammation. Circulation. Oct 
1979;60(4):866-876. 
16. Virmani R, Forman MB, Kolodgie FD. Myocardial reperfusion injury. Histopathological effects of 
perfluorochemical. Circulation. Mar 1990;81(3 Suppl):IV57-68. 
17. Velasco CE, Turner M, Inagami T, et al. Reperfusion enhances the local release of endothelin after 
regional myocardial ischemia. Am Heart J. Sep 1994;128(3):441-451. 
18. Piper HM, Garcia-Dorado D, Ovize M. A fresh look at reperfusion injury. Cardiovasc Res. May 
1998;38(2):291-300. 
19. Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: a review of mechanisms and therapies. 
Eur Heart J. May 2001;22(9):729-739. 
20. Maxwell SR, Lip GY. Reperfusion injury: a review of the pathophysiology, clinical manifestations and 
therapeutic options. Int J Cardiol. Jan 31 1997;58(2):95-117. 
21. Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? J Clin Invest. Nov 
1985;76(5):1713-1719. 
P A T H O P H Y S I O L O G Y  A N D  D I A G N O S I S  O F  M V O  
 37 
22. Engler RL, Dahlgren MD, Morris DD, et al. Role of leukocytes in response to acute myocardial ische-
mia and reflow in dogs. Am J Physiol. Aug 1986;251(2 Pt 2):H314-323. 
23. Babior BM. The respiratory burst of phagocytes. J Clin Invest. Mar 1984;73(3):599-601. 
24. Erbel R, Heusch G. Coronary microembolization. J Am Coll Cardiol. Jul 2000;36(1):22-24. 
25. Kawano H, Hayashida T, Ohtani H, et al. Histopathological findings of the no-reflow phenomenon 
following coronary intervention for acute coronary syndrome. Int Heart J. Mar 2005;46(2):327-332. 
26. Saber RS, Edwards WD, Bailey KR, et al. Coronary embolization after balloon angioplasty or throm-
bolytic therapy: an autopsy study of 32 cases. J Am Coll Cardiol. Nov 1 1993;22(5):1283-1288. 
27. Davies MJ, Thomas AC, Knapman PA, et al. Intramyocardial platelet aggregation in patients with 
unstable angina suffering sudden ischemic cardiac death. Circulation. Mar 1986;73(3):418-427. 
28. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction 
and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral emboliza-
tion culminating in total vascular occlusion. Circulation. Apr 1985;71(4):699-708. 
29. Frink RJ, Rooney PA, Jr., Trowbridge JO, et al. Coronary thrombosis and platelet/fibrin microemboli 
in death associated with acute myocardial infarction. Br Heart J. Feb 1988;59(2):196-200. 
30. Hong MK, Popma JJ, Pichard AD, et al. Clinical significance of distal embolization after transluminal 
extraction atherectomy in diffusely diseased saphenous vein grafts. Am Heart J. Jun 
1994;127(6):1496-1503. 
31. Kaplan BM, Benzuly KH, Kinn JW, et al. Treatment of no-reflow in degenerated saphenous vein graft 
interventions: comparison of intracoronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn. 
Oct 1996;39(2):113-118. 
32. Stone GW, Webb J, Cox DA, et al. Distal microcirculatory protection during percutaneous coronary 
intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. 
Jama. Mar 2 2005;293(9):1063-1072. 
33. Henriques JP, Zijlstra F, Ottervanger JP, et al. Incidence and clinical significance of distal emboliza-
tion during primary angioplasty for acute myocardial infarction. Eur Heart J. Jul 2002;23(14):1112-
1117. 
34. Silva-Orrego P, Colombo P, Bigi R, et al. Thrombus aspiration before primary angioplasty improves 
myocardial reperfusion in acute myocardial infarction: the DEAR-MI (Dethrombosis to Enhance 
Acute Reperfusion in Myocardial Infarction) study. J Am Coll Cardiol. Oct 17 2006;48(8):1552-1559. 
35. Ambrosio G, Weisman HF, Mannisi JA, et al. Progressive impairment of regional myocardial perfu-
sion after initial restoration of postischemic blood flow. Circulation. Dec 1989;80(6):1846-1861. 
36. Judd RM, Lugo-Olivieri CH, Arai M, et al. Physiological basis of myocardial contrast enhancement in 
fast magnetic resonance images of 2-day-old reperfused canine infarcts. Circulation. Oct 1 
1995;92(7):1902-1910. 
37. Villanueva FS. Myocardial contrast echocardiography in acute myocardial infarction. Am J Cardiol. 
Nov 18 2002;90(10A):38J-47J. 
38. Reffelmann T, Kloner RA. Microvascular reperfusion injury: rapid expansion of anatomic no reflow 
during reperfusion in the rabbit. Am J Physiol Heart Circ Physiol. Sep 2002;283(3):H1099-1107. 
39. Rochitte CE, Lima JA, Bluemke DA, et al. Magnitude and time course of microvascular obstruction 
and tissue injury after acute myocardial infarction. Circulation. Sep 8 1998;98(10):1006-1014. 
40. Kennedy JW, Ritchie JL, Davis KB, et al. The western Washington randomized trial of intracoronary 
streptokinase in acute myocardial infarction. A 12-month follow-up report. N Engl J Med. Apr 25 
1985;312(17):1073-1078. 
41. Brener SJ, Moliterno DJ, Aylward PE, et al. Reperfusion after primary angioplasty for ST-elevation 
myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI 
angiographic study. Eur Heart J. May 2008;29(9):1127-1135. 
42. Morishima I, Sone T, Okumura K, et al. Angiographic no-reflow phenomenon as a predictor of ad-
verse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty 
for first acute myocardial infarction. J Am Coll Cardiol. Oct 2000;36(4):1202-1209. 
C H A P T E R  2  
 36
References 
1. An international randomized trial comparing four thrombolytic strategies for acute myocardial 
infarction. The GUSTO investigators. N Engl J Med. Sep 2 1993;329(10):673-682. 
2. Ito H, Tomooka T, Sakai N, et al. Lack of myocardial perfusion immediately after successful throm-
bolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction. 
Circulation. May 1992;85(5):1699-1705. 
3. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlu-
sion in the dog. J Clin Invest. Dec 1974;54(6):1496-1508. 
4. Gerber BL, Rochitte CE, Melin JA, et al. Microvascular obstruction and left ventricular remodeling 
early after acute myocardial infarction. Circulation. Jun 13 2000;101(23):2734-2741. 
5. Hombach V, Grebe O, Merkle N, et al. Sequelae of acute myocardial infarction regarding cardiac 
structure and function and their prognostic significance as assessed by magnetic resonance imaging. 
Eur Heart J. Mar 2005;26(6):549-557. 
6. Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of 'no-reflow' after percutaneous 
coronary intervention. Circulation. Jun 1994;89(6):2514-2518. 
7. Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by mag-
netic resonance imaging in patients with acute myocardial infarction. Circulation. Mar 3 
1998;97(8):765-772. 
8. Roe MT, Ohman EM, Maas AC, et al. Shifting the open-artery hypothesis downstream: the quest for 
optimal reperfusion. J Am Coll Cardiol. Jan 2001;37(1):9-18. 
9. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. Sep 13 2007;357(11):1121-
1135. 
10. Buja LM. Myocardial ischemia and reperfusion injury. Cardiovasc Pathol. Jul-Aug 2005;14(4):170-
175. 
11. Stanley WC. Cardiac energetics during ischaemia and the rationale for metabolic interventions. 
Coron Artery Dis. Feb 2001;12 Suppl 1:S3-7. 
12. Reimer KA, Lowe JE, Rasmussen MM, et al. The wavefront phenomenon of ischemic cell death. 1. 
Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation. Nov 1977;56(5):786-
794. 
13. Jennings RB, Steenbergen C, Jr., Reimer KA. Myocardial ischemia and reperfusion. Monogr Pathol. 
1995;37:47-80. 
14. Kloner RA, Rude RE, Carlson N, et al. Ultrastructural evidence of microvascular damage and myocar-
dial cell injury after coronary artery occlusion: which comes first? Circulation. Nov 1980;62(5):945-
952. 
15. Reimer KA, Jennings RB. The changing anatomic reference base of evolving myocardial infarction. 
Underestimation of myocardial collateral blood flow and overestimation of experimental anatomic 
infarct size due to tissue edema, hemorrhage and acute inflammation. Circulation. Oct 
1979;60(4):866-876. 
16. Virmani R, Forman MB, Kolodgie FD. Myocardial reperfusion injury. Histopathological effects of 
perfluorochemical. Circulation. Mar 1990;81(3 Suppl):IV57-68. 
17. Velasco CE, Turner M, Inagami T, et al. Reperfusion enhances the local release of endothelin after 
regional myocardial ischemia. Am Heart J. Sep 1994;128(3):441-451. 
18. Piper HM, Garcia-Dorado D, Ovize M. A fresh look at reperfusion injury. Cardiovasc Res. May 
1998;38(2):291-300. 
19. Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: a review of mechanisms and therapies. 
Eur Heart J. May 2001;22(9):729-739. 
20. Maxwell SR, Lip GY. Reperfusion injury: a review of the pathophysiology, clinical manifestations and 
therapeutic options. Int J Cardiol. Jan 31 1997;58(2):95-117. 
21. Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? J Clin Invest. Nov 
1985;76(5):1713-1719. 
P A T H O P H Y S I O L O G Y  A N D  D I A G N O S I S  O F  M V O  
 37 
22. Engler RL, Dahlgren MD, Morris DD, et al. Role of leukocytes in response to acute myocardial ische-
mia and reflow in dogs. Am J Physiol. Aug 1986;251(2 Pt 2):H314-323. 
23. Babior BM. The respiratory burst of phagocytes. J Clin Invest. Mar 1984;73(3):599-601. 
24. Erbel R, Heusch G. Coronary microembolization. J Am Coll Cardiol. Jul 2000;36(1):22-24. 
25. Kawano H, Hayashida T, Ohtani H, et al. Histopathological findings of the no-reflow phenomenon 
following coronary intervention for acute coronary syndrome. Int Heart J. Mar 2005;46(2):327-332. 
26. Saber RS, Edwards WD, Bailey KR, et al. Coronary embolization after balloon angioplasty or throm-
bolytic therapy: an autopsy study of 32 cases. J Am Coll Cardiol. Nov 1 1993;22(5):1283-1288. 
27. Davies MJ, Thomas AC, Knapman PA, et al. Intramyocardial platelet aggregation in patients with 
unstable angina suffering sudden ischemic cardiac death. Circulation. Mar 1986;73(3):418-427. 
28. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction 
and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral emboliza-
tion culminating in total vascular occlusion. Circulation. Apr 1985;71(4):699-708. 
29. Frink RJ, Rooney PA, Jr., Trowbridge JO, et al. Coronary thrombosis and platelet/fibrin microemboli 
in death associated with acute myocardial infarction. Br Heart J. Feb 1988;59(2):196-200. 
30. Hong MK, Popma JJ, Pichard AD, et al. Clinical significance of distal embolization after transluminal 
extraction atherectomy in diffusely diseased saphenous vein grafts. Am Heart J. Jun 
1994;127(6):1496-1503. 
31. Kaplan BM, Benzuly KH, Kinn JW, et al. Treatment of no-reflow in degenerated saphenous vein graft 
interventions: comparison of intracoronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn. 
Oct 1996;39(2):113-118. 
32. Stone GW, Webb J, Cox DA, et al. Distal microcirculatory protection during percutaneous coronary 
intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. 
Jama. Mar 2 2005;293(9):1063-1072. 
33. Henriques JP, Zijlstra F, Ottervanger JP, et al. Incidence and clinical significance of distal emboliza-
tion during primary angioplasty for acute myocardial infarction. Eur Heart J. Jul 2002;23(14):1112-
1117. 
34. Silva-Orrego P, Colombo P, Bigi R, et al. Thrombus aspiration before primary angioplasty improves 
myocardial reperfusion in acute myocardial infarction: the DEAR-MI (Dethrombosis to Enhance 
Acute Reperfusion in Myocardial Infarction) study. J Am Coll Cardiol. Oct 17 2006;48(8):1552-1559. 
35. Ambrosio G, Weisman HF, Mannisi JA, et al. Progressive impairment of regional myocardial perfu-
sion after initial restoration of postischemic blood flow. Circulation. Dec 1989;80(6):1846-1861. 
36. Judd RM, Lugo-Olivieri CH, Arai M, et al. Physiological basis of myocardial contrast enhancement in 
fast magnetic resonance images of 2-day-old reperfused canine infarcts. Circulation. Oct 1 
1995;92(7):1902-1910. 
37. Villanueva FS. Myocardial contrast echocardiography in acute myocardial infarction. Am J Cardiol. 
Nov 18 2002;90(10A):38J-47J. 
38. Reffelmann T, Kloner RA. Microvascular reperfusion injury: rapid expansion of anatomic no reflow 
during reperfusion in the rabbit. Am J Physiol Heart Circ Physiol. Sep 2002;283(3):H1099-1107. 
39. Rochitte CE, Lima JA, Bluemke DA, et al. Magnitude and time course of microvascular obstruction 
and tissue injury after acute myocardial infarction. Circulation. Sep 8 1998;98(10):1006-1014. 
40. Kennedy JW, Ritchie JL, Davis KB, et al. The western Washington randomized trial of intracoronary 
streptokinase in acute myocardial infarction. A 12-month follow-up report. N Engl J Med. Apr 25 
1985;312(17):1073-1078. 
41. Brener SJ, Moliterno DJ, Aylward PE, et al. Reperfusion after primary angioplasty for ST-elevation 
myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI 
angiographic study. Eur Heart J. May 2008;29(9):1127-1135. 
42. Morishima I, Sone T, Okumura K, et al. Angiographic no-reflow phenomenon as a predictor of ad-
verse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty 
for first acute myocardial infarction. J Am Coll Cardiol. Oct 2000;36(4):1202-1209. 
C H A P T E R  2  
 38
43. Gibson CM, Murphy SA, Rizzo MJ, et al. Relationship between TIMI frame count and clinical out-
comes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. 
Circulation. Apr 20 1999;99(15):1945-1950. 
44. Iwakura K, Ito H, Takiuchi S, et al. Alternation in the coronary blood flow velocity pattern in patients 
with no reflow and reperfused acute myocardial infarction. Circulation. Sep 15 1996;94(6):1269-
1275. 
45. Lepper W, Hoffmann R, Kamp O, et al. Assessment of myocardial reperfusion by intravenous myo-
cardial contrast echocardiography and coronary flow reserve after primary percutaneous translu-
minal coronary angioplasty [correction of angiography] in patients with acute myocardial infarction. 
Circulation. May 23 2000;101(20):2368-2374. 
46. Furber AP, Prunier F, Nguyen HC, et al. Coronary blood flow assessment after successful angioplasty 
for acute myocardial infarction predicts the risk of long-term cardiac events. Circulation. Dec 7 
2004;110(23):3527-3533. 
47. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of TIMI myocardial perfusion grade to mor-
tality after administration of thrombolytic drugs. Circulation. Jan 18 2000;101(2):125-130. 
48. van 't Hof AW, Liem A, Suryapranata H, et al. Angiographic assessment of myocardial reperfusion in 
patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. 
Zwolle Myocardial Infarction Study Group. Circulation. Jun 16 1998;97(23):2302-2306. 
49. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of the TIMI myocardial perfusion grades, flow 
grades, frame count, and percutaneous coronary intervention to long-term outcomes after throm-
bolytic administration in acute myocardial infarction. Circulation. Apr 23 2002;105(16):1909-1913. 
50. Henriques JP, Zijlstra F, van 't Hof AW, et al. Angiographic assessment of reperfusion in acute myo-
cardial infarction by myocardial blush grade. Circulation. Apr 29 2003;107(16):2115-2119. 
51. Kaul S. Coronary angiography cannot be used to assess myocardial perfusion in patients undergoing 
reperfusion for acute myocardial infarction. Heart. Nov 2001;86(5):483-484. 
52. Villanueva FS, Glasheen WP, Sklenar J, et al. Assessment of risk area during coronary occlusion and 
infarct size after reperfusion with myocardial contrast echocardiography using left and right atrial 
injections of contrast. Circulation. Aug 1993;88(2):596-604. 
53. Ito H, Okamura A, Iwakura K, et al. Myocardial perfusion patterns related to thrombolysis in myo-
cardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall 
myocardial infarction. Circulation. Jun 1 1996;93(11):1993-1999. 
54. Greaves K, Dixon SR, Fejka M, et al. Myocardial contrast echocardiography is superior to other 
known modalities for assessing myocardial reperfusion after acute myocardial infarction. Heart. Feb 
2003;89(2):139-144. 
55. Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the 'no reflow' phenomenon. A predic-
tor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarc-
tion. Circulation. Jan 15 1996;93(2):223-228. 
56. Porter TR, Li S, Oster R, et al. The clinical implications of no reflow demonstrated with intravenous 
perfluorocarbon containing microbubbles following restoration of Thrombolysis In Myocardial In-
farction (TIMI) 3 flow in patients with acute myocardial infarction. Am J Cardiol. Nov 15 
1998;82(10):1173-1177. 
57. Lima JA, Judd RM, Bazille A, et al. Regional heterogeneity of human myocardial infarcts demon-
strated by contrast-enhanced MRI. Potential mechanisms. Circulation. Sep 1 1995;92(5):1117-1125. 
58. Orn S, Manhenke C, Greve OJ, et al. Microvascular obstruction is a major determinant of infarct 
healing and subsequent left ventricular remodelling following primary percutaneous coronary inter-
vention. Eur Heart J. Jun 6 2009. 
59. Nijveldt R, Hofman MB, Hirsch A, et al. Assessment of microvascular obstruction and prediction of 
short-term remodeling after acute myocardial infarction: cardiac MR imaging study. Radiology. Feb 
2009;250(2):363-370. 
P A T H O P H Y S I O L O G Y  A N D  D I A G N O S I S  O F  M V O  
 39 
60. Yan AT, Gibson CM, Larose E, et al. Characterization of microvascular dysfunction after acute myo-
cardial infarction by cardiovascular magnetic resonance first-pass perfusion and late gadolinium en-
hancement imaging. J Cardiovasc Magn Reson. 2006;8(6):831-837. 
61. Simonetti OP, Kim RJ, Fieno DS, et al. An improved MR imaging technique for the visualization of 
myocardial infarction. Radiology. Jan 2001;218(1):215-223. 
62. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible 
injury, infarct age, and contractile function. Circulation. Nov 9 1999;100(19):1992-2002. 
63. Wu KC, Kim RJ, Bluemke DA, et al. Quantification and time course of microvascular obstruction by 
contrast-enhanced echocardiography and magnetic resonance imaging following acute myocardial 
infarction and reperfusion. J Am Coll Cardiol. Nov 15 1998;32(6):1756-1764. 
64. Lund GK, Stork A, Saeed M, et al. Acute myocardial infarction: evaluation with first-pass enhance-
ment and delayed enhancement MR imaging compared with 201Tl SPECT imaging. Radiology. Jul 
2004;232(1):49-57. 
65. Bekkers SC, Backes WH, Kim RJ, et al. Detection and characteristics of microvascular obstruction in 
reperfused acute myocardial infarction using an optimized protocol for contrast-enhanced cardio-
vascular magnetic resonance imaging. Eur Radiol. Jul 9 2009. 
66. Nijveldt R, Beek AM, Hirsch A, et al. Functional recovery after acute myocardial infarction: compari-
son between angiography, electrocardiography, and cardiovascular magnetic resonance measures 
of microvascular injury. J Am Coll Cardiol. Jul 15 2008;52(3):181-189. 
67. Barbash GI, Roth A, Hod H, et al. Rapid resolution of ST elevation and prediction of clinical outcome 
in patients undergoing thrombolysis with alteplase (recombinant tissue-type plasminogen activa-
tor): results of the Israeli Study of Early Intervention in Myocardial Infarction. Br Heart J. Oct 
1990;64(4):241-247. 
68. de Lemos JA, Antman EM, Giugliano RP, et al. ST-segment resolution and infarct-related artery 
patency and flow after thrombolytic therapy. Thrombolysis in Myocardial Infarction (TIMI) 14 inves-
tigators. Am J Cardiol. Feb 1 2000;85(3):299-304. 
69. Schroder R, Dissmann R, Bruggemann T, et al. Extent of early ST segment elevation resolution: a 
simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Car-
diol. Aug 1994;24(2):384-391. 
70. de Lemos JA, Braunwald E. ST segment resolution as a tool for assessing the efficacy of reperfusion 
therapy. J Am Coll Cardiol. Nov 1 2001;38(5):1283-1294. 
71. Feldman LJ, Coste P, Furber A, et al. Incomplete resolution of ST-segment elevation is a marker of 
transient microcirculatory dysfunction after stenting for acute myocardial infarction. Circulation. Jun 
3 2003;107(21):2684-2689. 
72. van 't Hof AW, Liem A, de Boer MJ, et al. Clinical value of 12-lead electrocardiogram after successful 
reperfusion therapy for acute myocardial infarction. Zwolle Myocardial infarction Study Group. Lan-
cet. Aug 30 1997;350(9078):615-619. 
73. Bekkers SC, Lemmert ME, Schalla S, et al. ST Segment Resolution After Reperfusion Therapy for 
Acute Myocardial Infarction is Related to Microvascular Obstruction (Abstr). Circulation. 2007;116 
Suppl II:II-425. 
74. Santoro GM, Valenti R, Buonamici P, et al. Relation between ST-segment changes and myocardial 
perfusion evaluated by myocardial contrast echocardiography in patients with acute myocardial in-
farction treated with direct angioplasty. Am J Cardiol. Oct 15 1998;82(8):932-937. 
75. Syed MA, Borzak S, Asfour A, et al. Single lead ST-segment recovery: a simple, reliable measure of 
successful fibrinolysis after acute myocardial infarction. Am Heart J. Feb 2004;147(2):275-280. 
76. Zeymer U, Schroder R, Tebbe U, et al. Non-invasive detection of early infarct vessel patency by 
resolution of ST-segment elevation in patients with thrombolysis for acute myocardial infarction; re-
sults of the angiographic substudy of the Hirudin for Improvement of Thrombolysis (HIT)-4 trial. Eur 
Heart J. May 2001;22(9):769-775. 
C H A P T E R  2  
 38
43. Gibson CM, Murphy SA, Rizzo MJ, et al. Relationship between TIMI frame count and clinical out-
comes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. 
Circulation. Apr 20 1999;99(15):1945-1950. 
44. Iwakura K, Ito H, Takiuchi S, et al. Alternation in the coronary blood flow velocity pattern in patients 
with no reflow and reperfused acute myocardial infarction. Circulation. Sep 15 1996;94(6):1269-
1275. 
45. Lepper W, Hoffmann R, Kamp O, et al. Assessment of myocardial reperfusion by intravenous myo-
cardial contrast echocardiography and coronary flow reserve after primary percutaneous translu-
minal coronary angioplasty [correction of angiography] in patients with acute myocardial infarction. 
Circulation. May 23 2000;101(20):2368-2374. 
46. Furber AP, Prunier F, Nguyen HC, et al. Coronary blood flow assessment after successful angioplasty 
for acute myocardial infarction predicts the risk of long-term cardiac events. Circulation. Dec 7 
2004;110(23):3527-3533. 
47. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of TIMI myocardial perfusion grade to mor-
tality after administration of thrombolytic drugs. Circulation. Jan 18 2000;101(2):125-130. 
48. van 't Hof AW, Liem A, Suryapranata H, et al. Angiographic assessment of myocardial reperfusion in 
patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. 
Zwolle Myocardial Infarction Study Group. Circulation. Jun 16 1998;97(23):2302-2306. 
49. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of the TIMI myocardial perfusion grades, flow 
grades, frame count, and percutaneous coronary intervention to long-term outcomes after throm-
bolytic administration in acute myocardial infarction. Circulation. Apr 23 2002;105(16):1909-1913. 
50. Henriques JP, Zijlstra F, van 't Hof AW, et al. Angiographic assessment of reperfusion in acute myo-
cardial infarction by myocardial blush grade. Circulation. Apr 29 2003;107(16):2115-2119. 
51. Kaul S. Coronary angiography cannot be used to assess myocardial perfusion in patients undergoing 
reperfusion for acute myocardial infarction. Heart. Nov 2001;86(5):483-484. 
52. Villanueva FS, Glasheen WP, Sklenar J, et al. Assessment of risk area during coronary occlusion and 
infarct size after reperfusion with myocardial contrast echocardiography using left and right atrial 
injections of contrast. Circulation. Aug 1993;88(2):596-604. 
53. Ito H, Okamura A, Iwakura K, et al. Myocardial perfusion patterns related to thrombolysis in myo-
cardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall 
myocardial infarction. Circulation. Jun 1 1996;93(11):1993-1999. 
54. Greaves K, Dixon SR, Fejka M, et al. Myocardial contrast echocardiography is superior to other 
known modalities for assessing myocardial reperfusion after acute myocardial infarction. Heart. Feb 
2003;89(2):139-144. 
55. Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the 'no reflow' phenomenon. A predic-
tor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarc-
tion. Circulation. Jan 15 1996;93(2):223-228. 
56. Porter TR, Li S, Oster R, et al. The clinical implications of no reflow demonstrated with intravenous 
perfluorocarbon containing microbubbles following restoration of Thrombolysis In Myocardial In-
farction (TIMI) 3 flow in patients with acute myocardial infarction. Am J Cardiol. Nov 15 
1998;82(10):1173-1177. 
57. Lima JA, Judd RM, Bazille A, et al. Regional heterogeneity of human myocardial infarcts demon-
strated by contrast-enhanced MRI. Potential mechanisms. Circulation. Sep 1 1995;92(5):1117-1125. 
58. Orn S, Manhenke C, Greve OJ, et al. Microvascular obstruction is a major determinant of infarct 
healing and subsequent left ventricular remodelling following primary percutaneous coronary inter-
vention. Eur Heart J. Jun 6 2009. 
59. Nijveldt R, Hofman MB, Hirsch A, et al. Assessment of microvascular obstruction and prediction of 
short-term remodeling after acute myocardial infarction: cardiac MR imaging study. Radiology. Feb 
2009;250(2):363-370. 
P A T H O P H Y S I O L O G Y  A N D  D I A G N O S I S  O F  M V O  
 39 
60. Yan AT, Gibson CM, Larose E, et al. Characterization of microvascular dysfunction after acute myo-
cardial infarction by cardiovascular magnetic resonance first-pass perfusion and late gadolinium en-
hancement imaging. J Cardiovasc Magn Reson. 2006;8(6):831-837. 
61. Simonetti OP, Kim RJ, Fieno DS, et al. An improved MR imaging technique for the visualization of 
myocardial infarction. Radiology. Jan 2001;218(1):215-223. 
62. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible 
injury, infarct age, and contractile function. Circulation. Nov 9 1999;100(19):1992-2002. 
63. Wu KC, Kim RJ, Bluemke DA, et al. Quantification and time course of microvascular obstruction by 
contrast-enhanced echocardiography and magnetic resonance imaging following acute myocardial 
infarction and reperfusion. J Am Coll Cardiol. Nov 15 1998;32(6):1756-1764. 
64. Lund GK, Stork A, Saeed M, et al. Acute myocardial infarction: evaluation with first-pass enhance-
ment and delayed enhancement MR imaging compared with 201Tl SPECT imaging. Radiology. Jul 
2004;232(1):49-57. 
65. Bekkers SC, Backes WH, Kim RJ, et al. Detection and characteristics of microvascular obstruction in 
reperfused acute myocardial infarction using an optimized protocol for contrast-enhanced cardio-
vascular magnetic resonance imaging. Eur Radiol. Jul 9 2009. 
66. Nijveldt R, Beek AM, Hirsch A, et al. Functional recovery after acute myocardial infarction: compari-
son between angiography, electrocardiography, and cardiovascular magnetic resonance measures 
of microvascular injury. J Am Coll Cardiol. Jul 15 2008;52(3):181-189. 
67. Barbash GI, Roth A, Hod H, et al. Rapid resolution of ST elevation and prediction of clinical outcome 
in patients undergoing thrombolysis with alteplase (recombinant tissue-type plasminogen activa-
tor): results of the Israeli Study of Early Intervention in Myocardial Infarction. Br Heart J. Oct 
1990;64(4):241-247. 
68. de Lemos JA, Antman EM, Giugliano RP, et al. ST-segment resolution and infarct-related artery 
patency and flow after thrombolytic therapy. Thrombolysis in Myocardial Infarction (TIMI) 14 inves-
tigators. Am J Cardiol. Feb 1 2000;85(3):299-304. 
69. Schroder R, Dissmann R, Bruggemann T, et al. Extent of early ST segment elevation resolution: a 
simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Car-
diol. Aug 1994;24(2):384-391. 
70. de Lemos JA, Braunwald E. ST segment resolution as a tool for assessing the efficacy of reperfusion 
therapy. J Am Coll Cardiol. Nov 1 2001;38(5):1283-1294. 
71. Feldman LJ, Coste P, Furber A, et al. Incomplete resolution of ST-segment elevation is a marker of 
transient microcirculatory dysfunction after stenting for acute myocardial infarction. Circulation. Jun 
3 2003;107(21):2684-2689. 
72. van 't Hof AW, Liem A, de Boer MJ, et al. Clinical value of 12-lead electrocardiogram after successful 
reperfusion therapy for acute myocardial infarction. Zwolle Myocardial infarction Study Group. Lan-
cet. Aug 30 1997;350(9078):615-619. 
73. Bekkers SC, Lemmert ME, Schalla S, et al. ST Segment Resolution After Reperfusion Therapy for 
Acute Myocardial Infarction is Related to Microvascular Obstruction (Abstr). Circulation. 2007;116 
Suppl II:II-425. 
74. Santoro GM, Valenti R, Buonamici P, et al. Relation between ST-segment changes and myocardial 
perfusion evaluated by myocardial contrast echocardiography in patients with acute myocardial in-
farction treated with direct angioplasty. Am J Cardiol. Oct 15 1998;82(8):932-937. 
75. Syed MA, Borzak S, Asfour A, et al. Single lead ST-segment recovery: a simple, reliable measure of 
successful fibrinolysis after acute myocardial infarction. Am Heart J. Feb 2004;147(2):275-280. 
76. Zeymer U, Schroder R, Tebbe U, et al. Non-invasive detection of early infarct vessel patency by 
resolution of ST-segment elevation in patients with thrombolysis for acute myocardial infarction; re-
sults of the angiographic substudy of the Hirudin for Improvement of Thrombolysis (HIT)-4 trial. Eur 
Heart J. May 2001;22(9):769-775. 
C H A P T E R  2  
 40
77. Cooper HA, de Lemos JA, Morrow DA, et al. Minimal ST-segment deviation: a simple, noninvasive 
method for identifying patients with a patent infarction-related artery after fibrinolytic administra-
tion. Am Heart J. Nov 2002;144(5):790-795. 
78. Krucoff MW, Johanson P, Baeza R, et al. Clinical utility of serial and continuous ST-segment recovery 
assessment in patients with acute ST-elevation myocardial infarction: assessing the dynamics of 
epicardial and myocardial reperfusion. Circulation. Dec 21 2004;110(25):e533-539. 
79. Gorgels AP, Vos MA, Letsch IS, et al. Usefulness of the accelerated idioventricular rhythm as a 
marker for myocardial necrosis and reperfusion during thrombolytic therapy in acute myocardial in-
farction. Am J Cardiol. Feb 1 1988;61(4):231-235. 
80. Gressin V, Gorgels A, Louvard Y, et al. ST-segment normalization time and ventricular arrhythmias as 
electrocardiographic markers of reperfusion during intravenous thrombolysis for acute myocardial 
infarction. Am J Cardiol. Jun 15 1993;71(16):1436-1439. 
81. Wehrens XH, Doevendans PA, Ophuis TJ, et al. A comparison of electrocardiographic changes during 
reperfusion of acute myocardial infarction by thrombolysis or percutaneous transluminal coronary 
angioplasty. Am Heart J. Mar 2000;139(3):430-436. 
82. Svilaas T, Vlaar PJ, van der Horst IC, et al. Thrombus aspiration during primary percutaneous coro-
nary intervention. N Engl J Med. Feb 7 2008;358(6):557-567. 
83. Amado LC, Kraitchman DL, Gerber BL, et al. Reduction of "no-reflow" phenomenon by intra-aortic 
balloon counterpulsation in a randomized magnetic resonance imaging experimental study. J Am 
Coll Cardiol. Apr 7 2004;43(7):1291-1298. 
84. Sjauw KD, Engstrom AE, Vis MM, et al. A systematic review and meta-analysis of intra-aortic balloon 
pump therapy in ST-elevation myocardial infarction: should we change the guidelines? Eur Heart J. 
Feb 2009;30(4):459-468. 
85. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thromboly-
sis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Cir-
culation. Jun 1 1999;99(21):2720-2732. 
86. de Lemos JA, Antman EM, Gibson CM, et al. Abciximab improves both epicardial flow and myocar-
dial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. Circula-
tion. Jan 25 2000;101(3):239-243. 
87. Kunichika H, Ben-Yehuda O, Lafitte S, et al. Effects of glycoprotein IIb/IIIa inhibition on microvascular 
flow after coronary reperfusion. A quantitative myocardial contrast echocardiography study. J Am 
Coll Cardiol. Jan 21 2004;43(2):276-283. 
88. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coro-
nary stenting for acute myocardial infarction. N Engl J Med. Jun 21 2001;344(25):1895-1903. 
89. Taniyama Y, Ito H, Iwakura K, et al. Beneficial effect of intracoronary verapamil on microvascular 
and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol. Nov 1 
1997;30(5):1193-1199. 
90. Prasad A, Stone GW, Stuckey TD, et al. Relation between leucocyte count, myonecrosis, myocardial 
perfusion, and outcomes following primary angioplasty. Am J Cardiol. Apr 15 2007;99(8):1067-1071. 
91. Shandelya SM, Kuppusamy P, Herskowitz A, et al. Soluble complement receptor type 1 inhibits the 
complement pathway and prevents contractile failure in the postischemic heart. Evidence that 
complement activation is required for neutrophil-mediated reperfusion injury. Circulation. Dec 
1993;88(6):2812-2826. 
92. Galiuto L, DeMaria AN, del Balzo U, et al. Ischemia-reperfusion injury at the microvascular level: 
treatment by endothelin A-selective antagonist and evaluation by myocardial contrast echocardi-
ography. Circulation. Dec 19 2000;102(25):3111-3116. 
93. Babbitt DG, Virmani R, Forman MB. Intracoronary adenosine administered after reperfusion limits 
vascular injury after prolonged ischemia in the canine model. Circulation. Nov 1989;80(5):1388-
1399. 
P A T H O P H Y S I O L O G Y  A N D  D I A G N O S I S  O F  M V O  
 41 
94. Ross AM, Gibbons RJ, Stone GW, et al. A randomized, double-blinded, placebo-controlled multicen-
ter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction 
(AMISTAD-II). J Am Coll Cardiol. Jun 7 2005;45(11):1775-1780. 
C H A P T E R  2  
 40
77. Cooper HA, de Lemos JA, Morrow DA, et al. Minimal ST-segment deviation: a simple, noninvasive 
method for identifying patients with a patent infarction-related artery after fibrinolytic administra-
tion. Am Heart J. Nov 2002;144(5):790-795. 
78. Krucoff MW, Johanson P, Baeza R, et al. Clinical utility of serial and continuous ST-segment recovery 
assessment in patients with acute ST-elevation myocardial infarction: assessing the dynamics of 
epicardial and myocardial reperfusion. Circulation. Dec 21 2004;110(25):e533-539. 
79. Gorgels AP, Vos MA, Letsch IS, et al. Usefulness of the accelerated idioventricular rhythm as a 
marker for myocardial necrosis and reperfusion during thrombolytic therapy in acute myocardial in-
farction. Am J Cardiol. Feb 1 1988;61(4):231-235. 
80. Gressin V, Gorgels A, Louvard Y, et al. ST-segment normalization time and ventricular arrhythmias as 
electrocardiographic markers of reperfusion during intravenous thrombolysis for acute myocardial 
infarction. Am J Cardiol. Jun 15 1993;71(16):1436-1439. 
81. Wehrens XH, Doevendans PA, Ophuis TJ, et al. A comparison of electrocardiographic changes during 
reperfusion of acute myocardial infarction by thrombolysis or percutaneous transluminal coronary 
angioplasty. Am Heart J. Mar 2000;139(3):430-436. 
82. Svilaas T, Vlaar PJ, van der Horst IC, et al. Thrombus aspiration during primary percutaneous coro-
nary intervention. N Engl J Med. Feb 7 2008;358(6):557-567. 
83. Amado LC, Kraitchman DL, Gerber BL, et al. Reduction of "no-reflow" phenomenon by intra-aortic 
balloon counterpulsation in a randomized magnetic resonance imaging experimental study. J Am 
Coll Cardiol. Apr 7 2004;43(7):1291-1298. 
84. Sjauw KD, Engstrom AE, Vis MM, et al. A systematic review and meta-analysis of intra-aortic balloon 
pump therapy in ST-elevation myocardial infarction: should we change the guidelines? Eur Heart J. 
Feb 2009;30(4):459-468. 
85. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thromboly-
sis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Cir-
culation. Jun 1 1999;99(21):2720-2732. 
86. de Lemos JA, Antman EM, Gibson CM, et al. Abciximab improves both epicardial flow and myocar-
dial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. Circula-
tion. Jan 25 2000;101(3):239-243. 
87. Kunichika H, Ben-Yehuda O, Lafitte S, et al. Effects of glycoprotein IIb/IIIa inhibition on microvascular 
flow after coronary reperfusion. A quantitative myocardial contrast echocardiography study. J Am 
Coll Cardiol. Jan 21 2004;43(2):276-283. 
88. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coro-
nary stenting for acute myocardial infarction. N Engl J Med. Jun 21 2001;344(25):1895-1903. 
89. Taniyama Y, Ito H, Iwakura K, et al. Beneficial effect of intracoronary verapamil on microvascular 
and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol. Nov 1 
1997;30(5):1193-1199. 
90. Prasad A, Stone GW, Stuckey TD, et al. Relation between leucocyte count, myonecrosis, myocardial 
perfusion, and outcomes following primary angioplasty. Am J Cardiol. Apr 15 2007;99(8):1067-1071. 
91. Shandelya SM, Kuppusamy P, Herskowitz A, et al. Soluble complement receptor type 1 inhibits the 
complement pathway and prevents contractile failure in the postischemic heart. Evidence that 
complement activation is required for neutrophil-mediated reperfusion injury. Circulation. Dec 
1993;88(6):2812-2826. 
92. Galiuto L, DeMaria AN, del Balzo U, et al. Ischemia-reperfusion injury at the microvascular level: 
treatment by endothelin A-selective antagonist and evaluation by myocardial contrast echocardi-
ography. Circulation. Dec 19 2000;102(25):3111-3116. 
93. Babbitt DG, Virmani R, Forman MB. Intracoronary adenosine administered after reperfusion limits 
vascular injury after prolonged ischemia in the canine model. Circulation. Nov 1989;80(5):1388-
1399. 
P A T H O P H Y S I O L O G Y  A N D  D I A G N O S I S  O F  M V O  
 41 
94. Ross AM, Gibbons RJ, Stone GW, et al. A randomized, double-blinded, placebo-controlled multicen-
ter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction 
(AMISTAD-II). J Am Coll Cardiol. Jun 7 2005;45(11):1775-1780. 
  42
 
 
D E T E C T I O N  A N D  C H A R A C T E R I S T I C S  O F  M V O  
 43 
 
CHAPTER 3 
 
Detection and characteristics of 
microvascular obstruction in reperfused 
acute myocardial infarction using an 
optimized protocol for contrast-
enhanced cardiovascular magnetic 
resonance imaging 
 
Chapter 3 
Detection and characteristics of MVO 
 
 
 
 
 
 
 
Bekkers SCAM, Backes WH, Kim RJ, Snoep G, Gorgels APM,  
Lima Passos V, Waltenberger JL, Crijns HJGM, Schalla S 
 
European Radiology 2009; 19 (12): 2904–2912 
  42
 
 
D E T E C T I O N  A N D  C H A R A C T E R I S T I C S  O F  M V O  
 43 
 
CHAPTER 3 
 
Detection and characteristics of 
microvascular obstruction in reperfused 
acute myocardial infarction using an 
optimized protocol for contrast-
enhanced cardiovascular magnetic 
resonance imaging 
 
Chapter 3 
Detection and characteristics of MVO 
 
 
 
 
 
 
 
Bekkers SCAM, Backes WH, Kim RJ, Snoep G, Gorgels APM,  
Lima Passos V, Waltenberger JL, Crijns HJGM, Schalla S 
 
European Radiology 2009; 19 (12): 2904–2912 
C H A P T E R  3  
 44
Abstract 
Several cardiovascular magnetic resonance imaging (CMR) techniques are used to 
detect microvascular obstruction (MVO) after acute myocardial infarction (AMI). To 
determine the prevalence of MVO and gain more insight into the dynamic changes 
in appearance of MVO, we studied 84 consecutive patients with a reperfused AMI 
on average 5 and 104 days after admission, using an optimized single breath-hold 
3D inversion recovery gradient echo pulse sequence (IR-GRE) protocol. Early MVO 
(2 min post-contrast) was detected in 53 patients (63%) and late MVO (10 min post-
contrast) in 45 patients (54%; p=0.008). The extent of MVO decreased from early to 
late imaging (4.3 ± 3.2% vs. 1.8 ± 1.8%, p<0.001) and showed a heterogeneous pat-
tern. At baseline, patients without MVO (early and late) had a higher left ventricular 
ejection fraction (LVEF) than patients with persistent late MVO (56 ± 7% vs. 48 ± 7%, 
p<0.001) and LVEF was intermediate in patients with early MVO but late MVO dis-
appearance (54 ± 6%). During follow-up, LVEF improved in all three subgroups but 
remained intermediate in patients with late MVO disappearance. This optimized 
single breath-hold 3D IR-GRE technique for imaging MVO early and late after con-
trast administration is fast, accurate and allows detection of patients with interme-
diate remodeling at follow-up. 
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Introduction 
Reperfusion therapy in patients with acute myocardial infarction (AMI) salvages 
myocardium and reduces mortality. 1–3 However, successful restoration of epicardial 
coronary artery patency after prolonged occlusion does not always lead to adequate 
reperfusion at the microvascular level. Previous studies have shown that the pres-
ence and absolute amount of microvascular obstruction (MVO) are associated with 
adverse left ventricular remodelling and prognosis. 4–7 Microvascular flow after re-
perfusion is spatially and temporally complex, with coexisting regions of hyperemia, 
impaired vasodilatory flow reserve, low flow and no reflow. The magnitude and 
spatial extent of these perfusion patterns vary over time. 8 
 MVO can be detected with cardiovascular magnetic resonance imaging (CMR) 
using the technique of first pass perfusion imaging (FPP) and traditional late con-
trast-enhanced CMR (late CE-CMR), but no consensus exists on which technique is 
more accurate. 5, 9–11 The importance of detecting MVO early after contrast injection 
is increasingly being recognized and has led to the development of additional CMR 
techniques. 12, 13 Whereas traditional late CE-CMR may underestimate the true ex-
tent of MVO as a result of diffusion of gadolinium into the area of MVO over time, 
FPP allows only incomplete coverage of the left ventricle and has a lower signal-to-
noise ratio and spatial resolution. When the technique of traditional late CE-CMR is 
performed early after contrast administration (early CE-CMR), the advantages of 
complete ventricular coverage, optimal signal-to-noise ratio (SNR) and spatial reso-
lution are combined and may overcome these shortcomings. 
 Optimal timing of imaging MVO and the dynamic changes of MVO over time in 
relation to clinical variables are not well known. In this study, a 3D inversion recov-
ery pulse sequence was used early and late after contrast administration to deter-
mine the prevalence of MVO and gain more insight into the dynamic changes in 
appearance of MVO in relation to clinical variables. For early imaging the inversion 
time of the imaging sequence was first optimized in a pilot study. 
Materials and methods 
Patients 
The study was approved by the institutional review board of our hospital, and pa-
tients were included after written informed consent was obtained. Between August 
2006 and March 2008, 84 consecutive patients with a first ST segment elevation 
myocardial infarction (STEMI) referred to our institution for primary percutaneous 
coronary intervention (PCI) and presentation less than 12 hours after symptom 
onset were prospectively studied. Definition of myocardial infarction (MI) was based 
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on the recent consensus document including appropriate rise and fall in cardiac 
biomarkers. 14 Excluded were patients with claustrophobia, contraindications for 
CMR (cerebral clips, pacemakers, defibrillators, neurostimulators), severe conges-
tive heart failure or cardiogenic shock (Killip class III and IV) at the time of CMR, 
atrial fibrillation, age below 18 years, severe renal failure (stage 4 or 5) and preg-
nancy. 
 Before emergency PCI all patients received aspirin (500 mg), heparin (5,000 U) 
and clopidogrel (600 mg). Use of thrombosuction and downstream administration 
of intravenous antiplatelet agents (abciximab), intracoronary nitroglycerine and 
adenosine were left to the discretion of the interventional cardiologist. 
 Cardiac biomarkers were sampled on admission, and at 6-, 12-, 18-, 24-, 36-, 48- 
and 72-hour intervals. Area under the curve (AUC) biomarker levels were derived 
and expressed as 1,000 h·units l-1. 
 
Figure 1. Look–Locker images (left panel) in a patient with regions of 
interest (ROIs) drawn in only one phase (right panel, enlarged from left 
panel). Left panel 39 phases of a single slice Look–Locker sequence in one 
of the eight patients. Right panel phase 20 is enlarged to demonstrate the 
different ROIs that were drawn in all phases: subendocardial hypoen-
hanced region (MVO) (dotted line), region directly adjacent to the hy-
poenhanced region (infarcted myocardium) (solid black line), region of 
noninfarcted (normal) myocardium (dotted-dashed line). 
CMR protocol 
Patients underwent CMR imaging 5 ± 2 days (range 2–10 days) and 104 ± 11 days 
(range 88–122 days) after admission. Images were acquired during multiple breath-
holds on a 1.5 Tesla MRI system (Philips Intera, Philips Medical Systems, Best, The 
Netherlands) with a cardiac software package and dedicated five-element phased 
array surface coil. ECG-gated cine images were obtained for functional analysis 
using a steady-state free precession sequence (slice thickness 6 mm, slice gap 4 mm, 
average repetition time (TR) and echo time (TE) 3.8/1.9 ms, respectively, flip angle 
50°, FOV 350 mm, matrix 256 × 256, typically 22–25 phases per cardiac cycle), in the 
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following orientations: single slice two-chamber long axis, three-chamber long axis, 
four-chamber long axis, and a short axis stack covering the left ventricle (LV) from 
the base to apex (typically 10–14 slices). 
 Subsequently, a single breath-hold (15–20 s) 3D inversion recovery gradient 
echo sequence completely covering the LV was used for early and late CE-CMR (ac-
quired slice thickness 12 mm, reconstructed slice thickness 6 mm, average TR/TE 
3.9/2.4 ms, multishot (50 profiles/shot) segmented partial echo readout every 
heartbeat (TFE), flip angle 15°, FOV 400 mm, matrix 256 × 256, acquired and recon-
structed pixel size 1.56 × 1.56 mm, typically 16–18 slices). The pulse sequence was 
run at 2 and 10 min after intravenous administration of 0.2 mmol/kg body weight 
gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA, Magnevist®, Schering, 
Germany; injection rate 3 ml/s). For early CE-CMR, the inversion time was first op-
timized in a pilot study: 
 
 
Figure 2. Signal intensity curves obtained from the Look–Locker sequence (A) and merit function of 
contrast and SNR. The MR-derived quantity was normalized to the maximum value (B). (A) Signal 
intensity (SI) curves in the region of microvascular obstruction (MVO), infarcted and noninfarcted 
myocardium obtained from Look–Locker inversion recovery images in a representative patient. Maxi-
mum contrast (i.e. SI difference) between MVO and infarcted myocardium would be obtained at an 
inversion time of approximately 340 ms. b Combining optimised contrast and overall signal, the merit 
function provides a much less broader optimum at an inversion time of 465 ms for this case than for 
the contrast between MVO and infarcted area. Note the broad maximum in (B) and the relatively low 
signal at 340 ms (i.e. maximal SI difference in this case) in (A). 
Pilot study to find optimal TI for early CE-CMR 
 
We set out to find an optimal inversion time (TI) for early CE-CMR. For this, Look–
Locker images acquired 2 min after intravenous administration of gadolinium 
(0.2 mmol/kg body weight; injection rate 3 ml/s) were quantitatively analyzed in 
eight separate patients. This Look–Locker gradient echo (GRE) pulse sequence (slice 
thickness 10 mm, average TR/TE 3.6/1.7 ms, multishot (3 profiles/shot) segmented 
full echo readout every heartbeat, flip angle 8°, FOV 370 mm, resolution 256 × 256, 
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on the recent consensus document including appropriate rise and fall in cardiac 
biomarkers. 14 Excluded were patients with claustrophobia, contraindications for 
CMR (cerebral clips, pacemakers, defibrillators, neurostimulators), severe conges-
tive heart failure or cardiogenic shock (Killip class III and IV) at the time of CMR, 
atrial fibrillation, age below 18 years, severe renal failure (stage 4 or 5) and preg-
nancy. 
 Before emergency PCI all patients received aspirin (500 mg), heparin (5,000 U) 
and clopidogrel (600 mg). Use of thrombosuction and downstream administration 
of intravenous antiplatelet agents (abciximab), intracoronary nitroglycerine and 
adenosine were left to the discretion of the interventional cardiologist. 
 Cardiac biomarkers were sampled on admission, and at 6-, 12-, 18-, 24-, 36-, 48- 
and 72-hour intervals. Area under the curve (AUC) biomarker levels were derived 
and expressed as 1,000 h·units l-1. 
 
Figure 1. Look–Locker images (left panel) in a patient with regions of 
interest (ROIs) drawn in only one phase (right panel, enlarged from left 
panel). Left panel 39 phases of a single slice Look–Locker sequence in one 
of the eight patients. Right panel phase 20 is enlarged to demonstrate the 
different ROIs that were drawn in all phases: subendocardial hypoen-
hanced region (MVO) (dotted line), region directly adjacent to the hy-
poenhanced region (infarcted myocardium) (solid black line), region of 
noninfarcted (normal) myocardium (dotted-dashed line). 
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quired slice thickness 12 mm, reconstructed slice thickness 6 mm, average TR/TE 
3.9/2.4 ms, multishot (50 profiles/shot) segmented partial echo readout every 
heartbeat (TFE), flip angle 15°, FOV 400 mm, matrix 256 × 256, acquired and recon-
structed pixel size 1.56 × 1.56 mm, typically 16–18 slices). The pulse sequence was 
run at 2 and 10 min after intravenous administration of 0.2 mmol/kg body weight 
gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA, Magnevist®, Schering, 
Germany; injection rate 3 ml/s). For early CE-CMR, the inversion time was first op-
timized in a pilot study: 
 
 
Figure 2. Signal intensity curves obtained from the Look–Locker sequence (A) and merit function of 
contrast and SNR. The MR-derived quantity was normalized to the maximum value (B). (A) Signal 
intensity (SI) curves in the region of microvascular obstruction (MVO), infarcted and noninfarcted 
myocardium obtained from Look–Locker inversion recovery images in a representative patient. Maxi-
mum contrast (i.e. SI difference) between MVO and infarcted myocardium would be obtained at an 
inversion time of approximately 340 ms. b Combining optimised contrast and overall signal, the merit 
function provides a much less broader optimum at an inversion time of 465 ms for this case than for 
the contrast between MVO and infarcted area. Note the broad maximum in (B) and the relatively low 
signal at 340 ms (i.e. maximal SI difference in this case) in (A). 
Pilot study to find optimal TI for early CE-CMR 
 
We set out to find an optimal inversion time (TI) for early CE-CMR. For this, Look–
Locker images acquired 2 min after intravenous administration of gadolinium 
(0.2 mmol/kg body weight; injection rate 3 ml/s) were quantitatively analyzed in 
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39 phases, phase interval 15 ms) was applied at the short axis level with the most 
pronounced wall motion abnormalities. For analysis, epicardial and endocardial 
contours were manually drawn in each phase. Additional regions of interest (ROIs) 
were defined in: (1) a subendocardial hypoenhanced region (MVO), (2) a region 
adjacent to the hypoenhanced region (infarcted myocardium) and (3) noninfarcted 
(normal) myocardium (Figure 1). All contours and ROIs were carefully adjusted for 
cardiac motion as a result of contraction and breathing. The signal intensities (SI) of 
MVO, infarcted and noninfarcted myocardium were determined as a function of the 
Look–Locker TI (Figure 2A). Measured inversion recovery SI curves were mathemati-
cally fitted to the inversion recovery magnetization function, which provides esti-
mates of the T1 relaxation time of these tissue regions 15. T1 parameter estimations 
were calculated in the MATLAB (The MathWorks, Natick, MA) programming envi-
ronment using a Levenberg–Marquardt nonlinear fitting algorithm. As the imple-
mented Look–Locker pulse sequences provided magnitude images, the Rician noise 
distribution was taken into account. 16 
 
Subsequently, the fitted SI curves of MVO and infarcted myocardium were sub-
tracted to find the TI of maximum contrast, where contrast was defined as the dif-
ference in signal intensity (SI) between MVO and adjacent infarcted myocardium: 
 
ΔSI (TI) = SIinfarct (TI) − SIMVO (TI) 
 
The TI for which this contrast between MVO and adjacent infarcted myocardium 
was maximal would at first sight provide the optimal TI for early CE-CMR (Fig-
ure 2A). However, a broad range of TI values (approximately 300–700 ms) were 
found with suboptimal overall signal characteristics of normal and infarcted myo-
cardium. 
It was beneficial to use higher TI values, because higher signal levels will be acquired 
at nearly constant contrast, but with improved endocardial and epicardial border 
definition. This observation led us to define a merit function (MF), which was de-
fined as the product of the signal difference between MVO and infarcted myocar-
dium multiplied by the signal intensity of noninfarcted myocardium (SInormal) (Fig-
ure 2B): 
MF(TI) = [SIinfarct (TI) − SIMVO (TI)] × SInormal 
 
With this approach, both contrast and signal characteristics were simultaneously 
optimized. The merit function had a more narrow range of optimal TI values. The TI 
value of 530 ms (528 ± 201 ms), for which this merit function has its maximum, was 
used for subsequent early CE-CMR. 
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Early CE-CMR 
 
With the inversion time (TI) set to 530 ms, images showed increased signal intensity 
of the blood pool in the ventricular lumen, infarcted and noninfarcted myocardium. 
MVO was defined as a central hypoenhanced region within the area of the infarct-
related artery (Figure 3, left panel). 
Late CE-CMR 
 
Based on the results of a Look–Locker sequence run at 10 min after contrast injec-
tion (8 min after early CE-CMR), images were then acquired with an individually set 
inversion time (typical range 200–280 ms) to optimally “null” noninfarcted myocar-
dium. MVO was defined as a persistent central hypoenhanced area within the 
hyperenhanced area (Figure 3, right panel). 
 
 
Figure 3. Early (left panel) and late CE-CMR images (right panel) in one of 
the patients. Two sets of four contiguous short axis slices at midlevel of 
the LV in a patient 5 days after reperfused acute anteroseptal wall myo-
cardial infarction. Left panel 2 min after contrast injection: the blood pool 
(*) and myocardium show increased signal intensity (arrow), except for a 
central dark anteroseptal rim (arrowhead; early MVO). Right panel late 
hyper- and hypoenhancement: 10 min after contrast injection, signal from 
noninfarcted myocardium is “nulled” (black arrow) and the infarcted 
myocardium is hyperenhanced (white arrow). A dark central rim is ob-
served within the bright area (late MVO; arrowhead). 
CMR image analysis 
CMR images were analyzed off-line using commercially available software (CAAS 
MRV 3.0, Pie Medical Imaging, Maastricht, the Netherlands) blinded to clinical in-
formation. Endocardial and epicardial contours were manually traced in end-
diastolic and end-systolic short axis slices to determine left ventricular end-diastolic 
volume (LVEDV) and left ventricular end-systolic volume (LVESV), left ventricular 
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39 phases, phase interval 15 ms) was applied at the short axis level with the most 
pronounced wall motion abnormalities. For analysis, epicardial and endocardial 
contours were manually drawn in each phase. Additional regions of interest (ROIs) 
were defined in: (1) a subendocardial hypoenhanced region (MVO), (2) a region 
adjacent to the hypoenhanced region (infarcted myocardium) and (3) noninfarcted 
(normal) myocardium (Figure 1). All contours and ROIs were carefully adjusted for 
cardiac motion as a result of contraction and breathing. The signal intensities (SI) of 
MVO, infarcted and noninfarcted myocardium were determined as a function of the 
Look–Locker TI (Figure 2A). Measured inversion recovery SI curves were mathemati-
cally fitted to the inversion recovery magnetization function, which provides esti-
mates of the T1 relaxation time of these tissue regions 15. T1 parameter estimations 
were calculated in the MATLAB (The MathWorks, Natick, MA) programming envi-
ronment using a Levenberg–Marquardt nonlinear fitting algorithm. As the imple-
mented Look–Locker pulse sequences provided magnitude images, the Rician noise 
distribution was taken into account. 16 
 
Subsequently, the fitted SI curves of MVO and infarcted myocardium were sub-
tracted to find the TI of maximum contrast, where contrast was defined as the dif-
ference in signal intensity (SI) between MVO and adjacent infarcted myocardium: 
 
ΔSI (TI) = SIinfarct (TI) − SIMVO (TI) 
 
The TI for which this contrast between MVO and adjacent infarcted myocardium 
was maximal would at first sight provide the optimal TI for early CE-CMR (Fig-
ure 2A). However, a broad range of TI values (approximately 300–700 ms) were 
found with suboptimal overall signal characteristics of normal and infarcted myo-
cardium. 
It was beneficial to use higher TI values, because higher signal levels will be acquired 
at nearly constant contrast, but with improved endocardial and epicardial border 
definition. This observation led us to define a merit function (MF), which was de-
fined as the product of the signal difference between MVO and infarcted myocar-
dium multiplied by the signal intensity of noninfarcted myocardium (SInormal) (Fig-
ure 2B): 
MF(TI) = [SIinfarct (TI) − SIMVO (TI)] × SInormal 
 
With this approach, both contrast and signal characteristics were simultaneously 
optimized. The merit function had a more narrow range of optimal TI values. The TI 
value of 530 ms (528 ± 201 ms), for which this merit function has its maximum, was 
used for subsequent early CE-CMR. 
 
 
D E T E C T I O N  A N D  C H A R A C T E R I S T I C S  O F  M V O  
 49 
Early CE-CMR 
 
With the inversion time (TI) set to 530 ms, images showed increased signal intensity 
of the blood pool in the ventricular lumen, infarcted and noninfarcted myocardium. 
MVO was defined as a central hypoenhanced region within the area of the infarct-
related artery (Figure 3, left panel). 
Late CE-CMR 
 
Based on the results of a Look–Locker sequence run at 10 min after contrast injec-
tion (8 min after early CE-CMR), images were then acquired with an individually set 
inversion time (typical range 200–280 ms) to optimally “null” noninfarcted myocar-
dium. MVO was defined as a persistent central hypoenhanced area within the 
hyperenhanced area (Figure 3, right panel). 
 
 
Figure 3. Early (left panel) and late CE-CMR images (right panel) in one of 
the patients. Two sets of four contiguous short axis slices at midlevel of 
the LV in a patient 5 days after reperfused acute anteroseptal wall myo-
cardial infarction. Left panel 2 min after contrast injection: the blood pool 
(*) and myocardium show increased signal intensity (arrow), except for a 
central dark anteroseptal rim (arrowhead; early MVO). Right panel late 
hyper- and hypoenhancement: 10 min after contrast injection, signal from 
noninfarcted myocardium is “nulled” (black arrow) and the infarcted 
myocardium is hyperenhanced (white arrow). A dark central rim is ob-
served within the bright area (late MVO; arrowhead). 
CMR image analysis 
CMR images were analyzed off-line using commercially available software (CAAS 
MRV 3.0, Pie Medical Imaging, Maastricht, the Netherlands) blinded to clinical in-
formation. Endocardial and epicardial contours were manually traced in end-
diastolic and end-systolic short axis slices to determine left ventricular end-diastolic 
volume (LVEDV) and left ventricular end-systolic volume (LVESV), left ventricular 
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ejection fraction (LVEF), and left ventricular end-diastolic mass and were indexed to 
body surface area (BSA). Endocardial and epicardial contours were manually traced 
on both early and late CE-CMR images. The presence or absence of MVO was de-
termined independently by two experienced observers. Infarct size was measured 
on the late CE-CMR images by manual planimetry of hyperenhanced areas (includ-
ing central hypoenhancement if present) and expressed as a percentage of LV mass. 
Statistical analysis 
Continuous data are expressed as mean ± SD or as median and range when non-
normally distributed. Categorical data are expressed as frequencies with percentag-
es. Differences between patients with and without early MVO were tested using an 
unpaired t test. Spearman’s rank correlation coefficient (r) was used to determine 
correlations. The differences between proportions of paired categorical data were 
analyzed using McNemar’s test. All images were independently analyzed by two 
observers blinded to the clinical data to determine the presence or absence of 
MVO, both for early and late. The interobserver agreement between readers was 
analyzed by using kappa (κ) statistics. The same statistics was used to check agree-
ment between early and late MVO by one observer only. Unless otherwise stated, a 
two-tailed p-value less than 0.05 was considered statistically significant. 
 Depending on the MVO status, patients were classified into three groups: those 
without MVO on early and late CE-CMR (absence), those with MVO on both early 
and late CE-CMR (persistence), and those with MVO on early but not late CE-CMR 
(disappearance). Comparisons among these groups were conducted either with the 
parametric one-way ANOVA or the nonparametric Kruskal–Wallis test for conti-
nuous variables. Post hoc pairwise comparisons were Bonferroni corrected. For 
categorical variables Chi-squared or Fisher’s exact tests were applied. Logistic univa-
riable regression models were fitted to investigate which variables individually were 
significantly associated with presence of MVO (persistence or disappearance). Sub-
sequently, only significant predictors (at a 0.1 significance level) were added to a 
multivariate model to estimate their independent/adjusted effects. Similarly, univa-
riable logistic regression followed by multivariable analyses were conducted to 
detect independent predictors of MVO disappearance. 
 A paired sample t test was used to investigate whether LVEDV index and LVEF 
significantly changed between baseline and follow-up measurements. Statistical 
analysis was performed with SPSS software (version 15.0 for Windows; SPSS Inc., 
Chicago, Illinois). 
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Results 
The mean patient age was 60 ± 11 years and 61 (73%) were men (Table 1). Most 
myocardial infarctions involved the right coronary artery (55%), followed by the left 
anterior descending (32%) and circumflex artery (13%). More than half of the pa-
tients had single vessel disease (52%). PCI with stenting was performed in 80 pa-
tients (95%). In four patients no PCI was performed because of baseline thromboly-
sis in myocardial infarction (TIMI) 3 flow and a residual stenosis less than 30%. 
Thrombosuction was performed in 26 patients (31%), and intracoronary adenosine 
or nitroglycerine was given in 57 patients (68%). Downstream abciximab was given 
in 43 patients (51%). Final TIMI 3 flow was established in 75 patients (89%) and TIMI 
2 flow in the remaining 9 patients (11%). The mean time from symptom onset to 
first balloon inflation or stent placement (total ischemic time) was 219 ± 85 min. 
Mean CK area under the curve (AUC) was 54 ± 37 (1,000 h·units l-1). Mean infarct 
size was 16 ± 11% of the LV mass. 
 
Table 1. Patient characteristics 
Characteristic Value 
Age (years) 60 ± 11 
Male sex 61 (73) 
BMI 27 ± 4 
Smoking 74 (88) 
Hypercholesterolaemia 30 (36) 
Diabetes 5 (6) 
Previous angina pectoris 38 (45) 
Culprit 
 RCA 46 (55) 
 LAD 27 (32) 
 Cx 11 (13) 
Number of diseased vessels * 
 One 44 (52) 
 Two 19 (23) 
 Three 21 (25) 
Thrombosuction 26 (31) 
Time to balloon inflation (minutes) 219 ± 85 
Adenosine or nitroglycerine i.c. 57 (68) 
Abciximab downstream 43 (51) 
Final TIMI 3 flow 75 (89) 
CK (AUC, 1,000 h·units l−1) 54 ± 37 
Infarct size (% of LV mass) 16 ± 11 
Values are presented as number of patients with percentages in parentheses or
mean ± standard deviation. Abbreviations: i.c.=intracoronary, AUC=area under the 
curve, BMI=body mass index, RCA=right coronary artery, LAD=left anterior descend-
ing artery, Cx=circumflex artery. *stenosis greater than 70%. 
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Early CE-CMR 
 
MVO on early CE-CMR was observed in 53 patients (63%). The extent of MVO was 
4.3 ± 3.2% of the LV mass; expressed as absolute values this was 7.8 ± 6.4 g. Com-
pared with patients with absence of MVO, those with MVO had a higher left ventri-
cular end-systolic volume index (LVESVi) (45 ± 13 ml/m2 vs. 37 ± 11 ml/m2, p=0.008), 
lower ejection fraction (49 ± 7% vs. 56 ± 7%, p<0.001), larger infarct size (21 ± 9% vs. 
6 ± 8%, p<0.001) and higher CK AUC (68 ± 32 vs. 30 ± 31 (1,000 h U l−1), p<0.001). 
Left ventricular end-diastolic volume index (LVEDVi) and LV mass tended to be high-
er in patients with MVO but did not reach statistical significance (86 ± 17 ml/m2 vs. 
81 ± 14 ml/m2, p=0.2 and 64 ± 12 g/m2 vs. 59 ± 10g/m2, p=0.07, respectively). 
 In the multivariable analysis with variables from Table 1, only infarct size re-
mained an independent predictor of the presence of MVO (expβ (OR) 1.2, 95%CI 
1.1–1.3, p<0.0001). 
Late CE-CMR 
 
MVO on late CE-CMR (persistence of MVO) was observed in 45 patients (54%) com-
pared with 53 (63%) patients with MVO on early CE-CMR (p=0.008). Late MVO dis-
appeared in eight patients (9%) at the later time point. Late MVO was always found 
at the same location as early MVO (Figure 3). The agreement between early and late 
MVO (κ=0.8, p<0.001, Table 2) and the correlation between the extent of early and 
late MVO were good (r=0.8, p<0.0001, Figure 4). The interobserver agreement for 
the presence or absence of early and late MVO was excellent (k value 0.9 for both 
early and late measurements, p<0.001). 
 
Table 2. Agreement between early and late MVO 
Early MVO Late MVO 
 Yes (%) No (%) Total (%) 
Yes (%) 45 (54) 8 (9) 53 (63) 
No (%) 0 31 (37) 31 (37) 
Total (%) 45 (54) 39 (46) 84 (100) 
Values are presented as number of patients with percentages in parenthes-
es. Good agreement was found between early and late MVO (κ=0.8, 
p<0.001). 
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Figure 4. Correlation between early and late 
MVO. A good correlation was found between 
the extent of early and persistent late MVO. 
The average extent of early MVO was larger 
than that of persistent late MVO (r=0.78, 
p<0.001). The dotted line represents the line of 
identity and emphasizes the inequality of the 
measures. 
 
Figure 5. Change in the extent of MVO. In all pa-
tients, the extent of early MVO decreased signifi-
cantly but showed a heterogeneous pattern (MVO 
persistence (x····x)). In eight patients early MVO 
disappeared during late CE-CMR (•─•). These 
patients had a significantly smaller extent of early 
MVO than the patients with persistence of MVO 
(0.8% ± 0.4% vs. 5 ± 3.1%, p<0.001). 
Early vs. late CE-CMR 
 
In all except one patient, the extent of MVO decreased significantly from early to 
late imaging (4.3 ± 3.2% vs. 1.8 ± 1.8%, p<0.001, Figures 3 and 5). The median 
decrement in all patients was 66% (range 0–100%); expressed as absolute amounts 
this resulted in a median decrement of 3.4 g (range 0–21 g). The individual decre-
ment was quite heterogeneous (Figure 5). 
Thus, early MVO was absent in 31 (37%) patients, persisted in 45 (54%) patients and 
disappeared in 8 (9%) patients during late CE-CMR. Most baseline characteristics 
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Early CE-CMR 
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Late CE-CMR 
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Values are presented as number of patients with percentages in parenthes-
es. Good agreement was found between early and late MVO (κ=0.8, 
p<0.001). 
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Figure 4. Correlation between early and late 
MVO. A good correlation was found between 
the extent of early and persistent late MVO. 
The average extent of early MVO was larger 
than that of persistent late MVO (r=0.78, 
p<0.001). The dotted line represents the line of 
identity and emphasizes the inequality of the 
measures. 
 
Figure 5. Change in the extent of MVO. In all pa-
tients, the extent of early MVO decreased signifi-
cantly but showed a heterogeneous pattern (MVO 
persistence (x····x)). In eight patients early MVO 
disappeared during late CE-CMR (•─•). These 
patients had a significantly smaller extent of early 
MVO than the patients with persistence of MVO 
(0.8% ± 0.4% vs. 5 ± 3.1%, p<0.001). 
Early vs. late CE-CMR 
 
In all except one patient, the extent of MVO decreased significantly from early to 
late imaging (4.3 ± 3.2% vs. 1.8 ± 1.8%, p<0.001, Figures 3 and 5). The median 
decrement in all patients was 66% (range 0–100%); expressed as absolute amounts 
this resulted in a median decrement of 3.4 g (range 0–21 g). The individual decre-
ment was quite heterogeneous (Figure 5). 
Thus, early MVO was absent in 31 (37%) patients, persisted in 45 (54%) patients and 
disappeared in 8 (9%) patients during late CE-CMR. Most baseline characteristics 
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were not found to be related to absence, persistence and disappearance of MVO 
(Table 3). 
 At baseline, infarct size and CK AUC were smallest and lowest in patients with 
absence of MVO, and largest for patients with persistence of late MVO (30 ± 31 vs. 
73 ± 32 (1,000 h·units l-1) and 6 ± 8% vs. 23 ± 9%, p<0.001 for both). In addition, LVEF 
was highest in patients with absence of MVO, and lowest for patients with persis-
tence of MVO (56 ± 7 vs. 48 ± 7%, p<0.001).  
 The eight patients with disappearance of MVO had an infarct size and LVEF that 
was intermediate between those of patients with absence and persistence of MVO 
(12 ± 4% and 54 ± 6%, respectively, Table 3). These eight patients had a significantly 
smaller extent of early MVO than patients with persistent late MVO (0.8 ± 0.4% vs. 
5 ± 3.1%, p<0.001, Figure 5). 
 None of the clinical variables from Table 3 was found to be a significant predic-
tor of MVO disappearance. From the CMR variables and after correction, only a 
smaller extent of early MVO remained independently associated with disappear-
ance of late MVO (expβ (OR) 0.034, 95%CI 0.001–0.908, p<0.04). 
Follow-up CMR 
LVEDV index decreased and LVEF increased in all three subgroups as compared with 
baseline (Table 3). LVEF remained highest in patients without MVO as compared 
with patients with persistence of late MVO (59 ± 6% vs. 51 ± 7%, p<0.001). LVEF in 
patients with late MVO disappearance remained intermediate (55 ± 4%). 
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Table 3. Patient characteristics in relation to MVO category (absence, disappearance and persistence) 
 Early MVO  
 Absent Present  
  (n=31) Disappearance  Persistence p-value 
Age (years) 61 ± 9 61 ± 10 59 ± 13 0.8 
Male sex  22 (71) 5 (63) 34 (76) 0.7 
BMI  27 ± 4 26 ± 2 27 ± 4 0.7 
Smoking  26 (84) 7 (88) 41 (91) 0.6 
Hypercholesterolaemia   8 (35) 2 (29) 13 (37) 0.9 
Diabetes   3 (10) 0 2 (4) 0.4 
Previous angina pectoris  11 (36) 2 (25) 20 (44) 0.5 
Anterior localisation of MI   7 (23) 1 (13) 19 (42) 0.08 
3 vessel disease*  8 (26) 1 (13) 12 (27) 0.7 
Thrombosuction  9 (29) 2 (25) 15 (33) 0.9 
Time to balloon inflation (minutes) 232 ± 96 196 ± 80 215 ± 80 0.6 
Adenosine or nitroglycerine i.c.  21 (68) 5 (63) 31 (69) 0.9 
Abciximab downstream  12 (39) 5 (63) 26 (58) 0.2 
Final TIMI 3 flow  27 (90) 5 (71) 41 (91) 0.3 
Total CK (AUC,  1,000 h·units l−1) 30 ± 31† 39 ± 14‡ 73 ± 32†, ‡ <0.001 
Baseline CMR     
 LVEDVi (ml/m2) 81 ± 14 87 ± 17 86 ± 17 0.2 
 LVEF (%) 56 ± 7† 54 ± 6 48 ± 7† <0.001 
 Infarct size  (% LV) 6 ± 8† 12 ± 4‡  23 ± 9†, ‡ <0.001 
 Early MVO size (% of LV) 0† 0.8 ± 0.4 5 ± 3.1† <0.001 
Follow-up CMR     
 LVEDVi (ml/m2) 76 ± 17 85 ± 16 84 ± 20 0.2 
 LVEF (%) 59 ± 6† 55 ± 4 51 ± 7† <0.001 
Values are presented as number of patients with percentages in parentheses or mean ± standard devia-
tion. Abbreviations: BMI=body mass index; MI=myocardial infarction; i.c.=intracoronary; AUC=area 
under the curve; LVEDVi left ventricular end-diastolic volume index; LVEF left ventricular ejection frac-
tion; MVO=microvascular obstruction. *Stenosis greater than 70%. The superscripts (†, ‡) indicate signifi-
cant pairwise group comparison.  
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Discussion 
The findings of this study in 84 patients with a reperfused first acute STEMI can be 
summarized as follows. First, the prevalence of MVO early after contrast injection at 
2 min. (early MVO) is higher than with traditional late CE-CMR at 10 min. (late MVO) 
using an optimized single breath-hold 3D inversion recovery gradient echo tech-
nique. Second, the extent of MVO decreases significantly depending on the time of 
imaging after contrast administration and this decrease is quite heterogeneous 
(Figures 3 and 5). Only the extent of early MVO is independently associated with 
persistence of late MVO. At baseline, patients with absence of MVO (early and late) 
have a significantly smaller infarct size and higher LVEF than patients with persis-
tence of late MVO. In patients with early but late disappearance of MVO (n=8), 
infarct size and LVEF are intermediate between those with absence and persistence 
of MVO and LVEF remains intermediate at follow-up. 
 The prevalence of MVO not only depends on the timing of imaging after infarc-
tion but also on the timing of imaging after contrast administration. 9, 17 In addition, 
it depends on the imaging technique used and as a consequence the reported pre-
valence of MVO has been inconsistent, ranging between 38 and 84% using FPP and 
between 28 and 36% using traditional late enhancement imaging. 9, 18 Although the 
numbers were not greatly different, we found that the prevalence of MVO using 
early CE-CMR at 2 min after contrast administration was significantly higher com-
pared with late CE-CMR. Early MVO completely filled in during late CE-CMR in 9% of 
patients. 
 Despite the importance of detecting MVO in AMI patients, a ‘gold standard’ for 
the clinical detection of MVO has not been established yet. Several techniques mea-
suring slightly different biological parameters are currently used (TIMI flow, blush 
grade, ST segment resolution, myocardial contrast echocardiography and scintigra-
phy). In addition, different CMR techniques are being used such as traditional late 
CE-CMR, contrast-enhanced cine MR imaging, T2-weighted imaging and FPP, but the 
sensitivity is still undetermined. 5, 9–11, 17, 19–22 
 For the detection of early MVO, FPP seems sensitive because of its histopatho-
logical correlation to MVO, as measured with thioflavin S staining and radioactive 
microsphere blood flow measurements in experimental studies. 23 FPP, however, is 
hampered by incomplete left ventricular coverage, low SNR and low spatial resolu-
tion. Because of these shortcomings, other fast CMR techniques are increasingly 
being used for the detection of MVO early after contrast administration, including 
3D T1-weighted inversion recovery gradient echo techniques. 13, 24 However, these 
studies did not specify the inversion times that were used for early imaging. Be-
cause we first optimized the inversion time for early imaging our approach allows 
imaging of the complete LV within a single breath-hold with good resolution, signal 
and contrast to noise. 
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 As we used the same pulse sequence for early and late CE-CMR, except for 
different inversion times, this enabled us to accurately evaluate the dynamic 
changes in appearance of MVO over time. In all but one patient the extent of MVO 
significantly decreased from early to late imaging. We found a great heterogeneity 
in the shrinkage of MVO over time, indicating that the prevalence of MVO is only 
one part of the larger underlying pathophysiology of MVO (Figures 3 and 5). For the 
first time we have described this heterogeneity in the shrinkage of MVO by using 
CMR. It likely represents the underlying heterogeneity in tissue perfusion, which 
was previously demonstrated in experimental studies. Negligible flow within the 
infarct core and progressively increasing flow towards the outer edges of the in-
farcted region are likely related to varying degrees of microvascular damage and 
obstruction. 23, 25, 26 Whether this relates to varying degrees of remodeling over time 
or carries adverse prognostic information is currently unknown and needs to be 
studied further. 
 Our protocol enabled us to distinguish an additional group of patients with early 
but disappearance of late MVO. Recently, Nijveldt et al. compared three CMR tech-
niques (early, intermediate and late hypoenhancement imaging) but did not specifi-
cally describe this subgroup. 13 They found intermediate hypoenhancement in only 
two additional patients (3%) compared with late hypoenhancement, whereas we 
observed this in eight additional patients (9%). Although late hypoenhancement was 
the strongest predictor of LV remodeling over time in their study, we have shown 
that these patients have an LVEF that is intermediate at baseline and after follow-
up. This may imply that these patients represent an intermediate risk group and 
should not be excluded from future therapies for MVO. 
 There are some limitations to our study. The inversion times used for the 3D 
inversion recovery sequence of both early and late CE-CMR were determined with a 
Look–Locker sequence. Although both sequences are gradient echo (GRE) readouts, 
the inherent difference in sequence parameters may cause differences in the 
amount of T1 weighting. It is therefore possible that the inversion times determined 
in our study are close but may be slightly out of kilter with the optimal inversion 
times for early and late CE-CMR. As the TI used in early CE-CMR was far above the 
“null” point for normal myocardium, small uncertainties in the optimal TI for early 
CE-CMR are not that critical as those for late CE-CMR. The optimal TI for late CE-
CMR is traditionally set to “null” healthy myocardium 10–15 min. after contrast 
administration in each patient. This is not possible for early CE-CMR, as the 2-min. 
interval is too short for individual patients. Therefore, optimal TI for early CE-CMR 
was first determined in a pilot study. 
 The 2-min. interval was chosen in line with histopathological validation of MVO 
in earlier studies. 17, 23 With even earlier imaging (i.e. 30 sec.) sensitivity may in-
crease but specificity may be decreased, because central hypoenhancement may 
appear in the setting of significant epicardial coronary disease even in the absence 
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of myocardial infarction. Moreover, in our study we were interested in the dynamic 
change in appearance of MVO over time. Earlier imaging might have possibly shown 
a greater level of dynamic change. However, because most patients showed sub-
stantial shrinkage of MVO, the exact timing of early imaging is not expected to be 
that critical. 
Conclusion 
Using an optimized single breath-hold 3D inversion recovery gradient echo pulse 
sequence, the prevalence of MVO early after the injection of contrast medium is 
higher than with traditional late CE-CMR. Our results show that the appearance of 
MVO is dynamic and heterogeneous, and imaging MVO early and late after contrast 
administration may give more information about the severity and pathophysiology 
of MVO. In addition, this approach allows the discrimination of MVO subgroups that 
have different infarct sizes and remodeling parameters. 
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Abstract 
Objectives 
To investigate the clinical implications of microvascular obstruction (MVO) and 
intramyocardial hemorrhage (IMH) in acute myocardial infarction (AMI). 
Methods 
Ninety patients with a first AMI undergoing primary percutaneous coronary inter-
vention (PCI) were studied. T2-weighted, cine and delayed enhancement cardiovas-
cular magnetic resonance imaging was performed at 5 ± 2 and 103 ± 11 days. Pa-
tients were categorized into three groups based on the presence or absence of 
MVO and IMH. 
Results 
MVO was observed in 54% and IMH in 43% of patients, and correlated significantly 
(r=0.8, p<0.001). Pre-PCI thrombolysis in myocardial infarction 3 flow was only ob-
served in MVO(−)/IMH(−) patients. Infarct size and impairment of systolic function 
were largest in MVO(+)/IMH(+) patients (n=39, 23 ± 9% and 47 ± 7%), smallest in 
MVO(−)/IMH(−) patients (n=41, 8 ± 8% and 55 ± 8%) and intermediate in 
MVO(+)/IMH(−) patients (n=10, 16 ± 7% and 51 ± 6%, p<0.001). LVEF increased in all 
three subgroups at follow-up, but remained intermediate in MVO(+)/IMH(−) and 
was lowest in MVO(+)/IMH(+) patients. Using random intercept model analysis, only 
infarct size was an independent predictor for adverse LV remodeling. 
Conclusions  
IMH and MVO are strongly related. Pre-PCI TIMI 3 flow is less frequently observed in 
patients with MVO and IMH. Only infarct size was an independent predictor of LV 
remodeling. 
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Introduction 
Coronary occlusion that persists for more than 40 min. leads to irreversible myocar-
dial damage that starts in the endocardium and progresses towards the epicardium 
as a wavefront phenomenon. 1 Although timely reperfusion salvages myocardium 
and reduces mortality, successful restoration of epicardial artery patency after pro-
longed occlusion does not always lead to adequate reperfusion at the microvascular 
level. Reperfused acute myocardial infarction (AMI) is characterized by myocyte 
swelling due to osmotic overload, intracellular calcium overload, myocyte hypercon-
traction, microvascular obstruction (MVO) and intramyocardial hemorrhage (IMH). 
2, 3 
 Both MVO and IMH occur exclusively in myocardium that sustains the most 
severe ischemia and are therefore confined to the central portions of infarcted 
myocardium. 3 As IMH is caused by extravasation of blood into the extravascular 
space as a consequence of ischemic microvascular damage, it only occurs in reper-
fused AMI. 4, 5 IMH does not depend on the magnitude of early reflow but, similar to 
MVO, on the severity of ischemia as reflected by a longer duration of coronary oc-
clusion and low collateral flow. 6, 7 
 Cardiovascular magnetic resonance imaging (CMR) is currently regarded as the 
reference standard to assess myocardial infarction and allows the detection of MVO 
and IMH in vivo, using delayed enhancement (DE) and T2-weighted (T2W) imaging. 
8–10 Previous studies have suggested that MVO might be associated with adverse 
ventricular remodeling and clinical outcome. 9, 11–14 The clinical significance of IMH is 
less well defined, and conflicting results have been reported. 15, 16 
 In this study, we sought to investigate the clinical implications of both MVO and 
IMH with regard to LV remodeling. 
Methods 
Study population 
We studied 90 consecutive patients (65 men, age 60 ± 11 years) with a first AMI 
referred for primary percutaneous coronary intervention (PCI) and presentation <12 
h after symptom onset. The definition of AMI was based on the recent consensus 
document including appropriate rise and fall in cardiac biomarkers. 17 Excluded were 
patients <18 years and those with contraindications for CMR. The institutional re-
view board of our hospital approved the study, and patients were included after 
written informed consent was obtained. 
 Before emergency PCI all patients received 500 mg aspirin, 5,000 U heparin and 
600 mg clopidogrel. The culprit coronary artery was the LAD in 31%, the RCA in 56% 
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and LCx in 13% of patients; single vessel disease was present in 52%, two vessel 
disease in 23% and three vessel disease in 25%. All patients received standard post-
PCI care, including dual antiplatelet therapy for at least 1 month. Thrombosuction, 
which was not standard treatment at the time of this study, and downstream ad-
ministration of intravenous abciximab, intracoronary nitroglycerine and adenosine 
were left to the discretion of the interventional cardiologist. 
Cardiovascular magnetic resonance imaging protocol 
CMR was performed at 5 ± 2 days and 103 ± 11 days after admission. Images were 
acquired on a 1.5 Tesla MRI system (Intera, Philips Medical Systems, Best, The 
Netherlands) with a dedicated five-element phased array surface coil. For functional 
analysis, ECG-gated cine images were obtained in the LV short axis plane covering 
the entire LV using a segmented balanced steady-state free precession sequence 
(slice thickness 6 mm, slice gap 4 mm, average repetition time (TR) and echo time 
(TE) 3.8/1.9 ms, respectively, flip angle 50°, FOV 350 mm, matrix 256 × 256, typically 
22–25 phases per cardiac cycle). Next, a breath-hold, multislice, black blood T2-
weighted turbo spin-echo sequence with short inversion time and fat suppression 
was used (T2 SPIR, slice thickness 8 mm, slice gap 2 mm, TR two R-R intervals and TE 
100 ms, FOV 350 mm, matrix 236 x 186). DE CMR was performed 10 min. after an 
intravenous bolus of 0.2 mmol/kg body weight gadolinium-diethylenetri-
aminepentaacetic acid (Magnevist®, Bayer Schering Pharma, Berlin, Germany) using 
a breathhold three-dimensional inversion-recovery gradient-echo sequence (ac-
quired slice thickness 12 mm, reconstructed slice thickness 6 mm, average TR/TE 
3.9/2.4 ms, multi-shot (50 profiles/shot) segmented partial echo readout every 
heart beat (TFE), flip angle 15°, FOV 400 mm, matrix 256 × 256, acquired and recon-
structed pixel size 1.56 × 1.56 mm). The inversion time that optimally suppressed 
signal of non-infarcted myocardium (typical range 200–280 ms) was determined 
with a preceding Look-Locker sequence. 
CMR image analysis 
The CMR images were analyzed independently by two observers blinded to clinical 
data, using commercially available software (CAAS MRV 3.0, Pie Medical Imaging, 
Maastricht, The Netherlands). The interobserver agreement was excellent (κ value 
0.9). Discrepancies were resolved in consensus. Endocardial and epicardial borders 
were manually traced, excluding the papillary muscles, in the end-diastolic and end-
systolic short-axis phases to determine left ventricular end-diastolic volume 
(LVEDV), end-systolic volume (LVESV), stroke volume (LVSV), ejection fraction (LVEF) 
and end-diastolic mass (LV mass). These parameters were indexed for body surface 
area. 
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 Likewise, endocardial and epicardial contours were manually traced on the DE 
and T2W images, which were viewed as separate sets. The T2W images of the first 
CMR examination were used to determine the presence or absence of IMH, defined 
as a central hypoenhanced area within the hyperintense edematous area, indicative 
of the area at risk (AAR). The AAR was quantified by semiautomatic detection using 
a signal intensity (SI) threshold of >2 SD above a remote non-infarcted region and 
expressed as a percentage of LV mass. Subendocardial ‘slow flow’ artifacts were 
carefully excluded, and areas of IMH were included in the AAR analysis by manual 
adjustment of contours. IMH was manually traced and expressed as a percentage of 
LV mass. 
 Infarct size (IS) was quantified on the DE images of the first CMR using an SI 
threshold of >5 SD above a remote non-infarcted reference region, including areas 
of MVO (central hypoenhancement within hyperenhanced area) and expressed as a 
percentage of LV mass. MVO was quantified by manually tracing the central hy-
poenhanced area and expressed as a percentage of LV mass. 
Statistics 
Summary statistics of continuous data with symmetric distribution are expressed as 
mean ± standard deviation (SD), otherwise as median with interquartile range (IQR). 
Categorical data are expressed as frequencies with percentages. Univariate group 
comparisons were conducted with the one-way ANOVA or the non-parametric 
Kruskal-Wallis test for continuous variables. For categorical variables, chi-square or 
Fisher’s exact tests were applied. Adjustment for multiple testing was conducted via 
the false discovery rate (FDR). Detected differences were considered significant 
when the corrected FDR p-value was <0.05. A multiple OLS linear regression model 
was fitted to quantify the association between IMH and MVO for the 
MVO(+)/IMH(+) group, adjusting for other clinical variables. To stabilize residual 
variance, IMH and MVO values, expressed as a proportion of the LV mass, were 
logarithmically transformed (ln). The final model was used to predict IMH size for 
the remaining 10 MVO(+)/IMH(−) patients. The estimated IMH values could provide 
some indication of the possible underlying reasons for the absence of IMH in these 
patients. A random intercept model analysis was conducted to determine indepen-
dent predictors of LV remodeling. Statistical analysis was performed with SPSS soft-
ware (version 17.0 for Windows; SPSS Inc., Chicago, IL). 
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Figure 1. Correlation between IMH and MVO. (A) Original scale values. (B) Log transformed values. A 
good linear correlation is seen between MVO and IMH (r=0.86, p<0.001). Open circles indicate observed 
values and stars indicate predicted values in the MVO(+)/IMH(-) group. Note that most of the predicted 
values are within the lower range of observed values. 
Results 
IMH and MVO 
Signal intensity on the T2W and LGE images within the territory of the IRA was in-
creased in all patients. The AAR and IS were 26 ± 12% and 15 ± 11% of LV mass, 
respectively. MVO was observed in 49 (54%) and IMH in 39 patients (43%), and both 
were always located subendocardially within the infarct core. IMH was only ob-
served in patients with MVO. A significant correlation was found between MVO and 
IMH extent (r=0.8, p<0.001, Figure 1), but absolute MVO extent was larger than that 
of IMH [3.1 ml (IQR 1.6–5.3) vs. 2.2 ml (IQR 1.6–3.5), p=0.04].  
 
Subgroups 
 
Based on the presence or absence of MVO and IMH, patients were classified into 
three groups: 41 patients with MVO(−)/IMH(−), 10 with MVO(+)/IMH(−) and 39 with 
MVO(+)/IMH(+) (Figure 2). For most of the baseline characteristics, there were no 
significant differences between groups (Table 1), except for pre-PCI TIMI 3 flow, 
which was only observed in the MVO(−)/IMH(−) group. There was no difference in 
the use of glycoprotein IIbIIIa inhibitor between groups. 
 The AAR and IS were largest in the MVO(+)/IMH(+) group, intermediate in the 
MVO(+)/IMH(−) group and smallest in the MVO(−)/IMH(−) group (Table 1). 
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Table 1. Baseline characteristics. 
 Group  
 MVO (-)/IMH(-) MVO(+)/IMH(-) MVO(+)/IMH(+) FDR 
Age (years) 61 ± 9 59 ± 15 59 ± 12 0.64 
Male (%) 27 (66) 6 (60) 32 (82) 0.29 
DM (%) 4 (10) 1 (10) 1 (3) 0.49 
Smoking (%) 33 (80) 9 (90) 36 (92) 0.38 
Hypertension (%) 20 (49) 3 (30) 12 (31) 0.35 
Hypercholesterolemia (%) 11 (27) 3 (30) 11 (28) 0.95 
Positive family history (%) 16 (39) 3 (30) 22 (56) 0.29 
Anterior location (%) 10 (24) 2 (20) 16 (41) 0.30 
Previous angina (%) 13 (32) 3 (30) 21 (54) 0.20 
     
GIIbIIIa inhibitor (%) 17 (41) 5 (50) 23 (59) 0.38 
TIMI 3      
 Pre-PCI (%) 10 (24)  0 (0)  0 (0)  0.004 
Rentrop ≥2 (%) 9 (22) 5 (50) 7 (18) 0.20 
Thrombosuction  (%) 9 (22) 2 (20) 11 (28) 0.89 
Time to PCI (min.) 217 (165-304) 177 (148-248) 201 (160-291) 0.65 
     
AAR (%) 19 ± 12*, † 27 ± 8* 33 ± 9† <0.001 
IS (%) 8 ± 8*, † 16 ± 7*, ‡ 23 ± 9†, ‡ <0.001 
Myocardial salvage (%) 54 ± 32* 40 ± 25 28 ± 24* 0.004 
MVO (% of LV mass) 0 0.8 (0.4-1.9) 1.7 (1.0-3.3) 0.07 
IMH (% of LV mass) 0 0 1.6 (1.0-2.4)  
Values are presented as mean ± SD or median and IQR; Abbreviations: AAR=area at risk; DM=diabetes 
mellitus; IS=infarct size at baseline; IHM=intramyocardial hemorrhage; MVO=microvascular obstruction; 
PCI=percutaneous coronary intervention. Superscripts (*, †, ‡) indicate significant post-hoc, pairwise 
group comparison. 
 
Myocardial salvage, defined as the difference between AAR and IS, was lowest in 
the MVO(+)/IMH(+) group, intermediate in the MVO(+)/IMH(−) group and highest in 
the MVO(−)/IMH(−) group (28 ± 24%, 40 ± 25% and 54 ± 32%, respectively, p<0.001, 
Table 1 and Figure 3). 
 The MVO extent tended to be larger in the MVO(+)/IMH(+) patients compared 
with the MVO(+)/IMH(−) patients (1.7% (IQR 1.0–3.3%) vs. 0.8% (IQR 0.4–1.9%) of 
LV mass, respectively, p=0.07). 
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Figure 2. Magnetic resonance image 
examples from each patient group. Top 
row (A, B): MVO(−)/IMH(−) patient; 
middle row (C, D): MVO(+)/IMH(−) 
patient; bottom row (E, F): MVO(+)/ 
(IMH(+) patient. T2-weighted images are 
shown on the left (A, C, E) and corres-
ponding delayed enhancement images 
on the right (B, D, F). Edema and infarct 
border zones are indicated by arrow-
heads and IMH and MVO by asterisks. 
 
 
Figure  3. Area at risk (AAR) and infarct size 
(IS). AAR (grey bars) and IS (white bars) 
represented as percentages of LV mass for 
each patient group. The MVO(+)/IMH(−) 
group represents an intermediate group. 
Myocardial salvage is the difference be-
tween AAR and IS. 
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Predicted IMH size in patients with MVO but without IMH 
The IMH in the MVO(+)/IMH(−) patients could have been missed as a result of the 
limits of spatial resolution of T2W-CMR. To investigate this, predicted IMH size val-
ues for MVO(+)/IMH(−) were calculated based on the following model derived from 
the MVO(+)/IMH(+) group data: 
 
(ln_IMH = -0.348 + 0.718 × ln_MVO + 0.454 × sex + 0.395 × smoke). 
 
All predictors in the above model were statistically significant. Observed and pre-
dicted IMH values are displayed in Figure 1A and 1B. Predicted values are marked as 
stars. In either case it is evident that only two patients had sufficiently small pre-
dicted IMH outside the observed value range in the other patients. Theoretically, 
these two values could have been missed by T2W-CMR. Conversely, several of the 
predicted values were still of sufficient size, at least comparable to that of the ob-
served counterparts, and as such they could have been detected by CMR. 
 
Table 2. Functional parameters at baseline and follow up.
 Group  
 MVO (-)/IMH(-) MVO(+)/IMH(-) MVO (+)/IMH(+) FDR 
LVEDVi (mL/m2)   
 Baseline 81 ± 14* 86 ± 15 88 ± 17* 0.24 
 Follow-up  78 ± 18† 76 ± 12 88 ± 20† 0.13 
LVESVi (mL/m2)     
 Baseline 38 ± 11* 43 ± 11 47 ± 13* 0.01 
 Follow-up 34 ± 12† 34 ± 6 45 ± 15† 0.01 
LVEF (%)     
 Baseline 55 ± 8* 51 ± 6 47 ± 7* <0.001 
 Follow-up 57 ± 7† 55 ± 3 50 ± 7† <0.001 
Values are presented as mean ± SD; Abbreviations: IMH=intramyocardial hemorrhage; LVEDVi=left ventri-
cular end diastolic volume index; LVESVi=left ventricular end-systolic volume index; LVEF=left ventricular 
ejection fraction; MVO=microvascular obstruction. Superscripts (*, †) indicate significant post-hoc, pairwise 
group comparison. 
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Figure 4. Left ventricular ejection frac-
tion (LVEF) at baseline and follow-up. 
LVEF significantly increased in all three 
groups from baseline (grey bars) to fol-
low-up CMR (white bars), but remained 
intermediate in the MVO(+)/IMH(−) 
group 
 
Functional parameters and LV remodeling 
The LVEDVi and LVESVi decreased from baseline to follow-up and were highest in 
the MVO(+)/MVO(+) group, intermediate in the MVO(+)/IMH(−) group and lowest in 
the MVO(−)/IMH(−) group at both time points (Table 2). Likewise, LVEF improved in 
all three groups, but remained lowest in the MVO(+)/MVO(+) group, intermediate in 
the MVO(+)/IMH(−) group and highest in the MVO(−)/IMH(−) group in the univariate 
comparisons (Figure 4). 
 Table 3 displays the fixed effect parameter estimates of the random intercept 
model. Subjects were taken as random effect, whereas time and MVO/IMH groups 
were taken as fixed effect factors adjusted for IS. LVEF significantly increased over 
time (for all groups), showing a significant negative association with IS. Note that 
the presence of IMH or MVO had no significant independent predictive value for 
LVEF once adjusted for IS. 
 
Table 3. Fixed effect parameter estimates of the random intercept model.
Outcome variable: LVEF. 
 β (SE) p-value
Intercept 55.651 (2.086) <0.001
IS -0.452 (0,071) <0.001 
Time 2.660 (0.623) <0.001 
MVO(-)/IMH(-) -0.023 (1.648) 0.989 
MVO(+)/IMH(-) 0.004 (2.059) 0.998 
MVO(+)/IMH(+) reference  
Abbreviations: IS=infarct size; MVO=microvascular obstruction. Error and 
random intercept variances were 15.762 and 20.571, respectively (p<0.001). 
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Discussion 
The findings of our study can be summarized as follows: (1) MVO and IMH are fre-
quently observed in reperfused AMI using T2W and LGE CMR, (2) IMH and MVO are 
strongly related phenomena, (3) patients with MVO and IMH have pre-PCI TIMI 3 
flow less often, and (4) infarct size, once adjusted for MVO and IMH presence, re-
mained the sole independent predictor of LV remodeling. 
 T2W-CMR is capable of detecting myocardial edema as regions of increased 
signal intensity due to prolongation of T2 relaxation time as a consequence of in-
creased tissue free water content. 18 IMH is thought to be caused by leakage of 
blood out of severely injured microvasculature into the interstitium that can be 
depicted as a central area of low signal intensity (SI) within the edematous area on 
T2W-CMR. This low SI is explained by local field heterogeneities due to the para-
magnetic effects of blood degradation products such as deoxyhaemoglobin, which 
shorten the T2 relaxation time. 10 In two case reports, Basso et al. demonstrated a 
good correlation among the location, spatial extent, and shape of IMH on CMR and 
histopathology. 8 Because of its excellent spatial resolution and high contrast, LGE 
CMR accurately assesses the extent of infarction and MVO. 19 Combined with T2W-
CMR, it is now possible to gain novel insights into the pathophysiology of IMH and 
MVO in vivo and evaluate their clinical significance. 
 Previous studies have shown that MVO infarcts show a lack of regional and 
global functional recovery compared with non-MVO infarcts; however, it remains 
unclear whether MVO provides independent prognostic information. 11, 12 Despite 
the strong relation of MVO with IS, some studies indicated that MVO is an impor-
tant determinant of LV recovery and prognosis, even after controlling for IS, whe-
reas others have reported that MVO loses its predictive power after adjusting for IS. 
13, 14, 20, 21 Persistence of MVO, but not MVO that disappeared at 1 week after infarc-
tion, was associated with attenuated infarct healing and subsequent adverse re-
modeling, indicating that the timing of MVO imaging is important. 22 In that study 
and similar to our findings, IS remained the major determinant of LV remodeling in a 
multivariate model. 
 Our clinical observation that MVO and IMH occur in the central portions of the 
infarct and not in patients with pre-PCI TIMI 3 flow is in line with experimental stu-
dies showing the association of IMH with markedly depressed flow before reperfu-
sion and severe ischemia. 5 Our finding that IMH was also observed in 10% of pa-
tients with post-PCI TIMI flow <3 supports experimental observations that IMH does 
not depend on the magnitude of early reflow. 6, 23 Conflicting results on the clinical 
significance of IMH have been reported. Our data are in contrast to those of Ga-
name et al., who found that LVEF did not improve in patients with hemorrhagic 
infarcts as opposed to patients with non-hemorrhagic infarcts. 16 IMH and infarct 
size were the strongest independent predictors of adverse LV remodeling in that 
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study. Our results are in accordance with those from Beek et al., who showed that 
IMH did not have prognostic significance beyond the presence of MVO. 15 
 The underlying pathophysiological mechanisms of MVO and IMH are complex 
and remain only partially understood. Irreversible ischemic myocardial cell injury 
progresses as a ‘wave front’ from the endocardium to the epicardium, with endo-
thelial cell injury occurring after myocardial cell injury. 1, 3 After varying periods of 
ischemia, sequential changes of the microvasculature occur. Endothelial protrusion 
by cell swelling together with capillary plugging by neutrophils, red blood cells and 
platelets and swelling of surrounding myocytes compressing capillaries may all 
cause MVO. As ischemic injury progresses, endothelial cell death causes loss of 
capillary integrity with resultant IMH in cases of myocardial reperfusion. Our data 
show that MVO and IMH are strongly related phenomena and suggest that IMH is a 
sign of severely injured microvasculature that easily leaks blood into the interstitial 
space. Furthermore, our results suggest that microvascular injury is predominantly a 
reflection of extensive myocardial necrosis rather than a separate entity identifying 
patients at higher risk. 
 Despite having MVO, IMH was absent in ten patients in our study. We postulate 
that, for some patients in the MVO(+)/IMH(−) group, the ischemic threshold for IMH 
may not have been reached yet. This could explain the discrepancy between the 
predicted IMH values and the negative findings at CMR. Lending support to this 
concept was the finding that all measured parameters, including MVO size, were in 
between the average values of the two other groups. It is therefore likely that the 
groups reflect a gradation of the severity of ischemic damage. 
Conclusions 
Microvascular obstruction and intramyocardial hemorrhage are frequently observed 
in reperfused AMI using T2W and LGE-CMR, and are strongly related phenomena. 
Patients with MVO and IMH have pre-PCI TIMI 3 flow less often, suggesting more 
severe ischemia before reperfusion. Only infarct size, but not the presence of IMH 
or MVO, was an independent predictor for LVEF. This suggests that MVO and IMH 
are not just separate entities, but rather ischemia-dependent consequences of se-
verely injured microvasculature in larger infarcts. 
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study. Our results are in accordance with those from Beek et al., who showed that 
IMH did not have prognostic significance beyond the presence of MVO. 15 
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by cell swelling together with capillary plugging by neutrophils, red blood cells and 
platelets and swelling of surrounding myocytes compressing capillaries may all 
cause MVO. As ischemic injury progresses, endothelial cell death causes loss of 
capillary integrity with resultant IMH in cases of myocardial reperfusion. Our data 
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Conclusions 
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Abstract 
Background  
The relation of early ST segment recovery (STR) with underlying infarct characteris-
tics and adverse remodeling in ST elevation myocardial infarction (STEMI) is incom-
pletely known.  
Methods  
In 79 first STEMI patients, eight different ST segment recovery (STR) variables were 
measured 30 and 60 minutes after percutaneous coronary intervention. Cardiovas-
cular magnetic resonance imaging (CMR) was performed 5 ± 2 and 104 ± 11 days 
after admission. Using K-means cluster analysis, three CMR risk groups for adverse 
remodeling were identified (low, n=16; intermediate, n=28; high risk, n=35) based 
on combinations of infarct size (IS), transmurality and microvascular obstruction 
(MVO). Stepwise discriminant analysis was used to determine which STR variable 
best discriminated between groups.  
Results  
Clustering based on MVO and IS allowed a better separation between groups than 
clustering based on MVO, IS and transmurality, in relation to adverse remodeling. 
Baseline LVEF improved in all groups, but remained lowest in the high risk group (41 
± 7% and 44 ± 6%), as compared to the intermediate (51 ± 5% and 56 ± 5%) and low 
risk group (56 ± 7% and 58 ± 5%). IS was significantly different among all groups (34 
± 5%, 19 ± 4% and 6 ± 4%, p<0.001) and mainly determined the effect on adverse 
remodeling. Of all STR variables, worst lead residual ST deviation (STD) 30 minutes 
after reperfusion accurately discriminated between the high and combined 
low/intermediate risk groups. 
Conclusion  
Worst lead residual STD 30 minutes after reperfusion allows accurate identification 
of patients at high risk for adverse remodeling after 3 months, which was mainly 
related to IS rather than transmurality or MVO.  
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Introduction 
Timely reperfusion in ST elevation myocardial infarction (STEMI) increases myocar-
dial salvage limits infarct size (IS) and improves clinical outcome. 1 A substantial 
number of patients fails to have adequate microvascular reperfusion despite suc-
cessful restoration of epicardial artery patency. 2, 3  
 Studies comparing angiographic measures of reperfusion with ST segment re-
covery (STR) early after treatment (early STR) have shown a significant correlation 
between greater STR and higher rates of TIMI grade 3 flow. 4 Incomplete STR in 
patients with TIMI grade 3 flow is widely accepted as an indicator of impaired tissue 
reperfusion, but only few studies have directly related STR to microvascular ob-
struction (MVO). 5-8 It appears that incomplete STR is also related to other infarct 
characteristics such as decreased myocardial salvage, increased IS, decreased left 
ventricular ejection fraction (LVEF) and consequently, adverse clinical outcome. 9-11  
 Functional recovery after STEMI is related to IS, infarct transmurality and MVO. 
Studies have reported inconsistent results, with some favoring IS 12, and others 
MVO 7 or transmurality 13, as independent predictors for adverse ventricular re-
modeling and outcome. Moreover, these infarct characteristics appear to be strong-
ly interrelated, hindering the elucidation of the relationship with STR. Thus, the 
exact relationship of STR with these underlying infarct characteristics and adverse 
remodeling remains to be established.  
 Cardiovascular magnetic resonance imaging (CMR) allows an accurate and inte-
grative assessment of IS, MVO, transmurality and LVEF 13-15 and was used to investi-
gate the relationship of STR with underlying infarct characteristics and adverse re-
modeling.  
Methods 
The study was approved by the ethics committee of our institution and patients 
were included after written informed consent was obtained. 
Study population 
We studied 86 consecutive patients with a first STEMI, who were referred to our 
institution between September 2006 and March 2008 for primary percutaneous 
coronary intervention (PCI). Patients were included when they had typical and pro-
longed (>30 minutes) chest pain, ST elevation at the J-point ≥0.2 mV in leads V2 - V3 
and/or ≥0.1 mV in other leads in ≥2 contiguous leads and an appropriate rise and 
fall in cardiac biomarkers. All patients received aspirin, heparin and clopidogrel 
before PCI and stenting. Thrombosuction and downstream administration of intra-
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venous abciximab, intracoronary nitroglycerine or adenosine were left at the discre-
tion of the interventional cardiologist. Patients with left bundle branch block and 
(relative) contraindications for CMR were excluded. The ECG recordings and CMR 
images were non-diagnostic due to artifacts in 4 and 3 patients, respectively, leaving 
79 patients for the final analysis.  
 Cardiac biomarkers were sampled on admission and at 6-hour intervals until 72 
hours after admission. Creatine kinase area-under-the-curve (CK AUC) was derived 
and expressed as 1,000 h·units l-1.  
ECG analysis 
Immediately upon admission and prior to PCI, each patient received a continuous 
24-h digital 12-lead Holter recorder (NEMON 180+, NorthEast Monitoring, Inc., 
Maynard, MA). The system acquires and stores a digital and complete Mason-Likar 
12-lead ECG every minute. ST segments were measured manually, 60 ms after the J-
point with the TP-segment as isoelectric line at baseline, 30 and 60 minutes after 
balloon inflation, using designated analysis software (Holter 5 LX Analysis version 
5.2, NorthEast Monitoring). ST elevation in leads V1 to V6, and /or I and aVL was 
defined as anterior, ST elevation in leads II, III, aVF and/or ST depression in leads V1 
to V4 as non-anterior STEMI. In all patients, single lead peak ST deviation (STD) and 
sum peak STD (sum of ST segment elevation plus ST segment depression) were 
measured.  
 Then, the following STR variables were calculated: 1) ΣSTR (30): percent reduc-
tion in total STD from baseline to 30 minutes post-PCI; 2) ΣSTR (60): percent reduc-
tion in total STD from baseline to 60 minutes post-PCI; 3) STR (30): percent reduc-
tion in single lead peak STD from baseline to 30 minutes post-PCI; 4) STR(60): per-
cent reduction in single lead peak STD from baseline to 60 minutes post-PCI; 5) 
ΣSTD (30): sum of residual STD 30 minutes post-PCI; 6) ΣSTD (60): sum of residual 
STD 60 minutes post-PCI; 7) STD (30): worst lead residual STD 30 minutes post-PCI; 
8) STD (60): worst lead residual STD 60 minutes post-PCI. Single lead STR was calcu-
lated consistently in the lead with maximum baseline STD, worst lead residual STD 
was measured in the lead with maximum STD post-PCI, regardless if baseline peak 
STD was in a different lead. ECG’s were independently analyzed by two observers, 
blinded to the clinical and CMR data. The interclass correlation coefficient, as a 
measure of agreement, was 0.95 with 95%CI (0.92, 0.97). Discrepancies were re-
solved by consensus repeat analysis.  
Cardiovascular magnetic resonance imaging 
CMR (1.5 Tesla, Philips Intera, Philips Medical Systems, Best, The Netherlands) was 
performed 5 ± 2 days (range 2-10) and 104 ± 11 days (range 75-122) after admis-
S T  S E G M E N T  R E C O V E R Y  A N D  A D V E R S E  R E M O D E L I N G  
 79 
sion. Images were ECG-gated and acquired during multiple breathholds using a ded-
icated 5-element phased array surface coil. Cine images were acquired in short axis 
views, completely covering the left ventricle, with a steady-state free precession 
sequence (average repetition time (TR) and echo time (TE) 3.8/1.9 ms respectively, 
flip angle 50°; slice thickness 6 mm, gap 4 mm, FOV 350 mm, matrix 256 x 256, 22-
25 phases).  
 Delayed enhancement images (DE) were obtained 10 minutes after the intra-
venous administration of 0.2 mmol/kg body weight Gadolinium-diethylenetri-
aminepentaacetic acid (Magnevist®, Schering, Germany) in short and two orthogon-
al long axis views, completely covering the left ventricle, using a 3D inversion recov-
ery gradient-echo sequence (average TR/TE 3.9/2.4 ms, flip angle 15°; FOV 400 mm, 
matrix 256 × 256, acquired and reconstructed voxel size 1.56 × 1.56 mm x 6 mm). 
Immediately before DE imaging, a Look-Locker sequence was run to determine the 
inversion time (typical range 200-280 ms) to optimally suppress the signal of non-
infarcted myocardium. 
 CMR images were analyzed off-line by a single experienced reader using com-
mercially available software (CAAS MRV 3.0, Pie Medical Imaging, Maastricht, The 
Netherlands) blinded to the clinical and ECG data. Endocardial and epicardial bor-
ders were manually traced, excluding the papillary muscles, in the end-diastolic and 
end-systolic short-axis frames to determine end-systolic volume (LVESV), left ventri-
cular stroke volume (LVSV), left ventricular ejection fraction (LVEF) and left ventricu-
lar end-diastolic mass (LV mass). These parameters were indexed to body surface 
area (BSA). Likewise, endocardial and epicardial contours were manually traced on 
the DE images. IS was quantified using a SI threshold of >5 SD above a remote non-
infarcted region, including areas of MVO. When present, MVO was quantified by 
manually tracing the central hypoenhanced area within the hyperenhanced in-
farcted area. Both IS and MVO were expressed as a percentage of LV mass. The 
transmural extent of infarction was calculated by dividing the hyperenhanced area 
by the total area of the infarcted segment. 
Statistical analysis 
Multivariate techniques were used to analyze CMR and ECG variables separately. 
Subsequently, the predictive values of CMR variables on LV function at baseline and 
follow-up was conducted with a mixed linear regression model.  
 K-means cluster analyses were performed to identify three different subgroups 
of patients according to CMR based infarct characteristics, known to be associated 
with adverse LV remodeling and prognosis. 7, 13, 14 The number of clusters k=3 was 
selected as a compromise between a sufficiently large number to describe different 
CMR groups and the limited sample size. Two cluster classification models were 
used: 1) clustering based on MVO (%) and IS (%) and 2) based on MVO (%), IS (%) 
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and transmurality (%). Larger average differences of LVEF among groups were re-
garded as indicative of better risk stratification. The classification model that best 
predicted adverse LV remodeling (low LVEF at follow-up) was then used to correlate 
with the STR variables. Crude associations between different groups, clinical and ST 
variables were subsequently tested via one-way ANOVA. 
 A stepwise discriminant analysis was carried out to test which of the individual 
STR variables were sufficiently powerful to discriminate among the defined groups. 
A complementary analysis of the independent effect of the CMR variables on the 
most discriminative ST measurement was performed via a linear regression model. 
Data analysis was conducted with SPSS version 18.0 (SPSS Inc, Chicago, IL) and SAS 
version 9.2 (SAS Institute, Cary, NC). Multiple testing correction, when necessary, 
was made via False Discovery Rate. Significance level was 5% for all tests.  
Results 
Clustering based on CMR characteristics 
K-means cluster analysis identified three groups that differed significantly in their 
CMR risk profiles. First, patients were clustered based on MVO and IS (clustering 
model 1, Figure 1A) and second, based on MVO, IS and transmurality (clustering 
model 2, Figure 2A). In both figures, two more extreme groups can be identified 
that are quite antagonistic in their CMR risk profiles (high risk (red cluster) and low 
risk (green cluster)). The low risk group consisted of patients with either absent or 
small MVO, small (Figure 1A) and less transmural infarcts (figure 2A), whereas the 
opposite applies for the high risk group. Although the blue cluster is to a great ex-
tent an intermediate risk group, in terms of LV remodeling it closely resembled the 
low risk group (green cluster). The observed pair-wise correlations were 0.5, 0.66 
and 0.34 for MVO/IS, transmurality/IS and MVO/transmurality, respectively (p<0.05 
for all). Note that some patients had small but transmural infarcts with absent or 
small MVO (clustering model 1, green cluster, Figure 2A).  
 A comparative inspection of Figures 1B and 2B indicated that a larger average 
LVEF difference among the groups was observed in clustering model 1 (based on 
MVO and IS) than in model 2 (based on MVO, IS and transmurality). Thus, risk strati-
fication was not improved by taking transmurality into account. The larger mean 
differences in model 1 were confirmed by the mixed modeling approach. The esti-
mates of the fixed effect parameters of the random intercept model testing the 
independent effects of CMR profiles on LVEF over time are displayed in Table 1 
(random intercept and residual variances were 28.84 and 15.46, respectively). LVEF 
in the high risk group remained significantly different from the other two risk groups 
both at baseline and follow-up. Henceforth, further inferences relate only to cluster-
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ing model 1 (based on MVO/IS clustering). CMR images of representative patient 
examples for the three risk groups are shown in Figure 3. 
 
 
Figure 1. Cluster model 1 as a function of MVO and infarct size (A); left ventricular ejection fraction (LVEF) 
over time (from baseline to follow-up) for each of the three CMR risk groups (B). Red=high risk, 
blue=intermediate and green=low risk. 
 
 
Figure 2. Cluster model 2 as a function of MVO, infarct size and transmurality (A); left ventricular ejection 
fraction (LVEF) over time (from baseline to follow-up) for each of the three CMR risk groups (B). Red=high 
risk, blue=intermediate and green=low risk. 
 
 
Figure 3. Delayed enhancement short axis slices of three representative patients from the high (panel A), 
intermediate (panel B) and low risk group (panel C). The hyperenhanced infarcted myocardium (arrow-
heads) and MVO (*) are shown. While patients A and B have similar mean infarct transmurality and MVO 
(62% and 4.8% vs. 59% and 3.9%), infarct size in patient A was larger than in patient B (32.2% vs. 17.5%). 
Patient C had a small (5.4%), but transmural (87%) inferior wall infarct and no MVO. 
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Table 1. Fixed effect parameters of the multivariable random intercept model with 
LVEF as outcome (based on cluster model 1). 
 βˆ SE p-value 
Intercept 46.98 2.41 <0.0001 
CMR risk group    
 Low risk  13.12  2.02 <0.0001 
 Intermediate risk 9.23 2.07  <0.0001 
 High risk 0 (reference) 0  
Time point 1  -2.69 0.66 <0.0001 
Time point 2 0 (reference) 0  
    
Baseline characteristic    
 Sex (male) -2.22 1.52 n.s. 
 Anterior localisation -1.67 1.64 n.s. 
 Final TIMI 3 flow  1.92 2.13 n.s. 
βˆ indicates an average change in LVEF for one unit increase in explanatory variable. 
Abbreviations: LVEF=left ventricular ejection fraction; CMR=cardiovascular magnetic 
resonance imaging; TIMI=Thrombolysis In Myocardial Infarction. 
 
Differences between CMR risk groups 
Patients in the high risk group (n=16, large IS and MVO) were more likely to have an 
anterior MI and less likely to have baseline and final TIMI 3 flow as compared to 
patients with an intermediate (n=28) and low risk CMR profile (n=35, Table 2). Base-
line LVESVi was largest and LVEF lowest in the high risk group as compared to the 
intermediate and low risk group. At follow-up, LVEDVi increased in the high risk 
group and was significantly larger as compared to the intermediate and low risk 
group (99 ± 19 ml/m2, 79 ± 15 ml/m2, 77 ± 15 ml/m2, respectively, p=0.002). Aver-
age LVEF increased in every risk group, but more so in the intermediate risk group, 
leading to a loss of the initial difference in LVEF at baseline between the interme-
diate and low risk group. Note that LVEF in the intermediate risk group was on aver-
age higher than in the high risk group, despite a similar prevalence and extent of 
MVO (82% vs. 94% and 1.9 ± 1.8% vs. 1.9 ± 1.9%, respectively). At follow-up, LVEF 
remained lowest in the high risk group as compared to the intermediate and low 
risk group (44 ± 6%, 56 ± 5%, 58 ± 5%, respectively, p=0.002).  
 STR (either summed or single lead) was smallest in the high risk group as com-
pared to the intermediate and low risk group. This was only significant for the 30 
minute time point. Residual STD (either summed or worst lead) was significantly 
higher in the high risk group as compared to the other groups for the 30 and 60 
minute time point. 
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Table 2. Comparison of clinical characteristics between CMR risk groups. 
 CMR risk groups  
 High risk 
(n=16) 
Intermediate 
risk (n=28) 
Low risk 
(n=35) 
FDR  
p-value 
Age (years) 63 ± 15 58 ± 12 59 ± 9 0.46 
Male (%) 88 57 83 0.045 
Risk factors     
 Diabetes Mellitus (%) 0 0 9 0.19 
 Hyperlipidemia (%) 31 37 40 0.85 
 Hypertension (%) 38 30 43 0.65 
 Smoking (%) 81 93 89 0.57 
Anterior MI (%) 88 25 14 0.002 
Glycoprotein 2b3a inhibition (%) 63 57 49 0.65 
Thrombosuction (%) 31 25 36 0.77 
TIMI 3 flow     
 Baseline (%) 0 0 17 0.045 
 Final (%) 75 100 88 0.045 
Ischemic time (min.) 222 ± 87 231 ± 72 216 ± 91 0.77 
     
Baseline CMR     
 Infarct size (% of LV) 34 ± 5*, † 19 ± 4*, ‡ 6 ± 4†, ‡ 0.002 
 Transmurality (%) 79 ± 7* 71 ± 10† 52 ± 21*, † 0.002 
 MVO prevalence (%) 94* 82† 17*,† 0.002 
 MVO size (% of LV) 1.9 ± 1.9* 1.9 ± 1.8† 0.2 ± 0.4*, † 0.002 
 LVEDVi (ml/m2) 91 ± 20 83 ± 14 82 ± 14 0.19 
 LVESVi (ml/m2) 54 ± 15*, † 41 ± 10* 37 ± 11† 0.002 
 LVEF (%) 41 ± 7*, † 51 ± 5*, ‡ 56 ± 7†, ‡  
Follow-up CMR     
 LVEDVi (ml/m2) 99 ± 19*, † 79 ± 15* 77 ± 15† 0.002 
 LVESVi (ml/m2) 56 ± 15*, † 35 ± 9* 32 ± 9† 0.002 
 LVEF (%) 44 ± 6*, † 56 ± 5* 58 ± 5† 0.002 
 LVEDVi (ml/m2) 99 ± 19*, † 79 ± 15* 77 ± 15† 0.002 
      
CK AUC (1,000 h·units l-1) 94 ± 34*, † 57 ± 27*, ‡ 29 ± 24†, ‡ 0.002 
      
ECG variables     
 ΣSTR(30) (%) 42 ± 27*, † 66 ± 26* 72 ± 25† 0.007 
 ΣSTR(60) (%) 57 ± 23 74 ± 25 70 ± 29 0.17 
 STR(30) (%) 49 ± 28*, † 68 ± 24* 74 ± 25† 0.003 
 STR(60) (%) 62 ± 22 75 ± 25 75 ± 26 0.23 
 ΣSTD(30) (mm) 9.8 ± 5*, † 4.4 ± 3.1* 3.2 ± 3.5† 0.002 
 ΣSTD(60) (mm) 7.4 ± 3.9*, † 3.2 ± 2.7* 2.9 ± 2.6† 0.002 
 STD(30) (mm) 2.6 ± 1.5*, † 1.2 ± 0.9* 0.8 ± 0.7† 0.002 
 STD(60) (mm) 2 ± 1.4*, † 0.9 ± 0.9* 0.7 ± 0.6† 0.002 
Values are presented as percentages in parentheses or mean ± standard deviation. Abbreviations: MI=myocardial 
infarction, TIMI=thrombolysis in myocardial infarction; CMR=cardiovascular magnetic resonance imaging; 
MVO=microvascular obstruction; LVEDVi=left ventricular end-diastolic volume index; LVESVi=left ventricular end-systolic 
volume index; LVEF=left ventricular ejection fraction; CK=creatine kinase; AUC=area under the curve; STR=ST segment 
resolution; STD=ST segment deviation; Σ=summed (otherwise single lead is meant); (30), (60) = 30 and 60 minutes post-
PCI; FDR=false discovery rate; The superscripts (*, †, ‡) indicate significant pairwise group comparison.  
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CMR and ST segment variables: stepwise discriminant analysis 
With the objective to identify which of the STR variables were more useful in sepa-
rating the different CMR risk groups, a stepwise discriminant analysis was carried 
out. Only worst lead residual ST deviation 30 minutes post-PCI (STD (30)) was found 
to separate, though poorly, the three risk groups (classification and leave-one out 
cross-validation rates were both 55%). 
Because the intermediate and low risk group were on average closer to each other 
with respect to LV remodeling (Figure 1B), they were joined ad hoc to form one 
group. Following a new discriminant analysis, STD (30) remained the sole discrimi-
natory variable between the two groups (high vs. low/intermediate), but now the 
classification rate was considerably improved (82% cross-validated classification). 
The AUC under the ROC curve was 0.86, with 95% CI 0.77 and 0.96, respectively. 
Because of small numbers, it was not possible to define STD cutoff values for ante-
rior and non-anterior MI separately, but for the whole group a STD cutoff value of 
1.53 mm gave a sensitivity of 88% and specificity of 76%. Of the CMR variables (IS, 
MVO and transmurality) tested in a multivariable linear regression model, only IS 
was shown to be significant associated with STD (Table 3). 
 
Discussion 
The current study shows that worst lead residual STD 30 minutes after reperfusion 
allows accurate identification of patients at high risk for adverse remodeling after 3 
months, which was mainly related to IS rather than transmurality or MVO.  
 Studies investigating the role of infarct characteristics on functional recovery 
and LV remodeling after AMI have been inconclusive, indicating that it is a hetero-
geneous process hitherto incompletely understood. Some studies have favored 
infarct transmurality, whereas others have found either IS or MVO to be indepen-
dently associated with adverse remodeling or outcome. 7, 12-14 These studies primari-
ly focused on univariate procedures (either uni-or multivariable) to evaluate the 
prognostic value of aforementioned infarct characteristics. Although univariate 
techniques may show independent effects that can be combined in additive models, 
they offer only a piece-wise perspective into relationships and a broader picture 
may still be missed. Alternatively, to the one-variable at a time analysis, we ex-
plored the correlational information among the CMR variables by clustering patients 
into three different risk groups. This approach revealed that IS accounts for the 
most conspicuous average difference among the risk profiles with respect to their 
recovery of LV function over time. 
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 The downgraded role of the last two CMR parameters is at odds with previous 
reports. Our small-scale study does not provide a definite answer to this conten-
tious topic. Our findings may draw attention to alternative clinical hypotheses that 
may explain why risk stratification was not improved, once transmurality was added 
to the clustering model. Functional impairment after a large AMI is not only related 
to myocyte loss and inflammatory changes in the infarcted myocardium itself. In-
creased systolic work load on remote myocardium also contributes significantly to 
the loss in global ventricular function. The impact of remote myocardial dysfunction 
in small infarcts is minimal. Even if they are transmural, these small infarcts retain 
the ability to recover over time (Figure 3C). 16  
 The relation of MVO and myocardial necrosis is still unclear. The concept that 
reperfusion injury may increase final IS due to death of additional myocytes, still 
viable immediately before reperfusion, is questionable. 17 A solid argument against 
a causal role of MVO for infarct progression during reperfusion is that MVO lags 
behind myocyte death. 18 Experimental studies have shown a strong correlation 
between MVO and IS. 19 If this correlation holds, any predictive role that MVO may 
have on adverse outcome is potentially confounded by IS. Up to date, only a few 
investigations have been able to demonstrate an independent effect of MVO on 
poor prognosis, i.e. once adjusted for IS. However, consensus has not yet been es-
tablished and MVO’s independent prognostic role remains moot. 19 The present 
study does not reinforce this hypothesis. A positive, though moderate correlation of 
MVO with IS was observed. The correlation was especially weak for the high risk 
group, where small and high MVO values were linked with large IS (explaining why 
MVO was similar in the intermediate and high risk CMR group). This finding lends 
more support to a predictive role of IS rather than MVO on adverse remodeling. STR 
is widely used as a marker for myocardial reperfusion, irrespective of the degree of 
antegrade epicardial coronary flow. Its well established prognostic value 20, 21 may 
be explained by its relation with IS rather than MVO.  
 The association of STR with IS and long-term ventricular function has been pre-
viously reported, but, in contrast to the current study, the influence of MVO was not 
investigated. 10, 22 We found that STR could not discriminate satisfactorily among the 
three CMR risk groups. The discriminatory power increased considerably, when it 
came to separating between high vs. the combined low/intermediate risk groups. 
Analogous to the LVEF behavior, this suggests that the intermediate and low risk 
groups constitute a more homogeneous group with respect to STR, despite showing 
statistically significant differences in all three CMR parameters. Intermediate and 
high risk patients, on the other hand, were similar in their MVO and transmurality 
characteristics, differing only in IS. Thus, IS emerges, by exclusion, as the major 
factor affecting STR rather than MVO or transmurality. This conclusion is supported 
by the results of the multivariable regression model, with IS as the sole remaining 
CMR variable significantly associated with STD.  
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 Investigators have used a variety of different techniques to measure STR, either 
single or multiple lead and either resolution or worst lead residual STD after reper-
fusion. The latter is by far the simplest and clinically most applicable method for 
calculating STR. 23 Our results show that worst lead STD measured as early as 30 
minutes after reperfusion is at least as accurate as all other ST variables in predict-
ing adverse remodeling and identifying patients at high risk for adverse remodeling.  
 
Conclusions 
Worst lead residual STD 30 minutes after reperfusion accurately identifies patients 
at high risk for adverse remodeling after 3 months, which was mainly related to IS 
rather than transmurality or MVO.  
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Abstract 
Background 
Validation of area at risk (AAR) measurement methods in acute myocardial infarc-
tion (AMI) in humans is limited. We tested the performance of different AAR mea-
surement methods in AMI using established physiologic concepts to provide a ref-
erence standard.  
Methods and results 
In 78 percutaneously reperfused first ST-elevation myocardial infarction patients, 
AAR was measured by electrocardiographic (Aldrich), angiographic (BARI, AP-
PROACH), and cardiovascular magnetic resonance (CMR) methods (T2-weighted 
(T2W) hyperintensity, delayed enhanced (DE) endocardial surface area (ESA)). In-
farct size (IS) and transmurality were measured by DE-CMR. The following estab-
lished physiologic concepts were used to evaluate AAR methods: 1) AAR should be 
greater than or equal to IS, 2) in transmural infarcts, AAR should approach IS, 3) the 
correlation between AAR and IS should increase as infarct transmurality increases, 
4) myocardial salvage [(AAR-IS)/AAR x 100] should be inversely related to transmu-
rality, following the inverse line of identity. Overall, 65%, 87%, 76%, 87%, and 97% 
of patients using Aldrich, BARI, APPROACH, T2W, and ESA obeyed the concept 
AAR≥IS. In a sub-cohort of patients (n=22) with near transmural infarcts (>75%), the 
95% limits of agreement on Bland-Altman analysis were -22.9 to 29.6, -28.3 to 21.3, 
-16.9 to 20.0, -6.9 to 16.6 and -4.3 to 18.0 for BARI, Aldrich, APPROACH, T2W and 
ESA, respectively. Increasing correlation with increasing transmurality was only 
observed for APPROACH, T2W and ESA, with ESA having the highest correlation in 
the nearly transmural sub-cohort (r=0.93, p<0.001). Concerning salvage and infarct 
transmurality, the percentage of patients within a narrow margin (±30%) of the 
inverse line of identity (high=better) were 56%, 76%, 65%, 77% and 92% for Aldrich, 
BARI, APPROACH, T2W and ESA. 
Conclusions 
For measuring AAR, CMR methods were better than angiographic methods, which 
were better than electrocardiographic. Overall, ESA by DE-CMR appeared to be the 
best method for measuring AAR in vivo. 
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Introduction 
Clinical outcome after acute myocardial infarction (MI) largely depends on final 
infarct size (IS) and is improved by early reperfusion. 1 IS is determined by the extent 
of collateral flow, myocardial metabolic demand during occlusion, duration of coro-
nary occlusion and size of the initial area at risk (AAR). 2, 3 Determining both AAR and 
IS allows the assessment of myocardial salvage and evaluation of the efficacy of 
reperfusion strategies. 
 Delayed enhanced cardiovascular magnetic resonance imaging (DE-CMR) relia-
bly detects IS and accurately distinguishes between viable and nonviable myocar-
dium. 4, 5 However, determination of the AAR in the clinical setting remains challeng-
ing. Although single-photon emission computed tomographic (SPECT) is an accepted 
technique 6, 7, radiation exposure, low spatial resolution and difficult logistics requir-
ing tracer injection before reperfusion complicate this method. 
 STEMI diagnosis is supported by the electrocardiogram (ECG) that is routinely 
performed on admission and most patients will undergo coronary angiography fol-
lowed by percutaneous coronary intervention (PCI). Both electrocardiographic and 
coronary angiographic measures have previously been used to measure the AAR. 
The Aldrich score is based on the total amount of ST-segment deviation on admis-
sion 8, whereas BARI and APPROACH are based on vessel anatomy and location of 
coronary obstruction. 9, 10 Myocardial ischemia leads to inflammation and tissue 
edema in the infarct related artery (IRA) territory. 11 This edema is shown as an area 
of increased signal intensity on T2 weighted (T2W) CMR and animal studies suggest 
that this hyperintense area delineates the AAR in STEMI. 12, 13 More recently, endo-
cardial surface area (ESA) on DE-CMR was used for measuring AAR. 14, 15 Although 
promising, for all the proposed methods the number of studies is small and more 
validation in humans with appropriate reference standards is necessary. 16, 17 
 In this study electrocardiographic, angiographic, and CMR techniques for mea-
suring AAR were evaluated using established and straightforward physiologic con-
cepts based on the “wavefront phenomenon” of infarct progression from endocar-
dium to epicardium with only minimal lateral extension. 2 
Methods 
Patients 
The study was approved by the Institutional Review Board of our hospital and pa-
tients were included after written informed consent was obtained. Between August 
2006 and March 2008, 106 consecutive patients with a first ST segment elevation 
myocardial infarction (STEMI) referred to our institution for primary PCI and presen-
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tation <12 hours after symptom onset were prospectively studied. Incomplete data-
sets in 28 patients (coronary angiography in 8, ECG in 9 and T2W in 11 patients) 
were excluded and this study comprises the results of 78 patients. Definition of MI 
was based on the recent consensus document including appropriate rise and fall in 
cardiac biomarkers. 18 Excluded were patients with claustrophobia, contraindica-
tions for CMR (cerebral clips, pacemakers, defibrillators, neurostimulators), severe 
congestive heart failure or cardiogenic shock (Killip class III and IV) at the time of 
CMR, atrial fibrillation, age <18 years, severe renal failure (stage 4 or 5), and preg-
nancy. 
Coronary angiography 
After pre-treatment with aspirin, heparin and, clopidogrel, patients underwent 
standard catheterization with multiple selective contrast injections in the left and 
right coronary arteries prior to PCI. Thrombosuction and downstream administra-
tion of intravenous antiplatelet agents (abciximab), intracoronary nitroglycerine and 
adenosine were left at the discretion of the interventional cardiologist. PCI was 
performed in all patients and every patient received at least one stent. 
 Two observers, blinded to the electrocardiographic and CMR data, indepen-
dently reviewed all angiograms. Consensus was reached by discussion in all pa-
tients. Collaterals were defined by visual assessment using the Rentrop classification 
(19). Antegrade flow in the IRA before and after PCI was characterized using the 
Thrombolysis In Myocardial Infarction (TIMI) scoring system. 20 
Angiographic AAR assessment 
Angiographic AAR measurement was performed as previously described.9 In this 
study, we calculated the AAR for the IRA. 
BARI-score 
Using the Bypass Angioplasty Revascularization Investigation Myocardial Jeopardy 
Index (BARI), AAR was calculated by grading all terminating arteries. 9 All branches 
were scored 3, 2, 1 or 0 points, corresponding to large, medium, small or absent. 
The ventricular base to apex distance, approximated from the coronary angiogram, 
provided the basis for assessing the relative distribution of coronary branches. 
Branches were considered large if their length exceeded 2/3, medium if 1/3 to 2/3, 
small if less than 1/3 and absent if less than 1/5 of the distance from base to apex. 
The AAR was calculated as a percentage of the left ventricle (LV) by dividing 
summed scores of a jeopardized area by the total score of the entire LV. 
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Modified APPROACH-score 
In the APPROACH score, the LV was divided into regions that represent the propor-
tion of myocardium perfused by each coronary artery, which was estimated based 
on post-mortem pathology studies. 21 In this study we used the modified APPROACH 
score. 15 Scoring was performed using a template in which the culprit artery is se-
lected, as well as proximity of the lesion and size of side branches (small/absent, 
medium or large). For left circumflex artery (LCx) and right coronary artery (RCA) 
culprit lesion, left- or right dominance was determined. The template than provided 
one of 39 possible AAR scores as a percentage of the LV. 
Electrocardiographic AAR assessment (Aldrich method) 
Two observers, blinded from the coronary angiography and CMR data, indepen-
dently determined the Aldrich scores on the standard 12-lead admission ECG 8. 
Using the TP segment as the isoelectric line, ST-elevation was measured manually, 
60 ms after the J-point to the nearest 0.5mm in each lead. Any ST-elevation ≥1mm 
was measured in leads II, III, avF for inferior STEMI and in all leads for anterior STE-
MI. Electrocardiographic AAR was then calculated using the Aldrich score: anterior 
MI: 3 × [1.5 × (number of leads with ST↑) − 0.4]; inferior MI: 3 × [0.6 × (∑ST↑ II, III, 
AVF) + 2.0] and computed as a percentage of LV. 
Cardiovascular magnetic resonance imaging 
CMR was performed 5 ± 2 days after admission. Images were acquired during mul-
tiple breathholds on a 1.5 Tesla MRI system (Intera R 11.3, Philips Medical Systems, 
Best, The Netherlands) with a dedicated 5-element phased array surface coil. To 
image myocardial edema, a double inversion T2-weighted (T2W) turbo spin echo 
sequence with spectrally selective inversion recovery (SPIR) fat suppression was 
used in multiple contiguous short axis slices covering the entire LV (slice thickness 8 
mm, gap 2 mm, TR/TE: 2 R-R intervals/100 ms, flip angle 90°, FOV 350 mm, matrix 
236 x 186). DE was performed 10-15 minutes after administration of 0.2 mmol/kg 
body weight Gadolinium-diethylenetriaminepentaacetic acid (Magnevist®, Bayer 
Schering Pharma, Berlin, Germany) using a 3D segmented inversion-recovery gra-
dient-echo sequence (reconstructed slice thickness 6 mm, average TR/TE 3.9/2.4 
ms, flip angle 15°, FOV 400 mm, matrix 256 x 256, reconstructed pixel size 1.56 x 
1.56 mm). A Look-Locker sequence was used to find the inversion time that optimal-
ly suppressed the signal of non-infarcted myocardium (typical range 200-280 ms). 
CMR Image Analysis  
CMR images were analyzed off-line using commercially available software (CAAS 
MRV 3.0, Pie Medical Imaging, Maastricht, The Netherlands) and blinded to the 
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tation <12 hours after symptom onset were prospectively studied. Incomplete data-
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The ventricular base to apex distance, approximated from the coronary angiogram, 
provided the basis for assessing the relative distribution of coronary branches. 
Branches were considered large if their length exceeded 2/3, medium if 1/3 to 2/3, 
small if less than 1/3 and absent if less than 1/5 of the distance from base to apex. 
The AAR was calculated as a percentage of the left ventricle (LV) by dividing 
summed scores of a jeopardized area by the total score of the entire LV. 
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electrocardiography and angiography results. Endocardial and epicardial contours 
were manually traced on the T2W and DE images. 
 The AAR was quantified on the T2W images by delineating myocardium with a 
signal intensity (SI) threshold of >2 SD above the mean of a remote region outside 
the IRA territory. 17 Areas of central hypoenhancement were included and endocar-
dial ‘slow flow’ artifacts were excluded by manual adjustment of contours. 
IS was quantified on the DE images by delineating areas of hyperenhancement using 
a SI threshold of >5 SD above the mean of a remote non-infarcted region, including 
areas of microvascular obstruction (MVO). 22 
 AAR and IS were expressed as a percentage of LV mass. The transmural extent 
of infarction was calculated by dividing the hyperenhanced volume by the total 
volume of the infarcted segments. The infarct ESA was calculated as a percentage of 
the hyperenhanced endocardial surface area divided by total LV endocardial surface 
area (including MVO). 
 For each method, the data of 25 randomly selected patients were analyzed by 
one observer twice on two different occasions and a second observer independent-
ly analyzed all data, so that intra- and interobserver variability could be calculated. 
Physiologic concepts  
Patients were classified into three groups, based on the results of DE-CMR: a) sub-
endocardial infarction (transmurality <50%, n=13), b) near transmural infarction 
(transmurality >75%, n=22), and c) intermediate transmurality (transmurality 50-
75%, n=43). Each method was evaluated by using the following established physi-
ologic concepts: 1) AAR should always be larger than or equal to IS; 2) in nearly 
transmural infarcts, AAR should approach IS; 3) as infarct transmurality increases, 
the correlation between AAR and IS should increase; 4) myocardial salvage [defined 
as AAR − IS)/AAR × 100] should be inversely correlated with transmurality, closely 
following the inverse line of identity [salvage = 100% − transmurality]. The deviation 
from this ’line of identity’ was expressed as percentage of patients within a ± 30% 
margin and in the standard error of estimate (SEE). Individual AAR methods were 
ranked (1, worst to 5, best) based on how well they agreed to these physiologic 
concepts. 
Statistical Analyses 
Continuous variables were presented as mean ± standard deviations (SD) and pro-
portions (%) were used for categorical variables. In near transmural infarcts, agree-
ment between AAR and IS was tested using Bland-Altman analysis, with reporting of 
bias and 95% confidence intervals. Correlations were computed using Pearson’s 
correlation coefficient. The predictive accuracy of the AAR methods concerning the 
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inverse relation between myocardial salvage and infarct transmurality was meas-
ured using the standard error of the estimate (SEE). A two-tailed p-value ≤0.05 was 
considered statistically significant. The data were analyzed using SPSS 17.0 for Win-
dows (SPSS Inc., Chicago, IL). 
 
Table 1. Patient characteristics. 
Characteristic Value 
N 78 
Age (years) 59 ± 11 
Male (%) 55 (71) 
Current smoker (%) 43 (49) 
Diabetes (%) 5 (6) 
Hypertension (%) 29 (37) 
Hyperlipidemia (%) 21 (24) 
  
Infarct related artery (%)  
 LAD 26 (33) 
 RCA 41 (53) 
 LCx 11 (14) 
No. of diseased vessels (%)  
 One 40 (51) 
 Two 19 (24) 
 Three 19 (25) 
Symptom to balloon time (min.) 218 ± 83 
Glycoprotein 2b3a inhibition 40 (51) 
TIMI 3 flow  
 Pre PCI 9 (12) 
 Post PCI 71 (91) 
Collaterals (Rentrop≥2) 16 (21) 
  
Infarcts size (%) 16 ± 11 
Infarct transmurality (%) 65 ± 16 
Values are presented as numbers (%) or means ± stan-
dard deviation. Abbreviations: LAD=left anterior descen-
ding artery; RCA=right coronary artery; LCx=left circumf-
lex coronary artery; TIMI=thrombolysis in myocardial
infarction; PCI=percutaneous coronary intervention. 
Results 
Baseline characteristics are shown in Table 1. The majority of patients were men 
(71%), approximately half of patients had single vessel disease (51%) and in 53% the 
RCA was IRA. Final TIMI 3 flow was established in 91%. Mean IS was 16 ± 11% of LV 
mass. A trend in decreasing pre-PCI TIMI flow was observed with increasing trans-
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murality (p=0.07). Collaterals and symptom-to-balloon-time were not different 
between subgroups. 
Intra- and interobserver variability 
The intra- and interobserver variability for all methods were moderate to excellent 
(for Aldrich 0.95 and 0.75, for BARI 0.89 and 0.86, for APPROACH 0.89 and 0.79, for 
T2W-CMR 0.92 and 0.96, for IS by DE 0.91 and 0.96, for ESA by DE 0.90 and 0.87, 
respectively). 
 
Table 2. Number of patients (%) with AAR greater than or equal to infarct size. 
 Subgroup 
  Overall Subendocardial Intermediate Near transmural 
Aldrich (%) 51 (65) 13 (100) 29 (67) 9 (41) 
BARI (%)  68 (87) 13 (100) 41 (95) 14 (64) 
APPROACH (%) 59 (76) 13 (100) 35 (81) 11 (50) 
T2W (%) 68 (87) 13 (100) 36 (84) 19 (86) 
ESA (%) 76 (97) 13 (100) 43 (100) 20 (91) 
Abbreviations: AAR=area at risk; T2W=T2-weighted cardiovascular magnetic resonance; ESA=infarct en-
docardial surface area. 
AAR greater or equal to IS  
Table 2 shows that overall, 51 (65%), 68 (87%), 59 (76%), 68 (87%), and 76 (97%) of 
patients using Aldrich, BARI, APPROACH, T2W, and ESA, respectively, showed an 
AAR that was greater than or equal to IS. Thus, ESA performed best and Aldrich 
worst. T2W and BARI performed equally well and were given a similar score of 3 
(Table 4). In the subgroup of subendocardial infarcts, AAR was greater than or equal 
to IS in all patients, irrespective of the method used. The results of the other sub-
groups are shown in Table 2 as well. 
AAR approximation of IS in near transmural infarcts 
Bland-Altman analysis was used to assess the agreement between AAR and IS in a 
sub-cohort of patients (n=22) with near transmural infarcts (Figure 1). Because near 
transmurality was defined as >75% infarction and not 100% (mean transmurality 
was 82 ± 4%), a small positive bias was expected. This was true for all methods ex-
cept for Aldrich (-3.5), which was thus considered the worst technique. The 95% 
limits of agreement, going from worst to best, were -22.9 to 29.6 (Δ52.6), -28.3 to 
21.3 (Δ49.6), -16.9 to 20.0 (Δ36.8), -6.9 to 16.6 (Δ23.6) and -4.3 to 18.0 (Δ22.4) for 
BARI, Aldrich, APPROACH, T2w and ESA, respectively. Accordingly, ESA received the 
highest score, followed by T2w, APPROACH, BARI and Aldrich (Table 4). 
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Correlation of AAR and IS with respect to transmurality 
Figure 2 shows the correlation of AAR with IS, separated by transmurality sub-
groups. Physiology dictates that this correlation should improve with increasing 
infarct transmurality. For the Aldrich method, a reverse pattern was observed. For 
the BARI method, although the correlation went up from subendocardial to inter-
mediate transmurality infarcts, it went back down in near transmural infarcts. For 
the remaining techniques, the correlations increased with increasing amount of 
Figure 1. Bland-Altman plots showing the agree-
ment of AAR and IS in the sub-cohort of near 
transmural infarcts (n=22). A small positive bias is 
expected as our definition of transmurality was 
not 100% (mean transmurality was 82±4%). This 
was true for all methods, except for Aldrich; 95% 
confidence intervals were: -28.3 to 21.3 (Δ49.6), -
22.9 to 29.6 (Δ52.6), -16.9 to 20.0 (Δ36.8), -6.9 to 
16.6 (Δ23.6), and -4.3 to 18.0 (Δ22.4) for Aldrich, 
BARI, APPROACH, T2W and ESA. Abbreviations: 
AAR=area at risk; IS=infarct size; T2W=T2-weigh-
ted cardiovascular magnetic resonance; ESA=in-
farct endocardial surface area. 
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transmurality. The correlation in near transmural infarcts was highest for ESA 
(r=0.93, p≤0.001). Accordingly, ESA was given the highest relative score, followed by 
T2W, APPROACH, BARI, and Aldrich (Table 4). 
 
Figure 2. Correlation of AAR with IS for each 
transmurality sub-cohort. According to physi-
ologic rules, this correlation should increase 
with increasing infarct transmurality. This was 
observed for APPROACH, T2W and ESA and in 
the near transmural sub-cohort, the correlation 
was highest for ESA (0.93 (p<0.001). Abbrevia-
tions: ESA=infarct endocardial surface area; 
T2W=T2- weighted cardiovascular magnetic 
resonance. 
Inverse relationship of myocardial salvage with transmurality (Figure 3) 
The relationship of myocardial salvage with infarct transmurality is expected to be 
inverse (i.e. myocardial salvage is large in subendocardial infarcts and minimal in 
near transmural infarcts), and ideally, observations should be close to the inverse 
‘line of identity’ (defined as 100% minus transmurality). The percentage of patients 
within a ±30% margin around the inverse ‘line of identity’ (high=better) were 56%, 
76%, 65%, 77% and 92% for Aldrich, BARI, APPROACH, T2W and ESA, respectively 
(Table 3). The SEE values were 64.7, 44.8, 33.1, 26.6 and 21.7 for Aldrich, BARI, AP-
PROACH, T2W and ESA, respectively. Based on the latter, the ESA method was given 
the highest score and the Aldrich method the lowest (Table 4). 
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Figure 3. Correlation of myocardial salvage 
and mean transmurality. An inverse but 
moderate correlation was observed for each 
method (---). The highest number of observa-
tions within a ±30% margin of the inverse ‘line 
of identity’ (defined as: 100% - transmurality) 
was observed for ESA, followed by T2W, BARI, 
APPROACH and Aldrich (Table 3). The stan-
dard error of estimate (SEE) was smallest for 
ESA, followed by T2W, APPROACH, BARI and 
Aldrich. Abbreviations: T2W=T2-weighted car-
diovascular magnetic resonance; ESA=infarct 
endocardial surface area.  
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of identity’ (defined as: 100% - transmurality) 
was observed for ESA, followed by T2W, BARI, 
APPROACH and Aldrich (Table 3). The stan-
dard error of estimate (SEE) was smallest for 
ESA, followed by T2W, APPROACH, BARI and 
Aldrich. Abbreviations: T2W=T2-weighted car-
diovascular magnetic resonance; ESA=infarct 
endocardial surface area.  
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Table 3. Number of patients (%) within different margins of the ‘inverse line of identity’*. 
 Margin 
  ±10% (n=78) ±20% (n=78) ±30% (n=78) 
Aldrich (%) 13 (17) 32 (41) 44 (56)  
BARI (%) 18 (23) 49 (63) 59 (76) 
APPROACH (%) 20 (26) 38 (49) 51 (65) 
T2W (%) 33 (42) 53 (68) 60 (77) 
ESA (%) 38 (49) 62 (79) 72 (92) 
*Inverse line of identity: [(AAR − IS)/AAR] × 100]. Margins of ±10%, ±20% and ±30% were randomly 
chosen to indicate the proximity to the ‘inverse line of identity’. With respect to the ±30% margin,
ranking from best to worst is as follows: ESA, T2W, BARI, and APPROACH. Abbreviations: T2W=T2-
weighted cardiovascular magnetic resonance; ESA=infarct endocardial surface area. 
 
 
Table 4. Final scoring. 
 Physiologic concept  
 
Method 
 
AAR≥IS 
 
AAR=IS* 
Correlation with 
transmurality 
Line of identity 
fit† 
Final score 
Aldrich 1 1 1 1 4 
BARI 3 2 2 2 9 
APPROACH 2 3 3 3 11 
T2W 3 4 4 4 15 
ESA 5 5 5 5 20 
Each AAR method was ranked and given a relative score (1 (worst) to 5 (best)), according to how well 
they agreed with specified physiologic concepts. The last column shows the final scores after summa-
tion. The ESA method performed best, followed by T2W, APPROACH, BARI and Aldrich. * In near trans-
mural infarcts; † (salvage=100%-transmurality). Abbreviations: AAR=area at risk; IS=infarct size; T2W=T2- 
weighted cardiovascular magnetic resonance; ESA=infarct endocardial surface area. 
Final scores 
Table 4 shows the final scores assigned to each AAR method according to how well 
they agreed with the specified physiologic concepts. From worst to best, the me-
thods were as follows: Aldrich, BARI, APPROACH, T2W-CMR and ESA. 
Discussion 
The findings of our study can be summarized as follows. Using established physi-
ologic concepts to test the performance of different AAR methods in STEMI pa-
tients, CMR methods were better than angiographic methods (BARI and AP-
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PROACH), which were better than electrocardiographic (Aldrich). Concerning CMR, 
the ESA method performed consistently better than the hyperintense area on T2W-
CMR. 
 There is a major interest in measuring the AAR and myocardial salvage, which 
can be used as surrogate endpoints in clinical trials evaluating the effectiveness of 
new treatment strategies in AMI. Although being an accepted technique for the 
clinical assessment of AAR, SPECT suffers several limitations, such as 24-hour iso-
tope availability, the need for isotope injection before reperfusion, suboptimal spa-
tial resolution, and radiation burden.7 To validate the effectiveness of other me-
thods for measuring the AAR that are more clinically feasible, we used physiologic 
concepts that are based on the transmural “wavefront phenomenon” of infarct 
progression. In essence, animal models have shown that cell death in prolonged 
coronary occlusion progresses in a transmural wave front over a period of 3-6 
hours, and that the subendocardial lateral boundaries of the infarct are established 
within the first 40 minutes.2 Because DE-CMR accurately distinguishes between 
viable and nonviable myocardium, 4, 5 and has the potential to detect even small 
subendocardial infarcts, 23 it may be useful as a clinical reference standard for the 
relative comparison of methods that measure the AAR. Scoring systems based on 
the electrocardiogram and coronary angiogram are attractive since these tech-
niques are routinely performed in the acute phase of STEMI and are universally 
available.  
 The ST segment deviation score developed by Aldrich et al. is based on the 
number of leads with, and extent of, initial ST segment deviation. This AAR score 
was calibrated to predict final IS estimated by the Selvester QRS score in a popula-
tion that did not receive reperfusion therapy. 8 Our results show that the Aldrich 
score performed poor in estimating the AAR and confirm the result of a previous 
study using SPECT. 24 The poor performance of the ECG method might be explained 
by the fact that the ECG only momentarily captures the ST segment, which is known 
to behave dynamically during the acute phase of STEMI. In addition, the ST segment 
changes that are prominent during coronary occlusion represent the ischemic myo-
cardium, which will resolve when the ischemic myocardium is either infarcted or 
reperfused. With progressive myocardial necrosis, the ST segment deviation that is 
initially directing toward the ischemic region will be replaced by QRS deviation away 
from the infarcted region. 25, 26 The Aldrich score will therefore progressively unde-
restimate the initial AAR when infarction proceeds. 
 The angiographic BARI and APPROACH myocardial jeopardy scores have shown 
to provide independent prognostic information in patients with chronic ischemic 
heart disease. 10 In these methods, the jeopardized myocardium is based on the 
territory supplied by all significantly stenotic vessels (≥70% for the APPROACH and 
>50% for the BARI scoring system). Of interest, neither angiographic method has 
been validated with a proper reference standard, i.e. SPECT, nor for its use to quan-
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tify the AAR in STEMI patients. Moreover, a previous investigation evaluating 5 
other angiographic estimates of the AAR (not including BARI and APPROACH) 
showed a poor correlation with the AAR as defined by technetium-99m sestamibi 
imaging, suggesting a limited value of the coronary angiogram to measure the AAR. 
27 Of note, the extent of collateral flow is a major determinant of AAR that is not 
taken into account in any of the angiographic scoring systems. 28 Recently, Ortiz-
Pérez et al. found an excellent correlation between both BARI and APPROACH and IS 
in the subgroup of patients with near transmural infarcts, suggesting indirectly that 
these techniques might be useful to measure the AAR (r=0.90, p<0.001 for both). 15 
Despite the fact that our definition for near transmurality was more strict (>75% vs. 
>50% for Ortiz-Perez et al.), our correlations for BARI and APPROACH were only 
moderate at best (r=0.43 and r=0.67, respectively) and thus we could not confirm 
their results. In addition, our results showed that up to 50% of patients (for AP-
PROACH) had an AAR that was smaller than IS in the sub-cohort of near transmural 
infarcts. 
 An increasing number of studies are reporting on the assessment of the AAR by 
CMR, using dark-blood T2W-CMR sequences that are widely available on current 
scanners. 29, 30 Although promising, dark-blood T2W-CMR suffers several technical 
limitations 31 and validation and reproducibility are still limited. 12, 13, 16 Low-signal-
to-noise-ratios between normal and injured myocardium, artifacts, such as inferola-
teral wall signal loss due to cardiac motion and bright subendocardial rims due to 
stagnant blood either may under- or overestimate the AAR. Furthermore, the signal 
intensity thresholds used to define abnormal myocardium for both DE- and T2W-
CMR are arbitrary, which could clearly affect IS, AAR and salvage calculations. So far, 
the results of studies using dark-blood T2W-CMR for measuring the AAR are confus-
ing. While some studies have reported that the AAR≥IS in almost 100% of patients, 
we and others have observed this in only 87% and 65%. 32 Newer methods, such as 
bright blood T2-prepared steady state free precession (SSFP), hybrid methods be-
tween TSE and SSFP and contrast-enhanced SSFP-cine-imaging are promising and 
may improve accuracy. 33, 34, 35  
 In a recent small study (38 STEMI patients), Berry et al. also compared electro-
cardiographic (but not Aldrich) and angiographic methods (APPROACH and the Duke 
jeopardy score) with T2W-CMR imaging to assess the AAR. 29 They found a good 
correlation (r=0.78, p<0.0001) and agreement (2.5% bias on Bland-Altman analysis) 
between T2W-CMR and the APPROACH method for measuring the AAR. This finding 
led to their conclusion that T2W-CMR is a good measure for the AAR. In their study 
they only used one physiological concept to check for internal consistency, which 
was that AAR≥IS. For both T2W-CMR and APPROACH, higher percentages of pa-
tients with AAR≥IS were found than in our study (92% and 88% vs. 87% and 76%, 
respectively). They did not test the other complementary physiologic concepts as 
was performed in our study. Based on our findings it does not seem appropriate to 
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validate T2W-CMR against the angiographic techniques (i.e. APPROACH) since 1) we 
did not find a good relationship between T2W and angiographic measures of AAR 
and 2) APPROACH performed poorly against our reference standard. 
 The ESA method is a relatively new but promising method to assess the AAR, 
which is measured on DE-CMR images. 15 It is based on the transmural wave front 
progression of necrosis, and the setting of the lateral boundaries of the AAR by the 
lateral boundaries of infarction after 40 minutes.2 Variation in the percent of the 
AAR that becomes necrotic is primarily caused by the variation in transmural extent 
of infarction. 21 Measuring the infarct ESA as a percentage of total LV subendocardi-
al surface area would correspond to the AAR. Of all tested methods for measuring 
the AAR, we found that infarct ESA consistently performed best. Further validation 
is needed, because the results of two other studies have been conflicting. Although 
the AAR by the ESA method was smaller than by T2W-CMR in both studies, the 
correlation between them was good (r=0.77 (p<0.001) in one study, 14 but was low 
(r=0.41, p=0.002) in the other study. 36 Whether this discrepancy is caused by varia-
tion in either the ESA or T2W-CMR measurements remains unresolved.  
 For the determination of myocardial salvage, the use of different techniques to 
assess the individual components of AAR and IS may cause an offset problem. In 
other words, two different techniques may be highly correlated, but one may al-
ways be consistently under- or overestimating the other. Therefore the combined 
use appears problematic, especially in combining electrocardiographic and angio-
graphic measurements with CMR techniques. For instance if the AAR is smaller that 
IS, the measurement of salvage will be useless. 
Limitations 
Our results are based on a limited number of patients and should therefore be in-
terpreted with care. However this is a larger study so far to compare different tech-
niques for measuring the AAR against a reference standard. We did not have SPECT 
imaging available to provide precise measurements of the AAR, but based on our 
physiologic concepts we are confident that our conclusions are valid. For example, 
when using the APPROACH method, the AAR was smaller than IS by DE-CMR in 24% 
of patients overall and the correlation with near transmural infarcts was only mod-
erate, indicating this method is poor. We used specific cutoffs to quantify the AAR 
and IS by T2w and DE-CMR (>5 and >2 SD), which was based on the literature. There 
are certain limitations as we have discussed already with these cutoffs and although 
this may affect absolute size measurements, the correlation between methods 
remains unchanged. 
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Conclusion 
For measuring AAR, CMR methods performed better than angiographic methods, 
which performed better than electrocardiographic. Concerning CMR, ESA per-
formed consistently performed better than T2W. Our results also show that com-
bining electrocardiographic or angiographic methods of AAR with CMR determined 
infarct size, the determination of salvage may be problematic. 
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Chapter 7 discusses the results of this thesis in the light of existing evidence or con-
troversy and future perspectives will be given.  
MVO: underlying pathophysiology and clinical diagnosis 
Coronary occlusion results in ischemia within the region of the coronary distribu-
tion, defined as the area at risk (AAR). Without restoration of blood flow, myocardi-
al necrosis progresses as a 'wavefront' from the subendocardium toward the sub-
epicardium. 1 A complex relationship exists between myocyte necrosis and capillary 
damage, the latter resulting in the ‘no-reflow’ phenomenon or MVO. The underlying 
pathophysiological mechanisms of myocyte death and MVO are complex, multifac-
torial and not fully understood. Ischemia results in myocyte and vascular injury, and 
both can be aggravated by additional reperfusion injury. A balance exists between 
the benefits of reperfusion to reduce infarct size on the one hand and reperfusion 
injury on the other hand, depending on the duration of occlusion. If ischemic myo-
cardium is reperfused early, infarct size is limited and additional reperfusion injury 
minimal. At the other extreme, when ischemic myocardium is reperfused late, ne-
crosis will be near transmural and additional reperfusion injury will also be minimal. 
Thus, a relatively narrow time window exists, during which reperfusion injury may 
be preventable. 2  
 Ischemia induces the accumulation of intracellular sodium, hydrogen and cal-
cium ions in myocytes as well as in endothelial cells. 3 Corresponding changes in-
clude endothelial cell swelling, the formation of intraluminal blebs, fibrin deposition 
and extravascular compression by surrounding edematous myocytes. 4 Ambrosio et 
al., and later Reffelman et al., demonstrated a progressive expansion of microvascu-
lar damage during reperfusion, which is assumed to be the result of reperfusion 
injury. 5, 6 The precise pathophysiology of reperfusion injury remains to be estab-
lished, but involves several complex molecular and cellular mechanisms. Reperfu-
sion markedly enhances intracellular calcium loading, mitochrondrial permeability 
transition pore (mPTP) opening, infiltration of neutrophils and platelets into the 
ischemic region that adhere to endothelial cells, form aggregates and plug capilla-
ries. 4, 7 Furthermore, neutrophil adhesion is followed by activation, diapedesis, and 
migration into surrounding tissue and release of oxygen free radicals, proteolytic 
enzymes, and pro-inflammatory mediators. 8 This may then lead to additional myo-
cyte and endothelial cell damage.  
 Reperfusion injury thus affects both myocytes as well as the endothelium. 
Whether this always evolves in parallel or whether progressive MVO during reperfu-
sion can contribute to additional myocyte death is still controversial. 9 An argument 
against this comes from a recent randomized, double blind, placebo-controlled trial, 
investigating the efficacy of the naturally occurring peptide FX06 to reduce infarct 
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size. 10 The results of this trial showed that, although MVO was more than halved in 
patients treated with FX06, no major difference in infarct size at 5 days and 4 
months was found. Furthermore, animal studies have shown that the occurrence of 
microvascular damage is strongly related to the duration of ischemia prior to reper-
fusion and always lags behind myocardial cell injury. 11, 12 Whether this sequence of 
events is similar during reperfusion is unknown, but if so, would make additional 
myocyte death as a consequence of MVO less likely. Because infarct size has been 
shown to be the major determinant of MVO 13, the correlation of MVO with clinical 
outcome might solely reflect the correlation of MVO with infarct size. 14  
 After the first description of MVO in animal models, compromised reperfusion 
was also recognized clinically with a variable prevalence, ranging from 5% up to 
50%, depending on the methods used and population studied. 15 In humans, PCI-
related distal embolization of atherothrombotic material significantly contributes to 
MVO. Although there are several quantitative measures of angiographic perfusion 
such as Thrombolysis In Myocardial Infarction (TIMI) flow grading, corrected TIMI 
frame count, TIMI myocardial perfusion grade and blush score, none of these tech-
niques directly visualize the affected myocardium. 16-18 Similarly, rapid resolution of 
initial ST-segment elevation (STR) following reperfusion therapy indicates full and 
prompt restoration of myocardial tissue perfusion, but remains a surrogate bio-
marker. 19 In contrast, myocardial contrast echocardiography (MCE) and cardiovas-
cular magnetic resonance imaging (CMR) are able to directly visualize and quantify 
MVO. 20-24 Because CMR allows accurate and reproducible assessment of ventricular 
function, infarct size and MVO in one single examination as opposed to MCE, it is 
the preferred technique to assess the extent of injury after acute myocardial infarc-
tion (AMI).  
Detection and characteristics of MVO 
Investigators have used different CMR techniques for the detection of MVO, but 
there is no clear consensus about which technique is most accurate. First pass per-
fusion (FPP) CMR dynamically tracks the first pass of a contrast agent in the myo-
cardium during contrast injection. MVO can be shown as a persistent subendocardi-
al perfusion defect due to delayed wash-in of contrast in the infarct core. MVO 
using this technique was validated with thioflavin-S staining, one of the pathologic 
gold standards of detecting MVO. 22 With traditional delayed enhancement (DE) 
CMR, imaging starts 10-15 minutes after contrast injection and MVO can be ob-
served as a central hypointense region within the hyperenhanced (infarcted) myo-
cardium. 20 MVO detected either by FPP-CMR or DE-CMR has prognostic significance 
regarding LV remodeling and outcome. 20, 25-28 
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 As gadolinium is freely permeable through the vascular wall and passively dif-
fuses into the area of MVO within 10-15 minutes, FPP-CMR may be more sensitive 
than DE-CMR for the detection of MVO. On the other hand, FPP-CMR has a lower 
spatial resolution, signal-to-noise ratio and incomplete LV coverage as compared to 
DE-CMR. In chapter 3, we used an optimized single breathhold 3D inversion recov-
ery gradient echo technique (IR-GRE) for imaging MVO early and late after contrast 
injection. With this technique we combined the advantage of imaging MVO early 
after contrast injection with the higher spatial resolution and complete LV coverage 
of a regular DE-CMR sequence. With this approach, we found a higher prevalence of 
early MVO than late MVO (63% vs. 54%, p=0.008). In addition, we showed that pa-
tients with early MVO but not late MVO (MVO disappearance) had infarct sizes and 
LV ejection fractions (LVEF) that were intermediate between patients with persis-
tent (late) MVO and without any MVO.  
 There are only few comparisons in the literature between FPP-CMR and DE-
CMR for the detection of MVO. In the study by Lund et al., FPP-CMR depicted MVO 
in 38% of 60 patients, whereas MVO was observed on DE-CMR in only 28% of pa-
tients. 29 A limitation of this study was the incomplete LV coverage by FPP-CMR 
(single slice) and DE-CMR (3 slices). Nijveldt et al. used FPP-CMR (early hypoen-
hancement), a 3D IR-GRE sequence run at 2 minutes (intermediate enhancement), 
and a regular 2D DE-CMR sequence run at 12-15 minutes after contrast injection 
(late hypoenhancement) to detect MVO. 30 The prevalence of MVO on early, inter-
mediate and late hypoenhancement imaging was 70%, 62% and 59%, respectively, 
which is comparable to our findings. They also found that late hypoenhancement 
was the strongest predictor of LV volumes and LVEF at follow-up. They did not spe-
cifically investigate the long-term prognostic implications of intermediate hypoen-
hancement (MVO on early but not late imaging).  
 Microvascular flow following reperfusion is spatially and temporally complex 
with coexisting regions of hyperemia, impaired vasodilatory flow reserve, low flow 
and almost zero reflow. In addition, the spatial extent of these perfusion patterns 
may vary over time. 5, 31-33 Improvement in microvascular dysfunction may even 
occur early after myocardial infarction (<1 week) and may be beneficial in prevent-
ing left ventricular remodeling. 34 Our approach of using the same pulse sequence 
for early and late imaging - except for a longer inversion time - allowed us to study 
the dynamic changes of MVO over time going from early to late imaging, and occur-
ing within minutes. We demonstrated that the decrease of MVO even in this short 
time period is heterogeneous, which might reflect differences in underlying micro-
vascular damage. The decrease and disappearance of early MVO during late imaging 
was only related to the initial size of MVO, but not to other clinical variables. 
Whether this aspect has clinical implications is currently unknown, but could be 
helpful in evaluating therapies that limit reperfusion injury. We recommend that 
both early and late MVO imaging is performed in the current evaluation of AMI by 
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CMR. Our optimized single breathhold 3D IR-GRE technique is fast, accurate and can 
be easily implemented in current clinical and study protocols.  
Microvascular obstruction and intramyocardial hemorrhage 
MVO is a consequence of ischemia and reperfusion and may lead to intramyocardial 
hemorrhage (IMH) in the infarct core by extravasation of red blood cells through 
damaged endothelium. 35-37 IMH has been observed both after pharmacological 
reperfusion and mechanical reperfusion. 38, 39 Inflammation in AMI increases local 
myocardial water content and increases signal intensity (SI) on T2 weighted imaging 
(T2W-CMR). On T2W-CMR, IMH can be observed as a central dark region within a 
hyperintense region and is caused by shortening of T2-relaxation due to the para-
magnetic properties of predominantly deoxyhemoglobin. 40 Although validation is 
still limited, these hypointense regions on T2W-CMR seem to correspond to the 
histological evidence of IMH. 41 Thus, with CMR it is now possible to study these 
histological aspects of injury in AMI in vivo and in a single investigation and non-
invasively. Previous studies have suggested that MVO, as detected by CMR, is inde-
pendently related to adverse remodeling and clinical outcome. 20, 26, 33 The clinical 
significance of IMH is less evident.  
 The results of our study in chapter 4 show that IMH and MVO are strongly re-
lated and that infarct size was the only independent predictor of LV remodeling. In 
contrast to our results and those of Beek et al. 42, two recent other studies sug-
gested that IMH is an independent predictor of adverse LV remodeling regardless of 
infarct size and MVO. 43, 44 These discrepancies could be explained by differences in 
definition and quantification of IMH. In contrast to the study by Ganame et al., who 
defined IMH as hypointense areas with mean SI of 2 standard deviations (SD) below 
the SI of the hyperintense peripheral region, we manually delineated regions of 
IMH. In addition, a minimal volume of 1 mL for IMH was required for the definition 
in the study by Ganame et al. This may explain the lower prevalence of IMH in their 
study as compared to our study (24% vs. 43%), suggesting either that more severe 
forms of IMH were studied and more subtle forms of IMH were excluded. As a result 
of this, the independent role of severe forms of IMH on adverse remodeling might 
have become more prominent.  
 Myocyte necrosis, MVO and IMH in AMI are strongly related, time-sensitive 
phenomena and the real mechanisms underlying these features are not yet well 
understood in humans. Both MVO and IMH depend on the duration of coronary 
occlusion but lag behind myocyte death. 11, 12 Similar to myocardial necrosis, both 
progress from the endocardium toward the epicardium as a ‘wavefront’. After vary-
ing periods of ischemia, sequential changes of the microvasculature occur, resulting 
in MVO and loss of capillary integrity. Ensuing reperfusion then leads to extravasa-
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 As gadolinium is freely permeable through the vascular wall and passively dif-
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tion of erythrocytes from an already severely compromised microvasculature, re-
sulting in IMH. 35, 36 We have shown that some patients with MVO did not have IMH 
and that infarct size and LVEF were in between average values of patients who had 
both MVO and IMH, and patients without either MVO or IMH. In line with these 
experimental studies, this suggests that the co-existence of IMH and MVO are a 
gradation of the underlying severity of ischemic injury. Further studies are neces-
sary to clarify the clinical role of IMH beyond MVO or that it is just a marker of the 
already severely damaged microvasculature.  
ST segment recovery in relation to underlying infarct characteristics 
To decide whether patients may need adjunctive infarct size limiting therapies after 
optimal epicardial flow has been established, the determination of early STR is of 
great interest. Despite the general acceptance that early STR after successful epi-
cardial flow establishment reflects myocardial reperfusion 19, 45, only a limited num-
ber of studies has directly related incomplete STR to microvascular dysfunction. 24, 46 
Instead, incomplete STR has been predominantly investigated in relation to de-
creased myocardial salvage, larger infarct size, low LVEF, and adverse outcome. 47-50 
Studies investigating the relation of STR with myocardial blush grading (MBG) have 
shown that still 35% of patients with MBG 3 have incomplete STR 18. This suggests 
that STR is rather a direct reflection of injury to myocytes than of MVO, because the 
microvasculature in these patients is ‘patent’.  
 Whether MVO can contribute to additional myocyte death during reperfusion, 
or that both evolve in parallel remains unresolved. MVO and infarct size are strongly 
related and CMR studies investigating their independent relationship with adverse 
remodeling have been inconsistent, with some favoring MVO 20, 30, 51, 52 and others 
favoring infarct size. 23, 53-55 This then hinders the clarification of the relationship of 
STR with adverse remodeling in relation to these underlying infarct characteristics. 
In chapter 5 we investigated the value of STR 30 and 60 minutes after mechanical 
reperfusion in relation to underlying infarct characteristics and adverse remodeling. 
Instead of evaluating the relationship of STR with these individual infarct characte-
ristics, we used their correlational information and clustered patients into three 
different CMR groups at risk for adverse remodeling. Patients were clustered into a 
low, intermediate, and high CMR risk group, which was based on infarct size, trans-
murality, and MVO. By doing so, we first found that infarct size was more predictive 
for adverse remodeling than MVO and infarct transmurality. Second, and after eva-
luating multiple STR methods, we found that the most simple method of worst lead 
ST deviation (STD) determined as early as 30 minutes after reperfusion, accurately 
discriminated between the high and low CMR risk group.  
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 Our study is one of only few that have investigated STR in relation to CMR 
based characteristics of reperfused AMI and adverse remodeling during follow-up. 
Our results are different from those of Nijveldt et al., who found that residual ST 
segment elevation on the 12-lead ECG 60 minutes after reperfusion, was the 
strongest predictor of low initial LVEF and the presence of MVO at 4 ± 2 days, even 
after controlling for infarct size. 56 No follow-up data are reported in that study. In a 
recent randomized trial comparing primary PCI with combined proximal embolic 
protection and thrombus aspiration, no significant differences in complete ST-
segment resolution at 60 min. (primary end point) and infarct size or LVEF at follow-
up CMR were found. 57, 58 In a post hoc analysis, STR appeared to be a strong, inde-
pendent predictor of LVEF and infarct size at follow-up. 59 In that study, a relation-
ship of STR with MVO was not studied. A post hoc analysis of another clinical trial, 
investigating the effect of an infarct size limiting agent (FX06) in adjunction to PCI, 
demonstrated that 90 minute worst-lead residual STD was associated with both 
final infarct size and long-term left ventricular function at 4 months. Our study is the 
first to demonstrate that worst-lead residual STD, by far the simplest method for 
calculating ST-segment recovery, can be measured as early as 30 minutes after re-
perfusion to predict adverse remodeling, which was mainly related to infarct size. 
 Comparing different parameters (i.e. STR and MVO) that are assessed at differ-
ent time points after reperfusion might be problematic because both behave dy-
namically over time. This may explain the inconsistent results between our study 
and that of Nijveldt et al. 30 We suggest that when CMR is used to clarify the relation 
of STR with MVO in future studies, both early and late MVO imaging should be per-
formed as soon as possible after reperfusion.  
The area at risk 
The region of acutely hypoperfused myocardium within a coronary distribution 
during coronary occlusion is defined as the AAR. 60 Without restoration of blood 
flow the AAR will be subject to near transmural infarction. 1 If the AAR could be 
reliably estimated in combination with infarct size, then the ‘salvaged’ myocardium 
could be assessed, allowing evaluation of the quality of reperfusion and effective-
ness of reperfusion therapies. Infarct size is accurately measurable with DE-CMR 61, 
62, but clinical determination of the AAR remains challenging as the reference stan-
dard (i.e. SPECT) is hampered by radiation exposure, low spatial resolution and 
difficult logistics requiring tracer injection before reperfusion.  
 Both electrographic and coronary angiographic measures have been used to 
measure the AAR. 63-65 Experimental studies have suggested that the hyperintense 
area on T2W-CMR delineates the AAR in AMI. 66 This was soon followed by multiple 
clinical studies using this technique for measuring both AAR and myocardial salvage 
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in combination with DE-CMR. 67-71 A novel CMR technique is infarct endocardial 
surface area ─ ESA ─ by DE-CMR 65 as a proportion of the total LV endocardial sur-
face area. This method is based on the concept that myocardial necrosis progresses 
from endocardium toward the epicardium with minimal lateral extension. 1 Al-
though promising, more validation of these CMR methods in humans against ap-
propriate reference standards is necessary. Thus far, angiographic myocardial jeo-
pardy scores have been used to validate these CMR methods for measuring the AAR 
in humans. Of interest, these angiographic scores were originally developed to pro-
vide independent prognostic information in patients with chronic ischemic heart 
disease. 64 Moreover, these scores themselves have not been validated against a 
reference standard (i.e. SPECT), nor for their use to quantify the AAR in STEMI pa-
tients. The angiographic methods may thus not be sufficiently qualified to be used 
as an appropriate reference standard. Recent studies comparing the angiographic 
with CMR methods have reported inconsistent results. For example, Ortiz-Pérez et 
al. found excellent correlations between the angiographic methods and infarct ESA 
(r=0.90 for BARI and r=0.87 for APPROACH), whereas in a study by Wright et al., the 
correlation for BARI with ESA was only moderate (r=0.42). 65, 71 
 In chapter 6 we used multiple established physiologic concepts to evaluate the 
performance of electrocardiographic, angiographic and CMR methods for measuring 
the AAR. These physiologic concepts were based on the ‘wavefront phenomenon’ of 
infarct progression. 1 Our methodology was quite different from other studies that 
used only one of these physiologic concepts to validate the angiographic reference 
standard (i.e. BARI and APPROACH). Furthermore, our results were different. Ortiz 
Pérez et al. found excellent correlations between the angiographic scores and in-
farct size in the sub-cohort of near transmural infarcts (r=0.90), whereas this corre-
lation was only moderate at best in our study (r=0.43-0.67). 65 Berry et al. found that 
92% and 88% of patients using T2W-CMR and APPROACH had an AAR ≥ infarct size, 
while in our study this was 87% and 76%. 67 The conclusions of these studies that 
the T2W-CMR and APPROACH methods are accurate measures of the AAR thus 
seem premature. 
 We concluded that the CMR methods performed better than the angiographic 
methods, which performed better than electrocardiographic methods to measure 
the AAR. Of the CMR methods, ESA performed better than T2W-CMR. Based on our 
results, the angiographic methods, BARI and APPROACH, should in fact not be used 
to validate other methods that measure the AAR. 
Future perspectives  
Modern STEMI treatment has reduced 30-day mortality below 4% 72, making it less 
feasible to demonstrate the benefit of adjunctive cardioprotective therapies. For 
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demonstrating this, very large clinical trials would be needed. Given that quantifica-
tion of LVEF, ventricular volumes and infarct size by CMR is very accurate and highly 
reproducible, these parameters can provide useful surrogate end points. 73 In addi-
tion, these parameters have been shown to provide important independent prog-
nostic information. 74, 75 Thus, CMR will become increasingly important to evaluate 
the efficacy of adjunctive therapeutic strategies either in the form of pharmacologi-
cal 76 and mechanical interventions 77, 78 or cellular-based therapies. 79 Separating 
ischemic injury from additional reperfusion injury remains clinically challenging. 
Previous studies have shown that bursts of ventricular arrhythmias early after re-
perfusion in patients with TIMI 3 flow and ≥ 50% stable ST-segment recovery are 
associated with larger infarct sizes and lower LVEF as determined with SPECT. 80, 81 
Whether this ECG biomarker may be useful as a real-time parameter of reperfusion 
injury and also its relation to CMR derived parameters needs to be studied more 
thoroughly. Another important question to address in the future is the determina-
tion of the true prognostic significance of MVO and IMH and their disputable role in 
infarct progression. Since DE-CMR allows the simultaneous assessment of both 
MVO and IS, this technique is useful to demonstrate whether interventions that 
specifically ameliorate MVO or IMH could reduce final infarct size and improve 
prognosis. In addition, future developments such as molecular imaging and targeted 
contrast agents are likely to improve our understanding of reperfusion injury and 
determinants of LV remodeling. Infarct size and scar heterogeneity as determined 
with CMR are increasingly being recognized as significant risk factors for ventricular 
arrhythmias and sudden cardiac death (SCD). Eventually, this will better identify 
patients at risk for SCD, as current guidelines for implantation of internal cardiover-
ter defibrillators are predominantly based on LVEF and lack sufficient sensitivity and 
specificity. 82 Finally, the prognostic importance of non-Q-wave unrecognized MI 
(UMI) as detected by DE-CMR has recently been shown. 83 Given the increasing 
prevalence of diabetes mellitus worldwide, this may have important implications for 
individual patients and for public health care. Population studies to determine the 
prevalence of UMI in diabetes mellitus and evaluate if early diagnosis with appro-
priate treatment will alter prognosis, are needed.  
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Conclusions 
The studies from this thesis demonstrate that by using an optimized CMR tech-
nique, the prevalence of MVO early after contrast injection is higher than with tradi-
tional DE-CMR. The extent of MVO going from early to late imaging decreases and 
this decrement is heterogeneous. Patients with early but late MVO disappearance 
have an infarct size and remodeling parameters that are intermediate between 
patients without MVO and those with both early MVO and late MVO persistence. 
IMH and MVO are frequently observed after reperfused AMI and are strongly re-
lated phenomena. From two separate studies, one investigating the role of infarct 
size, MVO and IMH and the other investigating the role of infarct size, transmurality 
and MVO, we found that infarct size was the best predictor of adverse remodeling 
after 3 months. Worst lead residual STD, determined as early as 30 minutes after 
PCI, accurately discriminated between a high and combined low/intermediate CMR 
risk group and was mainly related to infarct size. For measuring AAR, CMR methods 
were better than angiographic methods, which were better than electrocardio-
graphic methods. ESA by DE-CMR appeared to be the best method for measuring 
AAR in vivo. Overall, the results of this thesis show that CMR accurately detects 
different underlying characteristics of injury in reperfused AMI and allows investi-
gating their relation with adverse remodeling. CMR has great potential to unravel 
the complex underlying pathophysiology of ischemia-reperfusion in AMI in humans 
that must lead to adjunctive infarct size limiting therapies. 
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Mortality from acute myocardial infarction (AMI) has declined the last decades, but 
remains high. Timely epicardial reperfusion significantly reduces infarct size but 
reperfusion is not always established at the tissue level. The mechanisms of this 
microvascular obstruction (MVO) remain incompletely understood. Reperfusion 
may paradoxically lead to additional myocyte death (reperfusion inury) and intra-
myocardial hemorrhage (IMH), because of leakage of erythrocytes from severely 
damaged microvasculature. Myocyte death, MVO and IMH are strongly related, 
time-sensitive phenomena, but MVO and IMH lag behind myocyte death. Infarct size 
is a well known predictor of outome after AMI but conflicting results have been 
published about the clinical significance of MVO and IMH beyond infarct size. With 
different techniques, cardiovascular magnetic resonance (CMR) provides a compre-
hensive, multifaceted investigation of the heart in AMI. The optimal timing of imag-
ing of MVO after contrast administration and the dynamic changes in its appearance 
in relation to the underlying infarct characteristics and remodeling are not well 
known. ST segment resolution (STR) on the electrocardiogram after reperfusion is 
an accepted marker for myocardial reperfusion and useful for early risk stratifica-
tion. However, the exact relation of STR with underlying infarct characteristics and 
remodeling as assessed with CMR is not well known. For the evaluation of addition-
al infarct size limiting therapies, there is a need to accurately measure the area at 
risk (AAR) and myocardial salvage. Despite an increased interest in angiographic, 
electrocardiographic and CMR techniques for measuring the AAR, validation in hu-
mans is still limited. In this thesis, characteristics of injury in reperfused AMI were 
assessed with CMR and their clinical significance in relation to remodeling was in-
vestigated. In addition, the relation of STR with these infarct characteristics and 
ventricular remodeling was investigated. Concerning AAR measurement, the per-
formance of different electrocardiographic, angiographic, and CMR methods was 
evaluated using established physiological concepts. 
 In chapter 2, the underlying pathophysiology of myocardial ischemia with an 
emphasis on MVO and current techniques to detect MVO are reviewed. 
 Chapter 3 describes an optimized single breathhold inversion recovery gradient 
echo pulse sequence for measuring MVO 2 minutes after contrast administration 
(early MVO). In this study, traditional delayed enhancement (DE) CMR 10 minutes 
after contrast administration was used to detect late MVO. Cine CMR was used to 
assess left ventricular (LV) volumes and ejection fraction (EF) at 5 days and 3 
months after admission. The prevalence of early MVO was higher than late MVO 
(63% vs. 54%, p=0.008). The extent of MVO decreased from early to late imaging 
(4.3 ± 3.2% vs. 1.8% ± 1.8%, p<0.001) and this decrement showed a heterogeneous 
pattern. At baseline, patients without MVO (early and late) had a higher LVEF than 
patients with persistent late MVO (56 ± 7% vs. 48 ± 7%, p<0.001) and LVEF was in-
termediate in patients with early MVO but late MVO disappearance (54 ± 6%). Dur-
ing follow-up, LVEF improved in all three subgroups but remained intermediate in 
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patients with late MVO disappearance. Our approach of imaging MVO early and late 
after contrast administration allowed the discrimination of a subgroup of patients 
with early but late disappearance of MVO. These patients had infarct sizes and re-
modeling parameters that were intermediate between patients without any MVO 
and patients who had both early and late MVO. 
 The prevalence and clinical implications of MVO and IMH in a group of reper-
fused first AMI patients were investigated in chapter 4. T2-weighted (T2W), cine 
and DE-CMR were performed at 5 days and 3 months after admission to assess IMH, 
LV function and late MVO. MVO was observed in 54% and IMH in 43% of patients. 
All patients with IMH had MVO, but not vice versa. MVO and IMH were always lo-
cated subendocardially and correlated strongly (r = 0.8, p<0.001). Pre-PCI TIMI 3 
flow was only observed in patients without MVO and IMH. Infarct size and impair-
ment of systolic function were largest in patients with both MVO and IMH, smallest 
in patients without MVO and IMH and intermediate in patients with MVO but with-
out IMH, both at baseline and follow-up. Infarct size was the only independent pre-
dictor of LV remodeling.  
 The relation of early post-percutaneous coronary intervention (PCI) STR with 
underlying infarct characteristics and adverse remodeling was investigated in Chap-
ter 5. For this study, 8 different STR methods (i.e. relative STR (%) and residual abso-
lute ST segment deviation (STD, mm), summed and single lead), were evaluated at 
30 and 60 minutes after PCI. Cine and DE-CMR were performed at 5 days and 3 
months after admission. Using K-means cluster analysis, three CMR risk groups (low, 
intermediate, high) for adverse remodeling were identified based on combinations 
of infarct size, infarct transmurality and late MVO. Infarct size was the main deter-
minant of adverse remodeling (low LVEF) after 3 months. Of all tested STR variables 
worst lead residual STD 30 minutes after reperfusion allowed accurate identification 
of patients at high risk for adverse remodeling after 3 months, which was mainly 
related to IS rather than transmurality or MVO.  
 In chapter 6, the performance of electrocardiographic (Aldrich), angiographic 
(BARI and APPROACH), and CMR methods (T2W hyperintensity and infarct endocar-
dial surface area (ESA) by DE-CMR) for measuring the AAR were evaluated, using the 
following established physiological concepts as a reference standard: 1) AAR ≥ in-
farct size, 2) in transmural infarcts, AAR should approach infarct size, 3) the correla-
tion between AAR and infarct size should increase as infarct transmurality increases, 
4) myocardial salvage [(AAR − infarct size)/AAR x 100] should be inversely related to 
infarct transmurality, following the inverse line of identity. For measuring AAR, CMR 
methods were better than angiographic methods, which were better than electro-
cardiographic. Overall, ESA by DE-CMR appeared to be the best method for measur-
ing AAR in vivo. 
 Chapter 7 discusses the main findings of this thesis in the light of existing evi-
dence or controversy. Future perspectives are given in the end. 
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Conclusions 
CMR allows accurate assessment of injury of reperfused AMI, showing that MVO 
and IMH are prevalent and strongly related phenomena. Furthermore, our results 
showed that infarct size was the most important predictor of adverse remodeling 
after 3 months. Worst lead residual STD 30 minutes after reperfusion allows accu-
rate identification of patients at high risk for adverse remodeling, which was mainly 
related to IS rather than transmurality or MVO.  For measuring the AAR, CMR me-
thods performed better than angiographic methods, which were better than elec-
trocardiographic methods.  
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Hoewel de sterfte t.g.v. het acute myocard infarct (AMI) de laatste decennia is ge-
daald, blijft deze hoog. Vroegtijdige epicardiale reperfusie beperkt de infarctgroot-
te, maar op weefselniveau wordt optimale reperfusie niet altijd bereikt. Het mecha-
nisme van deze microvasculaire obstructie (MVO) is onvolledig bekend. Reperfusie 
kan paradoxaal leiden tot additionele spiercelsterfte (reperfusieschade) en in-
tramyocardiale bloeding (IMH), doordat erytrocyten uit de ernstig beschadigde 
bloedvaatjes ‘lekken’. Spiercelsterfte, MVO en IMH zijn sterk aan elkaar gerelateer-
de en tijdsafhankelijke fenomenen, maar bekend is dat MVO en IMH pas ontstaan 
na het optreden van spiercelsterfte. De prognose na een AMI wordt in belangrijke 
mate bepaald door de infarctgrootte. Studies die de onafhankelijke invloed van 
MVO en IMH op prognose onderzoeken zijn echter niet éénduidig. Cardiovasculaire 
magnetische resonantie beeldvorming (CMR) maakt uitgebreid en veelzijdig onder-
zoek van het geïnfarceerde hart mogelijk. Na toediening van een contrastmiddel zijn 
het optimale tijdstip voor het opsporen en de dynamische veranderingen van MVO 
niet goed bekend. Hoewel ST segment resolutie (STR) op het elektrocardiogram na 
reperfusie een geaccepteerde maat is voor de kwaliteit van reperfusie en gebruikt 
wordt voor vroege risicostratificatie, is de relatie van STR met onderliggende in-
farctkarakteristieken en cardiale functieveranderingen (adverse remodeling) na een 
AMI onvolledig bekend. Voor de ontwikkeling en evaluatie van nieuwe therapieën 
die infarctgrootte verder kunnen beperken, is nauwkeurige meting van de area at 
risk (AAR) en myocardial salvage nodig. Hoewel er een toenemende belangstelling is 
in electrocardiografische, angiografische en CMR methoden om de AAR te meten, is 
klinische validatie nog beperkt. In dit proefschrift worden verschillende infarctkarak-
teristieken bepaald m.b.v. CMR en hun relatie met STR en adverse remodeling on-
derzocht. Tevens wordt onderzocht hoe bruikbaar verschillende electrocardiografi-
sche, angiografische en CMR methoden zijn om de AAR te meten, door ze onderling 
te vergelijken aan de hand van enkele fysiologische principes van infarctuitbreiding.  
 Hoofdstuk 2 geeft een overzicht van de onderliggende pathofysiologie van 
myocardischemie met de nadruk op MVO en de huidige methoden om MVO te diag-
nosticeren.  
 Hoofdstuk 3 beschrijft een geoptimaliseerde, in één adempauze verkregen, 
inversion recovery gradient echo pulse sequence voor de detectie van MVO 2 minu-
ten na contrasttoediening (vroege MVO). Na 10 minuten vond tevens traditionele 
delayed enhancement (DE) CMR plaats voor de detectie van late MVO. D.m.v. cine 
CMR werden linker ventrikel (LV) volumina en ejectie fractie (EF) 5 dagen en 3 
maanden na ziekenhuisopname gemeten. De prevalentie van vroege MVO was 
hoger dan van late MVO (63% vs. 54%, p=0.008). De grootte van MVO nam af van 
vroeg naar laat (4.3 ± 3.2% vs. 1.8% ± 1.8%, p<0.001) en vertoonde een heterogeen 
patroon. De uitgangs-EF was hoger bij patiënten zonder MVO (vroeg en laat) dan bij 
patiënten met persisterende late MVO (56 ± 7% vs. 48 ± 7%, p<0.001) en intermedi-
air bij patiënten met wel vroege maar geen late MVO (54 ± 6%). De follow-up EF 
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verbeterde in alle 3 groepen maar bleef intermediair in de patiënten bij wie late 
MVO verdween. Door deze strategie konden patiënten worden onderscheiden die 
wel vroege maar geen late MVO hadden (verdwijning) en bij wie infarctgrootte en 
adverse remodeling intermediair waren tussen patiënten zonder MVO en patiënten 
met zowel vroege als late MVO. 
 De prevalentie en klinische rol van MVO en IMH in een groep patiënten met een 
gereperfundeerd eerste AMI werden onderzocht in hoofdstuk 4. MVO, IMH en LV 
functie werden 5 dagen en 3 maanden na ziekenhuisopname bepaald d.m.v. DE-, 
T2-gewogen (T2W) en cine CMR. De prevalentie van MVO en IMH was 54% en 43%. 
Alle patiënten met IMH hadden MVO maar niet vice versa. MVO en IMH waren 
sterk gecorreleerd (r = 0.8, p<0.001) en altijd subendocardiaal gelokaliseerd. TIMI 3 
flow vóór percutaneous coronary intervention (PCI) werd alleen waargenomen bij 
patiënten zonder MVO en IMH. De begin- en follow-up infarctgrootte en LV disfunc-
tie waren het grootst in patiënten met zowel MVO als IMH, het kleinst in patiënten 
zonder MVO en IMH en intermediair in patiënten met MVO maar zonder IMH. In-
farctgrootte was de enige onafhankelijke voorspeller van adverse remodeling.  
 De relatie van vroege STR na PCI met onderliggende infarctkarakteristieken en 
adverse remodeling werd onderzocht in hoofdstuk 5. In deze studie werden 8 ver-
schillende methoden om STR te meten (proportionele STR (%) en absolute ST seg-
ment deviatie (STD, mm), cumulatief en in één afleiding), geëvalueerd 30 en 60 
minuten na PCI. Cine en DE-CMR werden verricht, 5 dagen en 3 maanden na zie-
kenhuisopname. Gebaseerd op infarctgrootte, MVO en infarcttransmuraliteit wer-
den m.b.v. k-means clusteranalyse, 3 CMR groepen onderscheiden met een verschil-
lend risico op adverse remodeling (laag, intermediair, en hoog). Infarctgrootte was 
de belangrijkste determinant van adverse remodeling (low LVEF) na 3 maanden. 
Absolute STD in de ‘slechtste’ afleiding, 30 minuten na PCI, identificeerde het beste 
patiënten met een verhoogd risico op adverse remodeling en was sterker gerela-
teerd aan infarctgrootte dan MVO en transmuraliteit.  
 In hoofdstuk 6 werden electrocardiografische (Aldrich), angiografische (BARI, 
APPROACH) en CMR methoden (T2W hyperintensiteit, endocardiaal infarct opper-
vlak (ESA)) om de AAR te meten, onderling relatief vergeleken aan de hand van 
enkele fysiologische basisprincipes van infarctuitbreiding als referentie standaard: 
1) AAR ≥ infarctgrootte, 2) in transmurale infarcten is de AAR ongeveer gelijk aan 
infarctgrootte, 3) de correlatie tussen AAR en infarctgrootte neemt toe als infarct-
transmuraliteit toeneemt, 4) myocardial salvage [(AAR − infarctgrootte)/AAR x 100] 
is omgekeerd evenredig aan infarcttransmuraliteit en ligt dichtbij de identiteitslijn. 
CMR methoden waren beter dan angiografische, die weer beter waren dan electro-
cardiografische methoden om de AAR te meten. Over het algemeen, bleek ESA 
d.m.v. DE-CMR de beste methode om AAR in vivo te bepalen.  
 Hoofdstuk 7 beschrijft de belangrijkste bevindingen uit dit proefschrift en be-
schouwt deze tegen het licht van de huidige wetenschappelijke literatuur. 
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Conclusies 
CMR is in staat nauwkeurig de schade en karakteristieken van een gereperfundeerd 
acuut myocardinfarct te bepalen en toont aan dat MVO en IMH vaak voorkomen en 
sterk zijn gecorreleerd. Bovendien blijkt uit onze studies dat infarctgrootte de be-
langrijkste voorspeller is van adverse remodeling na 3 maanden. Absolute STD in de 
slechtste afleiding 30 minuten na PCI identificeerde het beste patiënten met een 
verhoogd risico op adverse remodeling na 3 maanden en was sterker gerelateerd 
aan infarctgrootte dan MVO en infarcttransmuraliteit. Om de area at risk te meten, 
zijn CMR methoden beter dan angiografische, die weer beter zijn dan electrocardio-
grafische methoden.  
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In 2006 begon ik dit proefschrift aan een nieuw, zelf ontworpen bureau dat door 
mijn mijn handige schoonbroer Cees werd gemaakt. De strakke lijnen, de diepe 
warmrode kleur van Jatobahout, de subtiele metalen verbindingsstukken geven het 
een moderne en klassieke uitstraling. Hoewel in de loop der jaren verdwenen onder 
stapels artikelen en aantekeningen, is het de spil gebleven in de organisatie van 
mijn proefschrift. Natuurlijk was dit proefschrift niet mogelijk geweest zonder de 
vele personen die mij de afgelopen jaren hebben geholpen. Ik bedank mijn beide 
promotoren, prof. dr. Anton P.M. Gorgels en prof. dr. Johannes L. Waltenberger.  
 Beste Ton, jouw idee voor de MAST studie vormde de basis van dit proefschrift. 
Als collega was ik een ongewone promovendus. Mede door jouw vertrouwen, heb ik 
veel zelfstandig kunnen doen. Ik ken je als een toegankelijke, warme persoonlijkheid 
en bewonder je kennis van de elektrocardiografie. Ik ben je opvattingen over ge-
neeskunst steeds meer gaan waarderen: de weg naar genezing begint bij een goede 
anamnese en zorgvuldig lichamelijk onderzoek.  
 Beste Johannes, ik bewonder je als ‘international professional’, iemand die zijn 
carrière buiten de eigen landsgrenzen succesvol opbouwt. Dank voor de uitnodiging 
te spreken over microvasculaire obstructie op het ESC congres in München in 2008. 
Het heeft geleid tot het overzichtsartikel dat nu als één van de hoofdstukken van dit 
proefschrift dient. 
 De leden van de beoordelingscommissie, Prof. dr. Joachim E. Wildberger (voor-
zitter), Prof. dr. Harry J.G.M. Crijns, Prof. dr. Mat J. Daemen, Prof. dr. Frank E. 
Rademakers en Prof. dr. Albert C. van Rossum ben ik erkentelijk voor het beoorde-
len van dit manuscript. Voor het opponeren bedank ik tevens Prof. dr. Frits W. Prin-
zen en Prof. dr. Hein J.J. Wellens, die aan de basis heeft gestaan van mijn opleiding 
tot cardioloog en eerste stappen in wetenschappelijk onderzoek.  
 Miguel Lemmert, hartelijk dank voor je hulp in de beginfase van de MAST studie 
en de eerste analyses. Nog even doorzetten en je eigen promotie is weldra daar.  
 Ook bedank ik Petra Erkens, die vele patiënten includeerde, case record forms 
bijhield en het SPSS moederbestand creëerde. Succes met je eigen promotie. 
 Begonnen als WESP student, heeft ook Martijn Smulders een belangrijke bijdra-
ge geleverd. Dank voor de vele analyses. Ik zie er naar uit jouw promotietraject de 
komende jaren te begeleiden. Mathijs Versteylen, ons artikel kende een lange reis 
met de eindbestemming bijna in het zicht. Dank voor jouw volhardendheid.  
 Beste Valéria, ik ben je zeer dankbaar voor de statistische ondersteuning en 
zorgvuldige argumenten. Je Braziliaanse temperament is hartverwarmend. 
 Ik bedank collega Simon Schalla voor het kritisch beoordelen van de artikelen. Ik 
hoop dat we CMR in het MUMC tot nog grotere hoogte kunnen brengen.  
 I thank Prof. dr. R.J. Kim, professor of Medicine at Duke University Medical Cen-
ter. Dear Ray, I am very grateful for the many hours we have spent during phone 
conferences and visits. Your knowledge and thoughts on research and scientific 
writing have been very inspiring. I look forward to our continuing cooperation. 
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 Beste Harry, dank voor je ondersteuning en dat je als afdelingshoofd mede 
mogelijk hebt gemaakt dat ik mijn tijd kon pakken om dit proefschrift af te ronden.  
 Beste Miel, door jou werd ik geënthousiasmeerd in cardiovasculaire beeldvor-
ming. Je blijft voor mij de beste echocardiografist van Nederland. Als opleider en 
overdrager van kennis zijn de woorden ‘trans’ en ‘ducere’ je op het lijf geschreven.  
 Beste Dirk, ik bewonder je doorzettingsvermogen. Jij wordt de eerste Neder-
landse hoogleraar ICCU geneeskunde. Dank voor alle bijzondere momenten op de 
werkvloer en op de fiets. 
 De verpleging van de ICCU en verpleegafdeling cardiologie, in het bijzonder Jean 
Partouns, dank ik voor de prettige samenwerking de afgelopen jaren en zorg voor 
de patiënten van de MAST studie. Jean, geniet van je welverdiende pensioen. 
 Dank aan de laboranten van de afdeling radiologie, speciaal Liesbeth en Kim, 
voor de CMR onderzoeken. Met plezier heb ik de afgelopen jaren samengewerkt 
met radiologen Riël Snoep, Tim Leiner en Suzanne Gommers. 
 Dank aan alle laboranten echocardiografie, in het bijzonder moederlaborant 
Andrea Palmans-Meulemans en ‘Sjwens’ Jos Habets, voor jullie bijdrage. Door de 
goede sfeer die jullie altijd weer weten te creëren op de echokamer ben ik er graag.  
 Ik bedank de assistenten cardiologie voor hun bijdrage de afgelopen jaren en 
mijn collega cardiologen, die af en toe een tandje bij moesten zetten in de kliniek, 
zodat ik dit proefschrift kon afronden.   
 Nicoline Nanninga en Nadine Hofman-Servais dank ik voor de secretariële on-
dersteuning en Anita Kaemingk voor de in- en uitwendige opmaak van dit boek. 
 Mijn goede vrienden, speciaal Marcel en Tom, bedank ik voor hun geduld de 
afgelopen jaren. Ik zie uit om weer samen met onze gezinnen erop uit te trekken.  
 Beste Jan en Henny, dank voor jullie luisterende oor en interesse in de bezighe-
den van jullie schoonzoon de afgelopen jaren.  
 Lieve Paul en Saskia, een broer als bankier en schoonzus werkzaam bij een fa-
meuze uitgever geeft gelukkig weer andere praat tijdens familiebijeenkomsten.  
 Lieve pa en ma, de waarden en normen die jullie meegaven vormen de basis 
voor ons succes. Dank voor jullie onvoorwaardelijke liefde en steun. Het warme nest 
van vroeger en nu, zal altijd een voorbeeld voor ons blijven.  
 Lieve Netty, liefde van mijn leven. Zonder jou was dit alles niet mogelijk ge-
weest. Promoveren naast een baan als cardioloog is geen sinecure gebleken. De 
afgelopen jaren zorgde jij dat ons gezinnetje draaide. Wat ben je toch een ongeloof-
lijk stabiele en sterke persoonlijkheid en wat prijs ik mij gelukkig het leven met jou 
te delen. En wat zijn we gezegend met onze twee kinderen, die het in alle opzichten 
fantastisch doen. Lieve Sam en Merel, papa is ongelooflijk trots op alles wat jullie op 
eigen kracht doen, op school, met jullie gitaarspel en op het hockeyveld, maar wat 
gaat de tijd toch snel. Gisteren nog in mijn armen, nu al of bijna naar de middelbare 
school. Vanaf morgen ga ik het bewuster meemaken. Jullie zijn mijn drijvende 
kracht.  
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